Macrocyclic compound

By blocking the interaction between cyclin and RxL-dependent protein using macrocyclic peptide molecules, the problem of insufficient selectivity and drug resistance of existing CDK inhibitors has been solved, achieving more effective inhibition of the cyclin-CDK complex and enhancing the anti-cancer therapeutic effect.

WO2026233359A1PCT designated stage Publication Date: 2026-11-12SIMCERE ZAIMING PHARMACEUTICAL CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2026/095180
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2026-01-04
Filing Date
2026-05-07
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Existing CDK inhibitors such as abecilibi, palbociclib, and ribociclib suffer from insufficient selectivity and drug resistance in cancer treatment, resulting in a small therapeutic window and difficulty in effectively inhibiting the function of cyclin-CDK complexes.

Method used

Develop macrocyclic peptide molecules that, by binding to hydrophobic patches of cyclin, block the interaction between cyclin and RxL-dependent proteins, thereby disrupting the function of the cyclin-CDK complex.

Benefits of technology

This study provides a novel strategy that enhances therapeutic selectivity and efficacy by inhibiting the binding of cyclin to RxL-dependent proteins, thereby blocking cyclin-CDK function and overcoming the shortcomings of existing CDK inhibitors.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2026095180_12112026_PF_FP_ABST
    Figure CN2026095180_12112026_PF_FP_ABST
Patent Text Reader

Abstract

Provided is a macrocyclic compound. Specifically disclosed are a compound as represented by formula (I) or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing same, and the use thereof in a drug for treating tumors.
Need to check novelty before this filing date? Find Prior Art

Description

macrocyclic compounds

[0001] Cross-references to related applications

[0002] This application claims Chinese patent application No. 202510590776.1 filed with the China National Intellectual Property Administration (CNIPA) on May 8, 2025; Chinese patent application No. 202510918375.4 filed with the CNIPA on July 3, 2025; Chinese patent application No. 202511125890.3 filed with the CNIPA on August 12, 2025; and Chinese patent application No. 2025112388 filed with the CNIPA on September 1, 2025. The priority and interests of Chinese patent application No. 94.2, Chinese patent application No. 202511397989.9 filed with the China National Intellectual Property Administration on September 28, 2025, Chinese patent application No. 202511703543.4 filed with the China National Intellectual Property Administration on November 19, 2025, and Chinese patent application No. 202610001139.0 filed with the China National Intellectual Property Administration on January 4, 2026, are hereby incorporated herein by reference in their entirety. Technical Field

[0003] This disclosure pertains to the field of pharmaceutical technology, specifically relating to a class of macrocyclic compounds or their stereoisomers or pharmaceutically acceptable salts, pharmaceutical compositions comprising them, and their use in oncology treatment drugs. Background Technology

[0004] Cyclins, as core regulators of the cell cycle, are expressed at different stages of the cell cycle. They drive the orderly passage of cells through checkpoints by forming complexes with cyclin-dependent kinases (CDKs). Cyclin D binds to CDK4 / 6, phosphorylating retinoblastoma protein (RB) and releasing the E2F transcription factor, regulating the transition from G1 to S phase. The Cyclin E-CDK2 complex further phosphorylates RB, activating DNA replication and regulating entry into S phase. The Cyclin A-CDK2 complex promotes DNA synthesis in S phase. The Cyclin B-CDK1 complex is a crucial molecule regulating the G2 / M transition of the cell cycle, controlling chromosome condensation, nuclear membrane breakdown, and cytokinesis. Abnormal cyclin expression (such as overexpression, gene amplification, or degradation defects) disrupts the function of cyclin-CDK complexes, leading to cell cycle dysregulation and promoting cancer development. Therefore, cyclin-CDK complexes are a popular target for anti-tumor drug development.

[0005] Currently, inhibitors targeting the cyclin-CDK complex primarily target and inhibit the activity of CDKs. Among them, abemaciclib, palbociclib, and ribociclib are CDK4 / 6 inhibitors and have been approved by the FDA for combination therapy with specific endocrine therapy for estrogen receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer patients. However, the application of CDK inhibitors is limited by their relatively lack of selectivity, small therapeutic window, and the eventual development of drug resistance.

[0006] Disrupting the binding of cyclins and CDKs, or the interaction between the cyclin-CDK complex and its substrate, is another strategy for regulating cyclin-CDK complex function. Cyclin hydrophobic patches (HPs) recognize and bind to their substrate RxL motifs, initiating cyclin / CDK-mediated substrate phosphorylation. Developing molecules that bind to cyclin HPs, blocking cyclin-RxL-dependent protein interactions, offers a novel therapeutic strategy for patients.

[0007] Macrocyclic peptides, with their complex structure (increasing opportunities for target selection optimization), programmable passive cell penetration, and oral bioavailability, offer a feasible strategy to block cyclin HP and RxL-dependent protein-protein interactions. This disclosure presents macrocyclic peptide molecules that disrupt cyclin-CDK function by inhibiting the binding of cyclin to RxL-dependent proteins. Summary of the Invention

[0008] This disclosure provides a compound of formula (I) or a stereoisomer thereof or a pharmaceutically acceptable salt thereof:

[0009] Among them, W 1 W 2 W 3 W 4 W 5 W 6 Independently selected from O or S;

[0010] X is selected from 5-10 heteroalkyl groups containing at least one heteroatom selected from O, S, or NH; -CH2-CH=CH-CH2-CH2-CH2-CH2-; -CH2-CH2-CH2-CH=CH-CH2-CH2-; -CH2-CH2-CH2-(CH 2)p -CH2-CH2-CH2-、-CR 1a R 1b -CR 2a R 2b -CR 3a R 3b -(CR 4a R 4b ) q -CR 5a R 5b -CR 6a R 6b -CR 7a R 7b - C6-C7 alkenyl groups substituted with deuterium or halogens, C8-C 10 alkenyl or C8-C 10 Alkylene, the C8-C 10 alkenyl or C8-C 10 The alkylene group may optionally be substituted with deuterium, halogen, or C1-C4 alkyl;

[0011] R 1a R 1b R 2a R 2b R 3a R 3b R 4a R4b R 5a R 5b R 6a R 6b R 7a R 7b It is independently selected from H, deuterium, halogen or C1-C4 alkyl, and at least one of them is not H;

[0012] p and q are independently selected from 0 or 1;

[0013] Or, R 1a R 1b R 2a R 2b R 3a R 3b R 4a R 4b R 5a R 5b R 6a R 6b R 7a R 7b Any two substituents located on two alternating carbon atoms and the atoms they are attached to form a C3-C6 cycloalkyl or a 4-6 membered heterocyclic group, wherein each of the C3-C6 cycloalkyl or 4-6 membered heterocyclic group is independently and optionally substituted by a halogen, OH or a C1-C4 alkyl.

[0014] Or, R 1a R 1b R 2a R 2b R 3a R 3b R 4a R 4b R 5a R 5b R 6a R 6b R 7a R 7b Any two substituents located on two adjacent carbon atoms and the atoms they are attached to form a C3-C6 cycloalkyl or a 4-6 membered heterocyclic group, wherein each of the C3-C6 cycloalkyl or 4-6 membered heterocyclic group is independently and optionally substituted by a halogen, OH or a C1-C4 alkyl group.

[0015] Or, R 1a R 1b R 2a R 2b R 3a R 3b R 4a R 4b R 5a R 5bR 6a R 6b R 7a R 7b Any two substituents located on the same carbon atom and the atoms they are attached to form a C3-C6 cycloalkyl or a 4-6 membered heterocyclic group, wherein each of the C3-C6 cycloalkyl or 4-6 membered heterocyclic group is independently and optionally substituted by a halogen, OH or a C1-C4 alkyl group.

[0016] R 8 Selected from H, C1-C6 alkyl or C3-C6 cycloalkyl, wherein the C1-C6 alkyl or C3-C6 cycloalkyl is optionally substituted with halogen or OH;

[0017] Or, R 7a R 8 The atoms attached thereto form 4-10 membered heterocyclic groups, which are optionally substituted with halogens, OH, C1-C4 alkyl, -O-C1-C4 alkyl or -O-C1-C4 haloalkyl;

[0018] Or, R 6a R 8 The atoms attached thereto form 4-8 membered heterocyclic groups, which are optionally substituted with halogens, OH, C1-C4 alkyl, -O-C1-C4 alkyl or -O-C1-C4 haloalkyl;

[0019] R 9 Selected from H, C1-C6 alkyl or C3-C6 cycloalkyl, wherein the C1-C6 alkyl or C3-C6 cycloalkyl is optionally substituted with halogen or OH;

[0020] R 10a R 10b Each is independently selected from H, C1-C6 alkyl, C2-C6 alkenyl, C1-C6 haloalkyl, C1-C6 alkoxy or C3-C6 cycloalkyl, wherein the C1-C6 alkyl, C2-C6 alkenyl or C3-C6 cycloalkyl is optionally substituted with OH, C1-C6 alkyl or C3-C6 cycloalkyl;

[0021] R 11 Selected from H, C1-C6 alkyl or C3-C6 cycloalkyl, wherein the C1-C6 alkyl or C3-C6 cycloalkyl is optionally substituted with halogen or OH;

[0022] R 12a R 12b Independently selected from H, deuterium, C1-C4 alkyl or C3-C6 cycloalkyl;

[0023] R 13Selected from H, C1-C6 alkyl, C1-C6 deuterated alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 alkyl-OH, C3-C6 cycloalkyl, 4-6 heterocyclic alkyl, phenyl, 5-6 heteroaryl, -C1-C6 alkyl-C3-C6 cycloalkyl, -C1-C6 alkyl-4-6 heterocyclic alkyl, -C1-C6 alkyl-phenyl, or -C1-C6 alkyl-5-6 heteroaryl, wherein each of the C3-C6 cycloalkyl, 4-6 heterocyclic alkyl, phenyl, or 5-6 heteroaryl groups is independently bounded by 0-3 R groups. a replace;

[0024] Each R a Independently selected from CN, halogen, C1-C6 alkyl, or C1-C6 haloalkyl;

[0025] R 14a R 14b Independently selected from H, C1-C6 alkyl, C1-C6 deuterated alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 alkyl-OH, C1-C4 alkyl-NR b R d C1-C4 alkyl-C(O)NHR b C1-C4 alkyl-C(O)OR b C3-C6 cycloalkyl, 4-6 heterocyclic alkyl, phenyl, 5-6 heteroaryl, -C1-C6 alkyl-C3-C6 cycloalkyl, -C1-C6 alkyl-4-6 heterocyclic alkyl, -C1-C6 alkyl-phenyl or -C1-C6 alkyl-5-6 heteroaryl, wherein each of the C3-C6 cycloalkyl, 4-6 heterocyclic alkyl, phenyl, and 5-6 heteroaryl groups is independently bounded by 0-3 R groups. e replace;

[0026] R b R d Independently selected from H, deuterium, C1-C6 alkyl or C1-C6 haloalkyl;

[0027] Each R e Selected from CN, halogens, C1-C6 alkyl groups, or C1-C6 haloalkyl groups;

[0028] Or, R 13 R 14a The atoms bonded to it form 5-8 membered heterocyclic groups;

[0029] R 15 Selected from H or C1-C4 alkyl groups;

[0030] R 16 Selected from C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C 10Cycloalkyl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, wherein the C1-C6 alkyl, C2-C6 alkenyl, C2-C6 ynyl, C3-C 10 Cycloalkyl, 4-10 membered heterocycloalkyl, and 5-10 membered heteroaryl groups are each independently bound by 0-5 R groups. f replace;

[0031] Each R f Independently selected from =CH2, =CF2, -SF5, OH, CN, =O, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or C3-C6 cycloalkyl;

[0032] R 17 Selected from H or C1-C6 alkyl groups;

[0033] R 18 Selected from H, halogens, C1-C6 alkyl groups, or C1-C6 haloalkyl groups;

[0034] Or, R 16 R 17 The atoms connected thereto form 5-12 membered heterocyclic groups, which are optionally substituted with OH, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkylene-OH or C1-C6 alkoxy.

[0035] Ring B is selected from C5-C 12 Cycloalkyl, 5-12 membered heterocyclic, 6-10 membered aryl or 5-10 membered heteroaryl;

[0036] m is selected from 0, 1, 2, 3, 4 or 5;

[0037] Each R B Selected from =O, -C(O)NR g R h -S(O)2R h -NR g C(O)R h Halogen, NH2, C1-C6 alkyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C6 cycloalkyl, C4-C6 cycloalkenyl, 4-10 membered heterocyclic, phenyl or 5-10 membered heteroaryl, wherein each of the NH2, C1-C6 alkyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C6 cycloalkyl, C4-C6 cycloalkenyl, 4-10 membered heterocyclic, phenyl or 5-10 membered heteroaryl is independently bound by 0-5 R M replace;

[0038] Each R g R h Independently selected from H or C1-C6 alkyl groups;

[0039] Each R M Selected from deuterium, halogens, CF2, -S(O)2-R X C1-C6 deuterated alkyl, C1-C6 alkyl, -C1-C6 alkylene-OH, -NHC1-C6 alkyl, -N(C1-C6 alkyl)2, C1-C6 alkyl, C3-C6 cycloalkyl, 4-7 membered heterocyclic or 5-6 membered heteroaryl, wherein each of the C1-C6 alkyl, -C1-C6 alkylene-OH, C3-C6 cycloalkyl, 4-7 membered heterocyclic or 5-6 membered heteroaryl is optionally independently R X replace;

[0040] R X Selected from halogens, C1-C6 alkyl, C1-C3 alkoxy or C3-C6 cycloalkyl, wherein the C1-C6 alkyl or C3-C6 cycloalkyl is optionally substituted with a halogen;

[0041] Alternatively, R on any two adjacent ring atoms B The atoms bonded to it form C3-C 10 cycloalkyl, C3-C 10 Cycloalkenyl, 4-10 membered heterocyclic, phenyl, or 5-6 membered heteroaryl, wherein the C3-C 10 cycloalkyl, C4-C 10 Cycloalkenyl, 4-10 membered heterocyclic, phenyl, or 5-6 membered heteroaryl groups are each independently bound by 0-5 R groups. C replace;

[0042] Each R C Selected from OH, halogen, NH2, C1-C6 alkyl, C3-C6 cycloalkyl, 5-6 membered heterocyclic group, phenyl or 5-6 membered heteroaryl;

[0043] Alternatively, R on any two adjacent ring atoms C The atoms bonded to it form C3-C 10 Cycloalkyl, 4-10 membered heterocyclic, phenyl, or 5-6 membered heteroaryl, wherein the C3-C 10 Cycloalkyl, 4-10-membered heterocyclic, phenyl, or 5-6-membered heteroaryl groups are independently and optionally R D replace;

[0044] R D Selected from OH, halogens, C1-C6 alkyl groups, or C1-C6 haloalkyl groups;

[0045] Or, R 12a R B The atoms attached thereto form C5-C7 cycloalkyl, C5-C7 cycloalkenyl, or 5-7 membered heterocyclic groups, wherein R B Located in CR 12a R12b The adjacent positions of the ring atoms in the connected ring B.

[0046] In some implementation schemes, W 1 W 2 W 3 W 4 W 5 W 6 At least one of them is S.

[0047] In some implementation schemes, W 1 W 2 W 3 W 4 W 5 W 6 Any one of them is S, and the rest are O.

[0048] In some implementation schemes, W 2 For S, W 1 W 3 W 4 W 5 W 6 All are O.

[0049] In some implementation schemes, W 1 For S, W 2 W 3 W 4 W 5 W 6 All are O.

[0050] In some implementation schemes, W 1 W 2 W 3 W 4 W 5 W 6 All are O.

[0051] In some embodiments, X is selected from 5-10 heteroalkyl groups containing at least one heteroatom selected from O, S or NH.

[0052] In some embodiments, X is a 6-7 heteroalkyl group containing at least one heteroatom selected from O, S or NH.

[0053] In some embodiments, X is a 6-7 heteroalkylene group containing one, two, or three heteroatoms independently selected from O, S, or NH.

[0054] In some implementations, X is a 6-7 membered heteroalkylene group containing 1, 2, or 3 O heteroatoms.

[0055] In some embodiments, X is a 6-7 membered heteroalkylene group containing one or two O heteroatoms.

[0056] In some implementations, X is a 6-7 membered heteroalkylene group containing two O heteroatoms.

[0057] In some implementations, X is -CH2-O-CH2-CH2-O-CH2-CH2-.

[0058] In some implementations, X is -CH2-CH2-CH2-CH2-O-CH2-CHR 7a -

[0059] In some implementations, X is selected from -CH2-CH=CH-CH2-CH2-CH2-CH2- or -CH2-CH2-CH2-CH=CH-CH2-CH2-.

[0060] In some implementations, X is selected from -CH2-CH2-CH2-CH2-CH2-CH2-CH2- or CH2-CH2-CH2-CH2-CH2-CH2-.

[0061] In some implementations, X is -CH2-CH2-CH2-CH2-CH2-CH2-CH2-CH2-.

[0062] In some implementations, X is selected from -CR 1a R 1b -CR 2a R 2b -CR 3a R 3b -CR 5a R 5b -CR 6a R 6b -CR 7a R 7b -or-CR 1a R 1b -CR 2a R 2b -CR 3a R 3b -CR 4a R 4b -CR 5a R 5b -CR 6a R 6b -CR 7a R 7b -, and R 1a R 1b R 2a R 2b R 3a R3b R 4a R 4b R 5a R 5b R 6a R 6b R 7a R 7b It is independently selected from H, deuterium, halogen or C1-C4 alkyl, and at least one of them is not H.

[0063] In some implementations, X is selected from -CR 1a R 1b -CR 2a R 2b -CR 3a R 3b -CR 4a R 4b -CR 5a R 5b -CR 6a R 6b -CR 7a R 7b -, and R 1a R 1b R 2a R 2b R 3a R 3b R 4a R 4b R 5a R 5b R 6a R 6b R 7a R 7b It is independently selected from H, deuterium, halogen or C1-C4 alkyl, and at least one of them is not H.

[0064] In some implementation schemes, R 1a R 1b R 2a R 2b R 3a R 3b R 4a R 4b R 5a R 5b R 6a R 6b R 7a R 7b It is independently selected from H, F or CH3, and at least one of them is not H.

[0065] In some implementations, X is selected from -CR 1a R 1b -CR 2aR 2b -CR 3a R 3b -CR 4a R 4b -CR 5a R 5b -CR 6a R 6b -CR 7a R 7b -, and R 1a R 1b R 2a R 2b R 3a R 3b R 4a R 4b R 5a R 5b R 6a R 6b R 7a R 7b It is independently selected from H, deuterium, halogen or C1-C4 alkyl, and one or two of them are selected from halogen or C1-C4 alkyl.

[0066] In some implementation schemes, R 1a R 1b R 2a R 2b R 3a R 3b R 4a R 4b R 5a R 5b R 6a R 6b R 7a R 7b It is independently selected from H, F or CH3, and one or two of them are selected from F or CH3.

[0067] In some implementations, X is selected from -CR 1a R 1b -CR 2a R 2b -CR 3a R 3b -CR 4a R 4b -CR 5a R 5b -CR 6a R 6b -CR 7a R 7b -, and R 1a R 1b R 2a R 2bR 3a R 3b R 4a R 4b Both are H, R 5a R 5b R 6a R 6b R 7a R 7b It is independently selected from H, deuterium, halogen or C1-C4 alkyl, and at least one of them is not H.

[0068] In some implementations, X is selected from -CR 1a R 1b -CR 2a R 2b -CR 3a R 3b -CR 4a R 4b -CR 5a R 5b -CR 6a R 6b -CR 7a R 7b -, and R 1a R 1b R 2a R 2b R 3a R 3b Both are H, R 4a R 4b R 5a R 5b R 6a R 6b R 7a R 7b One or two of them are selected from halogens or C1-C4 alkyl groups, and the rest are H.

[0069] In some implementations, CR in X 7a R 7b One end connects to CR 6a R 6b The other end is connected to a ring N atom.

[0070] In some implementation schemes, R 1a R 1b R 2a R 2b R 3a R 3b R 4a R 4b R 5a R 5b R 6a R 6b R7a R 7b Any two substituents located on two alternating carbon atoms form a C3-C6 cycloalkyl or a 4-6 membered heterocyclic group with the atoms they are attached to, wherein each of the C3-C6 cycloalkyl or 4-6 membered heterocyclic group is independently and optionally substituted by a halogen, OH or a C1-C4 alkyl group.

[0071] In some implementation schemes, R 1a R 1b R 2a R 2b R 3a R 3b R 4a R 4b R 5a R 5b R 6a R 6b R 7a R 7b Any two substituents located on two adjacent carbon atoms form a C3-C6 cycloalkyl or a 4-6 membered heterocyclic group with the atom they are attached to, wherein each of the C3-C6 cycloalkyl or 4-6 membered heterocyclic group is independently and optionally substituted by a halogen, OH or a C1-C4 alkyl.

[0072] In some implementation schemes, R 5a R 6a The carbon atom it is attached to forms a C3-C6 cycloalkyl group; or, R 2a R 3a The carbon atom attached thereto forms a C3-C6 cycloalkyl or a 4-6 membered heterocyclic group, each of which is optionally and independently substituted by a halogen, OH or a C1-C4 alkyl group.

[0073] In some implementation schemes, R 5a R 6a The carbon atom it is attached to forms a cyclopropyl group; or, R 2a R 3a The carbon atom it is attached to forms a cyclopropyl group.

[0074] In some implementation schemes, R 1a R 1b R 2a R 2b R 3a R 3b R 4a R 4b R 5a R 5b R 6a R 6b R 7a R 7bAny two substituents located on the same carbon atom and the atoms they are attached to form a C3-C6 cycloalkyl or a 4-6 membered heterocyclic group, wherein each of the C3-C6 cycloalkyl or 4-6 membered heterocyclic group is independently and optionally substituted by a halogen, OH or a C1-C4 alkyl.

[0075] In some implementation schemes, R 3a R 3b The carbon atom attached thereto forms a C3-C6 cycloalkyl or a 4-6 membered heterocyclic group, each of which is optionally and independently substituted with a halogen, OH, or a C1-C4 alkyl group; or, R 6a R 6b The carbon atom attached thereto forms a C3-C6 cycloalkyl or a 4-6 membered heterocyclic group, each of which is optionally and independently substituted by a halogen, OH or a C1-C4 alkyl group.

[0076] In some implementation schemes, R 3a R 3b The carbon atom it is attached to forms a cyclopropyl group; or, R 6a R 6b The carbon atom it is attached to forms a cyclopropyl group.

[0077] In some implementation schemes, R 3a R 3b The carbon atom attached thereto forms a C3-C6 cycloalkyl or a 4-6 membered heterocyclic group, each of which is optionally and independently substituted with a halogen, OH, or a C1-C4 alkyl group; or, R 6a R 6b The carbon atom attached thereto forms a C3-C6 cycloalkyl or a 4-6 membered heterocyclic group, each of which is optionally and independently substituted with a halogen, OH, or a C1-C4 alkyl group; or, R 5a R 6a The carbon atom attached thereto forms a C3-C6 cycloalkyl or a 4-6 membered heterocyclic group, each of which is optionally and independently substituted with a halogen, OH, or a C1-C4 alkyl group; or, R 2a R 3a The carbon atom attached thereto forms a C3-C6 cycloalkyl or a 4-6 membered heterocyclic group, each of which is optionally and independently substituted with a halogen, OH, or a C1-C4 alkyl group; or, R 7a R 8 The atoms attached thereto form 4-6 membered heterocyclic groups, each of which is optionally substituted by a halogen, OH, or C1-C4 alkyl group.

[0078] In some embodiments, X is a C6-C7 alkenyl group substituted with deuterium or halogen.

[0079] In some implementations, X is -CH2-CF=CH-CH2-CH2-CH2-CH2-, -CH2-CH=CF-CH2-CH2-CH2-CH2-, or -CH2-CH2-CH=CH-CH2-CF2-CH2-.

[0080] In some implementations, X is -CH2-CF=CH-CH2-CH2-CH2-CH2- or -CH2-CH=CF-CH2-CH2-CH2-CH2-.

[0081] In some implementations, X is selected from C8-C 10 alkenyl or C8-C 10 Alkylene, the C8-C 10 alkenyl or C8-C 10 The alkylene group may optionally be substituted with deuterium, halogen, or C1-C4 alkyl.

[0082] In some implementations, X is selected from -CH2-CH2-CH2-CH2-CH2-CH2-, -CH2-CH2-CH2-CH2-CHCH3-CH2-CH2-, -CH2-CH2-CH2-CH2-CH2-CHCH3-CH2-, -CH2-CH2-CH2-CHCH3-CH2-, -CH2-CH2-CH2-CHCH3-CH2-, -CH2-CH2-CH2-CH2-CH2-CHCH3-, -CHF2-CH2-CH2-CH2-CH2-CH2-CH2-, - CH2-CHF2-CH2-CH2-CH2-CH2-CH2-, -CH2-CH2-CHF2-CH2-CH2-CH2-CH2-, -CH2-CH2-CH2-CHF2-CH2-CH2-CH2-, -CH2-CF=C H-CH2-CH2-CH2-CH2-, -CH2-CH=CF-CH2-CH2-CH2-CH2-, -CH2-CH2-CH=CH-CH2-CF2-CH2-, -CH2-O-CH2-CH2-O-CH2-CH2-,

[0083] In some implementations, X is selected from -CH2-CH2-CH2-CH2-CH2-CH2-, -CH2-CH2-CH2-CH2-CHCH3-CH2-CH2-, -CH2-CH2-CH2-CH2-CH2-CHCH3-CH2-, -CH2-CH2-CH2-CHCH3-CH2-, -CH2-CH2-CH2-CHCH3-CH2-CH2-CH2-, -CH2-CH2-CH2-CH2-CH2-CHCH3-, -CHF2-CH2-CH2-CH2-CH2- CH2-CH2-CH2-, -CH2-CHF2-CH2-CH2-CH2-CH2-CH2-, -CH2-CH2-CHF2-CH2-CH2-CH2-CH2-, -CH2-CH2-CH2-CHF2-C H2-CH2-CH2-, -CH2-CF=CH-CH2-CH2-CH2-CH2-, -CH2-CH=CF-CH2-CH2-CH2-CH2-, -CH2-O-CH2-CH2-O-CH2-CH2-,

[0084] In some implementation schemes, R 7a R 8 The atoms attached thereto form 4-6 membered heterocyclic groups, which are optionally substituted with halogens, OH, or C1-C4 alkyl groups.

[0085] In some implementation schemes, R 7a R 8 The atoms attached thereto form 4-6 membered heterocyclic groups, which are optionally substituted with -O-C1-C4 alkyl or -O-C1-C4 haloalkyl groups.

[0086] In some implementation schemes, R 7a R 8 The atoms attached thereto form 7-10 membered heterocyclic groups, which are optionally substituted with halogens, OH, C1-C4 alkyl, -O-C1-C4 alkyl or -O-C1-C4 haloalkyl;

[0087] In some implementation schemes, R 7a R 8 The atoms attached thereto form a 7-8 membered heterocyclic group, which is optionally substituted with a halogen, OH, C1-C4 alkyl, -O-C1-C4 alkyl or -O-C1-C4 haloalkyl.

[0088] In some implementation schemes, R 7a R 8 The atoms connected to it form 7-8 membered bicyclic heterocyclic groups.

[0089] In some implementation schemes, R 6a R 8 The atoms connected to it form 4-6 membered heterocyclic groups.

[0090] In some implementation schemes, R 6a R 8 The atoms it connects to form a 4-membered heterocyclic group.

[0091] In some implementation schemes, R 8 It is a C1-C4 alkyl group. In some embodiments, R 8 It is CH3.

[0092] In some implementation schemes, R 9 It is a C1-C4 alkyl group. In some embodiments, R 9 It is CH3.

[0093] In some implementation schemes, R 10a R 10b Independently selected from H or C1-C4 alkyl groups. In some embodiments, R 10a It is a C1-C4 alkyl group, R 10b For H. In some implementations, R 10a For CH2CH(CH3)2, R 10b For H.

[0094] In some implementation schemes, R 11 Selected from H or C1-C6 alkyl groups. In some embodiments, R 11 For H.

[0095] In some implementation schemes, R 12a R 12b It is independently selected from H or deuterium. In some implementations, R 12a R 12b All are H.

[0096] In some implementation schemes, R 13 Selected from H, C1-C6 alkyl, C1-C6 deuterated alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C3-C6 cycloalkyl, 4-6 heterocyclic alkyl, phenyl, 5-6 heteroaryl, -C1-C6 alkyl-C3-C6 cycloalkyl, -C1-C6 alkyl-4-6 heterocyclic alkyl, -C1-C6 alkyl-phenyl, or -C1-C6 alkyl-5-6 heteroaryl, wherein each of the C3-C6 cycloalkyl, 4-6 heterocyclic alkyl, phenyl, or 5-6 heteroaryl groups is independently bounded by 0-3 R groups. a replace.

[0097] In some implementation schemes, R 13Selected from H, C1-C6 alkyl, C1-C6 deuterated alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C3-C6 cycloalkyl, or -C1-C6 alkyl-C3-C6 cycloalkyl, wherein the C3-C6 cycloalkyl group is surrounded by 0-3 R groups. a replace.

[0098] In some implementation schemes, R 13 It is selected from C1-C6 alkyl, C1-C6 deuterated alkyl, C1-C6 haloalkyl or C1-C6 alkyl-OH.

[0099] In some implementation schemes, R 13 It is selected from C1-C6 alkyl, C1-C6 haloalkyl or C1-C6 alkyl-OH.

[0100] In some implementation schemes, R 13 It is selected from C1-C6 alkyl or C1-C6 haloalkyl.

[0101] In some implementation schemes, R 13 It is selected from C1-C4 alkyl or C1-C4 haloalkyl.

[0102] In some implementation schemes, R 13 Selected from CH3, CH2CH3, CD3, CH2CH2F or CH2CH2OH.

[0103] In some implementation schemes, R 13 Selected from CH3, CH2CH2F or CH2CH2OH.

[0104] In some implementation schemes, R 13 Selected from CH3 or CH2CH2F.

[0105] In some implementation schemes, R 13 It is a C1-C4 alkyl group. In some embodiments, R 13 It is CH3.

[0106] In some implementation schemes, R 13 It is a C1-C4 haloalkyl group. In some embodiments, R 13 It is CH2CH2F.

[0107] In some implementation schemes, R 14a Selected from C1-C4 alkyl-NR b R d Or a C3-C6 cycloalkyl group, wherein the C3-C6 cycloalkyl group is formed by 0-3 R groups. e replace.

[0108] In some implementation schemes, R 14aSelected from C1-C4 alkyl-N(C1-C4 alkyl)2, C1-C4 alkyl-NH(C1-C4 alkyl) or C3-C6 cycloalkyl; and R 14b For H.

[0109] In some implementation schemes, R 14a Selected from C1-C4 alkyl-N(CH3)2, C1-C4 alkyl-NHCH3 or cyclopropyl, and R 14b For H.

[0110] In some implementation schemes, R 14a C1-C4 alkyl-NR b R d .

[0111] In some implementation schemes, R 14a It is -CH2CH2CH2CH2N(CH3)2.

[0112] In some implementation schemes, R 14b For H.

[0113] In some implementation schemes, R b R d It is independently selected from H or C1-C6 alkyl groups.

[0114] In some implementation schemes, R 13 R 14a The atoms connected to it form 5-6 membered heterocyclic groups.

[0115] In some implementation schemes, R 13 R 14a The atoms it is attached to form a 6-membered heterocyclic group.

[0116] In some implementation schemes, R 15 It can be H or CH3.

[0117] In some implementation schemes, R 15 For H.

[0118] In some implementation schemes, R 16 Selected from C1-C6 alkyl, C3-C 10 Cycloalkyl or 4-10 membered heterocycloalkyl, wherein the C1-C6 alkyl, C3-C 10 Cycloalkyl or 4-10 membered heterocycloalkyl groups are each independently bound by 0-5 R groups. f replace.

[0119] In some implementation schemes, R 16Selected from C1-C3 alkyl, C3-C6 cycloalkyl, or 4-6 membered heterocyclic alkyl, wherein each of the C1-C3 alkyl, C3-C6 cycloalkyl, or 4-6 membered heterocyclic alkyl is independently bound by 0-5 R. f replace.

[0120] In some implementation schemes, R 16 Selected from CH(CH3)2, tetrahydropyranyl, cyclobutyl, cyclopentyl, cyclohexyl or The CH(CH3)2, tetrahydropyranyl, cyclobutyl, cyclopentyl, cyclohexyl or Each is independently controlled by 0-5 R f replace.

[0121] In some implementation schemes, R 16 Selected from CH(CH3)2, tetrahydropyranyl, cyclobutyl, cyclopentyl, or cyclohexyl, wherein each of the CH(CH3)2, tetrahydropyranyl, cyclobutyl, cyclopentyl, or cyclohexyl groups is independently atomized by 0-5 R groups. f replace.

[0122] In some implementation schemes, R 16 For C3-C 10 cycloalkyl, the C3-C 10 Cycloalkyl groups are marked with 0-5 R groups. f replace.

[0123] In some implementation schemes, R 16 It is a C3-C6 cycloalkyl group, wherein the C3-C6 cycloalkyl group is surrounded by 0-5 R groups. f replace.

[0124] In some implementation schemes, R 16 Selected from cyclobutyl, cyclopentyl, or cyclohexyl, wherein the cyclobutyl, cyclopentyl, or cyclohexyl group is oxidized by 0-5 R groups. f replace.

[0125] In some implementation schemes, R 16 It is a cyclobutyl group, wherein the cyclobutyl group is surrounded by 0-5 R groups. f replace.

[0126] Each R f It is independently selected from OH, CN, =O, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C3-C6 cycloalkyl or =CF2.

[0127] In some implementation schemes, each R f It is independently selected from =CF2, -SF5, OH, CN, =O, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or C3-C6 cycloalkyl.

[0128] In some implementation schemes, each R f It is independently selected from OH, CN, =O, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or C3-C6 cycloalkyl.

[0129] In some implementation schemes, R f Selected from =CH2, =CF2, -SF5, halogens, or C1-C6 haloalkyl groups.

[0130] In some implementation schemes, R f Selected from =CF 2、 -SF5, halogen, or C1-C6 haloalkyl.

[0131] In some implementation schemes, R f Selected from =CF2, -SF5, F, or CF3.

[0132] In some implementation schemes, R f Selected from halogens, C1-C6 haloalkyl groups, or =CF2.

[0133] In some implementation schemes, R f Selected from halogens or C1-C6 haloalkyl groups.

[0134] In some implementation schemes, R 16 Selected from

[0135] In some implementation schemes, R 16 for

[0136] In some implementation schemes, R 16 R 17 The atoms attached thereto form 5-12 membered heterocyclic groups, which are optionally substituted with OH, halogen, C1-C6 alkyl or C1-C6 haloalkyl.

[0137] In some implementation schemes, R 16 R 17 The atoms attached thereto form 5-8 membered heterocyclic groups, which are optionally substituted with OH, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkyl-OH or C1-C6 alkoxy.

[0138] In some implementation schemes, R 16 R 17 The atoms attached thereto form 5-7 membered heterocyclic groups, which are optionally substituted with halogens, C1-C6 alkyl groups, C1-C6 haloalkyl groups or C1-C6 alkyl-OH groups.

[0139] In some implementation schemes, R 16 R 17 The atoms attached thereto form 5-8 membered heterocyclic groups, which are optionally substituted with halogens or C1-C6 alkyl groups.

[0140] In some implementation schemes, R 16 R 17 The atoms attached thereto form 5-6 membered heterocyclic groups, which are optionally substituted with halogens or C1-C6 alkyl groups.

[0141] In some implementation schemes, R 18 It is selected from halogens, C1-C6 alkyl groups, or C1-C6 haloalkyl groups.

[0142] In some implementation schemes, R 18 It is selected from C1-C6 alkyl or C1-C6 haloalkyl.

[0143] In some implementation schemes, R 18 It is a C1-C6 haloalkyl group. In some embodiments, R 18 It is CF3.

[0144] In some implementation schemes, R 18 It is a halogen, such as F.

[0145] In some embodiments, ring B is selected from C5-C8 alkyl, 5-8 heterocyclic, phenyl, or 5-6 heteroaryl.

[0146] In some implementations, ring B is selected from 6-10 aryl or 5-10 heteroaryl.

[0147] In some embodiments, ring B is selected from phenyl or 5-6 heteroaryl groups.

[0148] In some embodiments, ring B is selected from phenyl, pyridyl, or pyrimidinyl. In some embodiments, ring B is selected from phenyl or pyridyl. In some embodiments, ring B is phenyl.

[0149] In some implementations, ring B is selected from C5-C. 12 Cycloalkyl or 5-12 membered heterocyclic groups.

[0150] In some embodiments, ring B is selected from C5-C8 cycloalkyl or 5-8 membered heterocyclic groups.

[0151] In some embodiments, ring B is selected from C5-C6 cycloalkyl or 5-6 membered heterocyclic groups.

[0152] In some embodiments, cyclo B is selected from cyclopentyl, tetrahydrofuranyl, or...

[0153] In some embodiments, ring B is selected from cyclopentyl or tetrahydrofuranyl.

[0154] In some implementation schemes, each R B Selected from halogens, NH2, C1-C6 alkyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C6 cycloalkyl, C4-C6 cycloalkenyl, 4-10 membered heterocyclic, phenyl, or 5-10 membered heteroaryl, wherein each of the NH2, C1-C6 alkyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C6 cycloalkyl, C4-C6 cycloalkenyl, 4-10 membered heterocyclic, phenyl, or 5-10 membered heteroaryl is independently bound by 0-5 R groups. M replace.

[0155] In some implementation schemes, each R B Selected from halogens, NH2, C1-C6 alkyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C6 cycloalkenyl, 4-10 membered heterocyclic, phenyl, or 5-10 membered heteroaryl, wherein each of the NH2, C1-C6 alkyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C6 cycloalkenyl, 4-10 membered heterocyclic, phenyl, or 5-10 membered heteroaryl is independently bound by 0-5 R groups. M replace.

[0156] In some implementation schemes, each R B Selected from =O, -C(O)NR g R h -S(O)2R h -NR g C(O)R h Halogen, NH2, C1-C6 alkyl, C2-C6 alkynyl, C1-C6 alkoxy, C4-C6 cycloalkenyl, 4-6 membered heterocyclic, phenyl or 5-6 membered heteroaryl, wherein each of the NH2, C1-C6 alkyl, C2-C6 alkynyl, C1-C6 alkoxy, C4-C6 cycloalkenyl, 4-6 membered heterocyclic, phenyl or 5-6 membered heteroaryl is independently bound by 0-5 R M replace.

[0157] In some implementation schemes, each R B Selected from halogens, NH2, C1-C6 alkyl, C2-C6 alkynyl, C1-C6 alkoxy, C4-C6 cycloalkenyl, 4-6 membered heterocyclic, phenyl, or 5-6 membered heteroaryl, wherein each of the NH2, C1-C6 alkyl, C2-C6 alkynyl, C1-C6 alkoxy, C4-C6 cycloalkenyl, 4-6 membered heterocyclic, phenyl, or 5-6 membered heteroaryl is independently bound by 0-5 R groups. M replace.

[0158] In some implementation schemes, each R BSelected from halogens, NH2, C1-C6 alkyl, C2-C6 alkynyl, C4-C6 cycloalkenyl, 4-6 membered heterocyclic, phenyl, or 5-6 membered heteroaryl, wherein each of the NH2, C1-C6 alkyl, C2-C6 alkynyl, C4-C6 cycloalkenyl, 4-10 membered heterocyclic, phenyl, or 5-6 membered heteroaryl is independently bound by 0-5 R groups. M replace.

[0159] In some implementation schemes, R B It is a halogen, such as F or Cl.

[0160] In some implementation schemes, R g R h All are C1-C6 alkyl groups, such as CH3.

[0161] In some implementations, m is selected from 1, 2, or 3.

[0162] In some implementation schemes, each R M Selected from halogens, =CF2, -S(O)2-R X C1-C6 alkyl, -C1-C6 alkylene-OH, -NHC1-C6 alkyl, -N(C1-C6 alkyl)2, C1-C6 alkyl, C3-C6 cycloalkyl, 4-7-membered heterocyclic or 5-6-membered heteroaryl, wherein each of the C1-C6 alkyl, C1-C6 alkylene-OH, C3-C6 cycloalkyl, 4-7-membered heterocyclic or 5-6-membered heteroaryl is optionally independently R X replace.

[0163] Each R M Selected from halogens, =CF2, -S(O)2-R X C1-C6 alkyl, -NHC1-C6 alkyl, -N(C1-C6 alkyl)2, C1-C6 alkyl, C3-C6 cycloalkyl, 4-7-membered heterocyclic or 5-6-membered heteroaryl, wherein each of the C1-C6 alkyl, C3-C6 cycloalkyl, 4-7-membered heterocyclic or 5-6-membered heteroaryl is optionally independently R X replace.

[0164] In some implementation schemes, each R M Selected from =CF2, -S(O)2-R X C1-C6 alkyl, -NHC1-C6 alkyl, -N(C1-C6 alkyl)2, C1-C6 alkyl, C3-C6 cycloalkyl, 4-7-membered heterocyclic or 5-6-membered heteroaryl, wherein each of the C1-C6 alkyl, C3-C6 cycloalkyl, 4-7-membered heterocyclic or 5-6-membered heteroaryl is optionally independently RX replace.

[0165] In some implementation schemes, each R M Selected from halogens, =CF2, -S(O)2-R X C1-C6 alkyl, -NHC1-C6 alkyl, -N(C1-C6 alkyl)2, C1-C6 alkyl, C3-C6 cycloalkyl, 4-7-membered heterocyclic or 5-6-membered heteroaryl, wherein each of the C1-C6 alkyl, C3-C6 cycloalkyl, 4-7-membered heterocyclic or 5-6-membered heteroaryl is optionally independently R X replace.

[0166] In some implementation schemes, each R M Selected from =CF2, -S(O)2-R X C1-C6 alkyl, -N(CH3)2, C1-C6 alkyl, C3-C6 cycloalkyl, 4-7 heterocyclic or 5-6 heteroaryl, wherein each of the C1-C6 alkyl, C3-C6 cycloalkyl, 4-7 heterocyclic or 5-6 heteroaryl is optionally independently R X replace.

[0167] In some implementation schemes, R X It is selected from halogens, C1-C3 alkyl groups, C1-C3 alkoxy groups, or C3-C6 cycloalkyl groups, wherein the C3-C6 cycloalkyl groups are optionally substituted with halogens.

[0168] In some implementation schemes, each R B Selected from =O, -C(O)N(CH3)2, -S(O)2CH3, -N(CH3)C(O)CH3, Cl,

[0169] In some implementation schemes, each R B Selected from Cl,

[0170] In some implementation schemes, each R B Selected from Cl,

[0171] In some implementation schemes, each R B Selected from

[0172] In some implementations, R on any two adjacent ring atoms B The atoms bonded to it form C7-C10 Cycloalkenyl or 7-10 membered heterocyclic group, wherein the C7-C 10 Each cycloalkenyl or 7-10 membered heterocyclic group is independently bounded by 0-5 R groups. C replace.

[0173] In some implementations, R on any two adjacent ring atoms B The atoms bonded to it form 7, 8, 9, or 10-membered heterocyclic groups, which are separated by 0-5 R atoms. C replace.

[0174] In some implementations, R on any two adjacent ring atoms B The atoms bonded to it form a 7-membered heterocyclic group, which is then surrounded by 0-5 R atoms. C replace.

[0175] In some implementations, R on any two adjacent ring atoms B The atoms bonded to it form C7-C 10 Cycloalkenyl or 7-10 membered heterocyclic group, wherein the C7-C 10 Each cycloalkenyl or 7-10 membered heterocyclic group is independently bounded by 0-5 R groups. C Instead, the C7-C 10 R on any two adjacent ring atoms of a cycloalkenyl or 7-10 membered heterocyclic group C The atoms bonded to it form C3-C 10 Cycloalkyl, 4-10 membered heterocyclic, phenyl, or 5-6 membered heteroaryl, wherein the C3-C 10 Cycloalkyl, 4-10-membered heterocyclic, phenyl, or 5-6-membered heteroaryl groups are independently and optionally R D replace.

[0176] In some implementations, R on any two adjacent ring atoms B The atoms bonded to it form C7-C 10 Cycloalkenyl or 7-10 membered heterocyclic group, wherein the C7-C 10 Each cycloalkenyl or 7-10 membered heterocyclic group is independently bounded by 0-5 R groups. C Instead, the C7-C 10 R on any two adjacent ring atoms of a cycloalkenyl or 7-10 membered heterocyclic group C The atoms bonded to it form 5-6-membered heteroaryl groups, which are independently and optionally R D replace.

[0177] In some implementations, R on any two adjacent ring atoms BThe atoms bonded to it form a cycloheptene group or a 7-membered heterocyclic group, each of which is independently bound by 0-5 R atoms. C The substitution is made by replacing the R atoms on any two adjacent ring atoms of the cycloheptenyl or 7-membered heterocyclic group. C The atoms bonded to it form 5-6-membered heteroaryl groups, which are independently and optionally R D replace.

[0178] In some embodiments, ring B is selected from phenyl or 5-6-membered heteroaryl groups, wherein R is present on any two adjacent ring atoms of the phenyl or 5-6-membered heteroaryl group. B The atoms connected to it form C 7- C 10 Cycloalkenyl or 7, 8, 9 or 10-membered heterocyclic group, wherein the C7-C 10 Each cycloalkenyl or 7, 8, 9 or 10-membered heterocyclic group is independently bounded by 0-5 R groups. C Instead, the C 7- C 10 R on any two adjacent ring atoms of a cycloalkenyl or 7, 8, 9, or 10-membered heterocyclic group C The atoms bonded to it form C3-C 10 Cycloalkyl, 4-10 membered heterocyclic, phenyl, or 5-6 membered heteroaryl, wherein the C3-C 10 Cycloalkyl, 4-10-membered heterocyclic, phenyl, or 5-6-membered heteroaryl groups are independently and optionally R D replace.

[0179] In some embodiments, ring B is selected from phenyl, and R is located on any two adjacent ring atoms of the phenyl group. B The atoms connected to it form C 7- C 10 Cycloalkenyl or 7, 8, 9 or 10-membered heterocyclic group, wherein the C 7- C 10 Each cycloalkenyl or 7, 8, 9 or 10-membered heterocyclic group is independently bounded by 0-5 R groups. C Instead, the C 7- C 10 R on any two adjacent ring atoms of a cycloalkenyl or 7, 8, 9, or 10-membered heterocyclic group C The atoms bonded to it form 5-6-membered heteroaryl groups, which are independently and optionally R D replace.

[0180] In some embodiments, ring B is selected from phenyl, and R is located on any two adjacent ring atoms of the phenyl group. B The atoms bonded to it form a cycloheptene group or a 7-membered heterocyclic group, each of which is independently bound by 0-5 R atoms. CThe substitution is made by replacing the R atoms on any two adjacent ring atoms of the cycloheptenyl or 7-membered heterocyclic group. C The atoms bonded to it form 5-6-membered heteroaryl groups, which are independently and optionally R D replace.

[0181] In some embodiments, ring B is selected from phenyl, and R is located on any two adjacent ring atoms of the phenyl group. B The atoms bonded to it form a cycloheptene group or a 7-membered heterocyclic group, each of which is independently bound by 0-5 R atoms. C The substitution is made by replacing the R atoms on any two adjacent ring atoms of the cycloheptenyl or 7-membered heterocyclic group. C The atoms bonded to it form a pyrazol group, which is optionally R D replace.

[0182] In some embodiments, the 7-10 membered heterocyclic group or the 7, 8, 9 or 10 membered heterocyclic group contains one, two or three heteroatoms independently selected from O, S or N.

[0183] In some embodiments, the 7-10 membered heterocyclic group or the 7, 8, 9 or 10 membered heterocyclic group contains one or two O heteroatoms.

[0184] In some embodiments, ring B is selected from C5-C8 cycloalkyl or 5-8 membered heterocyclic groups, wherein R is present on any two adjacent ring atoms of the C5-C8 cycloalkyl or 5-8 membered heterocyclic group. B The atoms bonded to it form a phenyl group, which is denoted by 0-5 R atoms. C replace.

[0185] In some embodiments, ring B is selected from C5-C6 cycloalkyl or 5-6 membered heterocyclic groups, wherein R is present on any two adjacent ring atoms of the C5-C6 cycloalkyl or 5-6 membered heterocyclic group. B The atoms bonded to it form a phenyl group, which is denoted by 0-5 R atoms. C replace.

[0186] In some implementation schemes, each R C It is selected from OH, halogens or C1-C6 alkyl groups.

[0187] In some implementation schemes, each R C It is a halogen, such as F or Cl.

[0188] In some implementations, R on any two adjacent ring atoms C The atoms bonded to it form C3-C 10 Cycloalkyl, 4-10 membered heterocyclic, phenyl, or 5-6 membered heteroaryl, wherein the C3-C 10Cycloalkyl, 4-10-membered heterocyclic, phenyl, or 5-6-membered heteroaryl groups are independently and optionally R D replace.

[0189] In some implementations, R on any two adjacent ring atoms C The atoms attached thereto form phenyl or 5-6-membered heteroaryl groups, wherein each phenyl or 5-6-membered heteroaryl group is independently and optionally R D replace.

[0190] In some implementations, R on any two adjacent ring atoms C The atoms bonded to it form 5-6-membered heteroaryl groups, which are optionally R D replace.

[0191] In some implementations, R on any two adjacent ring atoms C The atoms bonded to it form a pyrazol group, which is optionally R D replace.

[0192] In some implementation schemes, structural units Selected from Where t is selected from 0, 1, 2, 3, 4, or 5; R B R C R D m is defined as above.

[0193] In some implementation schemes, structural units Selected from Where t is selected from 0, 1, 2, 3, 4, or 5; R B R C R D , m as defined above. In some implementations, t is 0, 1, 2, 3 or 4.

[0194] In some implementation schemes, structural units Selected from R B R C R D As defined above.

[0195] In some implementation schemes, structural units Selected from

[0196] In some implementation schemes, structural units Selected from

[0197] In some implementation schemes, structural units Selected from

[0198] In some implementation schemes, structural units Selected from

[0199] In some implementation schemes, R 12a R B The atoms bonded to it form C5-C7 cycloalkenyl or 5-7 membered heterocyclic groups, wherein R B Located in CR 12a R 12b The adjacent positions of the ring atoms in the connected ring B.

[0200] In some implementation schemes, R 12a R B The atoms connected to it form a C5 cycloalkenyl or a 5-membered heterocyclic group, wherein R B Located in CR 12a R 12b The adjacent positions of the ring atoms in the connected ring B.

[0201] In some embodiments, the 5-7 membered heterocyclic group or the 5, 6, 7 membered heterocyclic group contains one, two, or three heteroatoms independently selected from O, S, and N. In some embodiments, the 5-7 membered heterocyclic group or the 5, 6, 7 membered heterocyclic group contains one, two, or three O heteroatoms. In some embodiments, the 5-7 membered heterocyclic group or the 5, 6, 7 membered heterocyclic group contains one O heteroatom.

[0202] In some implementations, ring B is phenyl, and R 12a R B The atoms bonded to it form C5-C7 cycloalkenyl or 5-7 membered heterocyclic groups, wherein R B Located in CR 12a R 12b The adjacent positions of the ring atoms in the connected ring B.

[0203] In some implementation schemes, Selected from the following structural units:

[0204] In some embodiments, the compound represented by formula (I) or its stereoisomer or a pharmaceutically acceptable salt thereof is selected from the compound represented by formula (Ia) or its stereoisomer or a pharmaceutically acceptable salt thereof:

[0205] Among them, Z 1 Z 2 Z 3 Z 4 Z 5 Independently selected from CH and CR B Or N;

[0206] W 1 W 2 W 3 W 4 W 5 W 6 X, R 8 R 9 R 10a R 10b R 11 R 12a R 12b R 13 R 14a R 14b R 15 R 16 R 17 R 18 R B As defined above.

[0207] In some implementation schemes, Z 1 Z 2 Z 3 Z 4 Z 5 At least one of them is N.

[0208] In some implementation schemes, Z 4 For N, Z 1 Z 2 Z 3 Z 5 Independently selected from CH or CR B .

[0209] In some implementation schemes, Z 1 Z 2 Z 3 Z 4 Z 5 Independently selected from CH or CR B .

[0210] In some implementation schemes, Z 1 Z 3 Z 4 Both are CH; Z 2 Z 5 All are CR B .

[0211] In some implementation schemes, Z 1 Z 3 Z 4 Both are CH; Z 2 Z 5 All are CR B ;R 12a R B The atoms attached to it form C5-C7 cycloalkyl, C5-C7 cycloalkenyl or 5-7 membered heterocyclic groups.

[0212] In some implementation schemes, Z 1 Z 3 Both are CH; Z 2 Z 4 Z 5 All are CR B R on adjacent ring atoms B The atoms bonded to it form C7-C 10 Cycloalkenyl or 7-10 membered heterocyclic group, wherein the C7-C 10 Each cycloalkenyl or 7-10 membered heterocyclic group is independently bounded by 0-5 R groups. C replace.

[0213] In some implementation schemes, Z 2 Z 5 Both are CH; Z 1 Z 3 Z 4 All are CR B R on adjacent ring atoms B The atoms bonded to it form C7-C 10 Cycloalkenyl or 7-10 membered heterocyclic group, wherein the C7-C 10 Each cycloalkenyl or 7-10 membered heterocyclic group is independently bounded by 0-5 R groups. C replace.

[0214] In some embodiments, the compound represented by formula (Ia) or its stereoisomer or a pharmaceutically acceptable salt thereof is selected from the compound represented by formula (Ia-1) or its stereoisomer or a pharmaceutically acceptable salt thereof:

[0215] Among them, Z 4 Selected from CH, CR B Or N;

[0216] W 1 W 2 W 3 W 4 W 5 W 6 X, R 8 R 9 R 10aR 10b R 11 R 12a R 12b R 13 R 14a R 14b R 15 R 16 R 17 R 18 R B As defined above.

[0217] In some implementation schemes, Z 4 Selected from CH or N.

[0218] In some implementation schemes, R B Selected from NH2 or C1-C6 alkoxy groups, wherein the NH2 or C1-C6 alkoxy group is surrounded by 0-5 R groups. M replace.

[0219] In some implementation schemes, R B The NH2 is NH2, which is reacted by 0-5 R... M replace.

[0220] In some implementation schemes, R B It is a C1-C6 alkoxy group, wherein the C1-C6 alkoxy group is surrounded by 0-5 R groups. M replace.

[0221] In some embodiments, the compound of formula (I) or its stereoisomer or a pharmaceutically acceptable salt thereof is selected from the compound of formula (Ib) or its stereoisomer or a pharmaceutically acceptable salt thereof:

[0222] in, Indicates a single or double bond;

[0223] Y 1 Y 2 Y 3 Independently selected from CH2 and CHR C C(R) C 2. O, S, or NH;

[0224] Y 4 Y 5 Independently selected from CH2 and CR C CHR C C(R) C 2. O, S, or NH;

[0225] W 1 W 2 W 3 W 4W 5 W 6 X, R 8 R 9 R 10a R 10b R 11 R 12a R 12b R 13 R 14a R 14b R 15 R 16 R 17 R 18 Z 1 Z 2 Z 3 R C As defined above.

[0226] In some implementation schemes, Indicates a single key.

[0227] In some implementation schemes, Y represents a single bond. 1 Y 5 Both are O, Y 2 Y 4 Both are CH2, Y 3 Selected from CH2 or C(R) C )2.

[0228] In some implementation schemes, Y 4 Y 5 Independently selected from CR C or CHR C Y 1 Y 3 Both are CH2, Y 2 It is CH2 or O, and the R on the adjacent ring atom C The atoms bonded to it form C3-C 10 Cycloalkyl, 4-10 membered heterocyclic, phenyl, or 5-6 membered heteroaryl, wherein the C3-C 10 Cycloalkyl, 4-10-membered heterocyclic, phenyl, or 5-6-membered heteroaryl groups are independently and optionally R D replace.

[0229] In some implementation schemes, Y 4 Y 5 All are CR C Y 1 Y 3 Both are CH2, Y 2 It is CH2 or O, and the R on the adjacent ring atom CThe atoms bonded to it form 5-6-membered heteroaryl groups, wherein the 5-6-membered heteroaryl groups are optionally R D replace.

[0230] In some embodiments, the compound represented by formula (I) or its stereoisomer or a pharmaceutically acceptable salt thereof is selected from the compound represented by formula (Ib-1) or its stereoisomer or a pharmaceutically acceptable salt thereof:

[0231] in,

[0232] Y 1 Y 2 Y 3 Y 4 Y 5 Independently selected from CH2 and CHR C C(R) C 2. O, S, or NH;

[0233] W 1 W 2 W 3 W 4 W 5 W 6 X, R 8 R 9 R 10a R 10b R 11 R 12a R 12b R 13 R 14a R 14b R 15 R 16 R 17 R 18 Z 1 Z 2 Z 3 R C As defined above.

[0234] In some implementation schemes, Y 1 Y 2 Y 3 Y 4 Y 5 Independently selected from CH2 and CHR C O, S or NH.

[0235] In some implementation schemes, Y 1 Y 2 Y 3 Y 4 Y 5 At least one of them is O, S, or NH.

[0236] In some implementation schemes, Y 1 Y 2 Y 3 Y 4 Y 5 At least one of them is 0.

[0237] In some implementation schemes, Y 1 Y 5 Both are O, Y 2 Y 4 Both are CH2, Y 3 CH2 or C(R) C )2.

[0238] In some implementation schemes, Y 1 Y 5 Both are O, Y 2 Y 3 Y 4 Both are CH2.

[0239] In some implementation schemes, Y 4 Y 5 All are CHR C Y 1 Y 3 Both are CH2, Y 2 It can be CH2 or O.

[0240] In some implementation schemes, Y 4 Y 5 All are CHR C Y 1 Y 3 Both are CH2, Y 2 It is CH2 or O, and the R on the adjacent ring atom C The atoms bonded to it form C3-C 10 Cycloalkyl, 4-10 membered heterocyclic, phenyl, or 5-6 membered heteroaryl, wherein the C3-C 10 Cycloalkyl, 4-10-membered heterocyclic, phenyl, or 5-6-membered heteroaryl groups are independently and optionally R D replace.

[0241] In some embodiments, the compound represented by formula (I) or its stereoisomer or a pharmaceutically acceptable salt thereof is selected from the compounds represented by formulas (Ic-X) or their stereoisomers or pharmaceutically acceptable salts thereof:

[0242] in, Indicates a single or double bond;

[0243] R 6a R6b It is independently selected from H, deuterium, halogen or C1-C4 alkyl, and at least one of them is not H;

[0244] W 1 W 2 W 3 W 4 W 5 W 6 R 8 R 9 R 10a R 10b R 11 R 12a R 12b R 13 R 14a R 14b R 15 R 16 R 17 R 18 Ring B, R B m is defined as above.

[0245] In some embodiments, the compound of formula (I) or formulas (Ic-X), or its stereoisomers or pharmaceutically acceptable salts thereof, is selected from the compound of formula (Ic), or its stereoisomers or pharmaceutically acceptable salts thereof:

[0246] Among them, R 6a R 6b It is independently selected from H, deuterium, halogen or C1-C4 alkyl, and at least one of them is not H;

[0247] W 1 W 2 W 3 W 4 W 5 W 6 R 8 R 9 R 10a R 10b R 11 R 12a R 12b R 13 R 14a R 14b R 15 R 16 R 17 R 18 Ring B, R B m is defined as above.

[0248] In some implementation schemes, R 6aSelected from H, deuterium, halogens or C1-C4 alkyl groups, R 6b Selected from halogens or C1-C4 alkyl groups.

[0249] In some implementation schemes, R 6a Selected from H or halogen, R 6b Selected from halogens or C1-C4 alkyl groups.

[0250] In some implementation schemes, R 6a R 6b All are halogens, such as F. In some implementations, R 6a For H, R 6b It is CH3.

[0251] In some embodiments, the compound of formula (I) or its stereoisomer or a pharmaceutically acceptable salt thereof is selected from the compound of formula (II) or its stereoisomer or a pharmaceutically acceptable salt thereof:

[0252] Among them, rings B and W 1 W 2 W 3 W 5 W 6 X, R 8 R 9 R 10a R 10b R 11 R 12a R 12b R 15 R 16 R 17 R 18 R B m is defined as above.

[0253] In some embodiments, the compound of formula (I) or its stereoisomer or a pharmaceutically acceptable salt thereof is selected from the compound of formula (III) or its stereoisomer or a pharmaceutically acceptable salt thereof:

[0254] Among them, rings B and W 1 W 2 W 3 W 5 W 6 X, R 8 R 9 R 10a R 10b R 11 R 12a R 12b R 14 R 15 R16 R 17 R 18 R B m is defined as above.

[0255] In some embodiments, the compound represented by formula (I) or its stereoisomer or a pharmaceutically acceptable salt thereof is selected from the following compounds or their stereoisomers or pharmaceutically acceptable salts:

[0256] On the other hand, this disclosure provides pharmaceutical compositions comprising a compound of formula (I) or formula (Ia) or formula (Ia-1) or formula (Ib) or formula (Ib-1) or formula (Ic) or formula (Ic-X) or formula (II) or formula (III) of this disclosure, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

[0257] On the other hand, this disclosure provides a method for treating diseases mediated by Cyclin A and / or Cyclin B in mammals, comprising administering to a mammal, preferably a human, a therapeutically effective amount of a compound of formula (I) or formula (Ia) or formula (Ia-1) or formula (Ib) or formula (Ib-1) or formula (Ic) or formula (Ic-X) or formula (II) or formula (III) or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

[0258] On the other hand, this disclosure provides the use of compounds of formula (I) or formula (Ia) or formula (Ia-1) or formula (Ib) or formula (Ib-1) or formula (Ic) or formula (Ic-X) or formula (II) or formula (III) or their stereoisomers or pharmaceutically acceptable salts, or pharmaceutical compositions thereof, in the preparation of medicaments for the prevention or treatment of Cyclin A and / or Cyclin B mediated diseases.

[0259] On the other hand, this disclosure provides the use of compounds of formula (I) or formula (Ia) or formula (Ia-1) or formula (Ib) or formula (Ib-1) or formula (Ic) or formula (Ic-X) or formula (II) or formula (III) or their stereoisomers or pharmaceutically acceptable salts, or pharmaceutical compositions thereof, in the prevention or treatment of Cyclin A and / or Cyclin B mediated diseases.

[0260] On the other hand, this disclosure provides compounds of formula (I) or formula (Ia) or formula (Ia-1) or formula (Ib) or formula (Ib-1) or formula (Ic) or formula (Ic-X) or formula (II) or formula (III) for the prevention or treatment of Cyclin A and / or Cyclin B mediated diseases, or stereoisomers thereof, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof.

[0261] In some implementations, the diseases mediated by Cyclin A and / or Cyclin B are selected from tumors.

[0262] On the other hand, this disclosure provides a method for preventing or treating tumors in mammals, comprising administering to a mammal, preferably a human, a therapeutically effective amount of a compound of formula (I) or formula (Ia) or formula (Ia-1) or formula (Ib) or formula (Ib-1) or formula (Ic) or formula (Ic-X) or formula (II) or formula (III) or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

[0263] On the other hand, this disclosure provides the use of compounds of formula (I) or formula (Ia) or formula (Ia-1) or formula (Ib) or formula (Ib-1) or formula (Ic) or formula (Ic-X) or formula (II) or formula (III) or their stereoisomers or pharmaceutically acceptable salts, or pharmaceutical compositions thereof, in the preparation of medicaments for the prevention or treatment of tumors.

[0264] On the other hand, this disclosure provides the use of compounds of formula (I) or (Ia) or (Ia-1) or (Ib) or (Ib-1) or (Ic) or (Ic-X) or (II) or (III) or their stereoisomers or pharmaceutically acceptable salts, or pharmaceutical compositions thereof, in the prevention or treatment of tumor diseases.

[0265] On the other hand, this disclosure provides compounds of formula (I) or formula (Ia) or formula (Ia-1) or formula (Ib) or formula (Ib-1) or formula (Ic) or formula (Ic-X) or formula (II) or formula (III) for the prevention or treatment of tumors, or stereoisomers thereof, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof.

[0266] In some implementations, the tumor is selected from cancer.

[0267] In some implementations, the cancer is selected from ovarian cancer or lung cancer.

[0268] Any embodiment of any aspect of this disclosure may be combined with other embodiments without contradiction. Furthermore, in any embodiment of any aspect of this disclosure, any technical feature may be applied to the same technical feature in other embodiments without contradiction.

[0269] Terminology Definitions and Explanations

[0270] Unless otherwise stated, the terms used in this disclosure have the following meanings: the definitions of groups and terms recorded in this disclosure, including their definitions as examples, exemplary definitions, preferred definitions, definitions recorded in tables, definitions of specific compounds in the examples, etc., can be arbitrarily combined and combined with each other. A particular term should not be considered uncertain or unclear unless specifically defined, but should be understood in accordance with its ordinary meaning in the art. When trade names appear herein, they are intended to refer to the corresponding product or its active ingredient.

[0271] In this article Indicates the connection site.

[0272] The compounds labeled in this article The term indicates a double bond cis-trans isomer, meaning that the position is either a cis isomer or a trans isomer, or a mixture of cis-trans isomers.

[0273] When a compound's chiral center is marked "or 1", it indicates a single isomer, and the absolute configuration has not yet been determined. For example, The representative is One of the compounds has a single configuration, and its chirality is not confirmed.

[0274] The term "stereoisomer" refers to isomers that are produced by different spatial arrangements of atoms in a molecule, including cis-trans isomers, enantiomers and diastereomers.

[0275] The compounds disclosed herein may have asymmetric atoms such as carbon, sulfur, nitrogen, and phosphorus atoms, or asymmetric double bonds, and therefore may exist in specific geometric or stereoisomeric forms. Specific geometric or stereoisomeric forms may be cis and trans isomers, E- and Z-type geometric isomers, (-)- and (+)-enantiomers, (R)- and (S)-enantiomers, diastereomers, (D)- isomers, (L)- isomers, and racemic mixtures thereof or other mixtures, such as mixtures enriched with enantiomers or diastereomers. All such isomers and mixtures thereof are within the scope of the definition of the compounds disclosed herein. Alkyl groups or other substituents may contain additional asymmetric carbon atoms, asymmetric sulfur atoms, asymmetric nitrogen atoms, or asymmetric phosphorus atoms. All such isomers involved in all substituents, and mixtures thereof, are also included within the scope of the definition of the compounds disclosed herein. The compounds containing asymmetric atoms disclosed herein can be isolated in optically active pure form or in racemic form. The optically active pure form can be separated from racemic mixtures or synthesized using chiral starting materials or chiral reagents.

[0276] The term "substituted" refers to the substitution of one or more hydrogen atoms on a specific atom by a substituent, provided that the valence state of the specific atom is normal and the resulting compound is stable. When the substituent is oxo (i.e., =O), it means that two hydrogen atoms are substituted; oxo substitution does not occur on aromatic groups.

[0277] The terms “optional” or “optionally” mean that the event or condition subsequently described may or may not occur, including both the occurrence and non-occurrence of said event or condition. For example, “optionally” substituted with a halogen means that the ethyl group can be unsubstituted (CH2CH3), monosubstituted (CH2CH2F, CH2CH2Cl, etc.), polysubstituted (CHFCH2F, CH2CHF2, CHFCH2Cl, CH2CHCl2, etc.), or fully substituted (CF2CF3, CF2CCl3, CCl2CCl3, etc.). Those skilled in the art will understand that for any group containing one or more substituents, no substitution or substitution pattern that is spatially impossible and / or cannot be synthesized is introduced.

[0278] When any variable (e.g., R) a R b When a group appears more than once in the composition or structure of a compound, its definition is independent in each case. For example, if a group is surrounded by two R... b Replaced, then each R b Each has its own independent options.

[0279] When a substituent is cross-bonded to two atoms on a ring, it can bond with any atom on that ring.

[0280] If the linking group mentioned in this article does not specify its linking direction, then its linking direction is arbitrary. For example, when the structural unit... When X is selected from "-CH2-O-CH2-CH2-O-CH2-CH2-", X can be connected from left to right to form the following units. Alternatively, the following units can be formed by connecting them from right to left.

[0281] When a substituent is cross-bonded to two atoms on a ring, it can bond with any atom on that ring.

[0282] C in this article m -C n It refers to having an integer number of carbon atoms in the range mn. For example, "C1-C 10"" means that the group can have 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 carbon atoms.

[0283] The term "alkyl" refers to a compound with the general formula C1. n H 2n+1 The alkyl group can be straight-chain or branched. The term "C1-C" refers to a hydrocarbon group. 10 "Alkyl" can be understood as representing a straight-chain or branched saturated hydrocarbon group having 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 carbon atoms. Specific examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl, 2-methylbutyl, 1-methylbutyl, 1-ethylpropyl, 1,2-dimethylpropyl, neopentyl, 1,1-dimethylpropyl, 4-methylpentyl, 3-methylpentyl, 2-methylpentyl, 1-methylpentyl, 2-ethylbutyl, 1-ethylbutyl, 3,3-dimethylbutyl, and 2,2-dimethylbutyl. 1,1-Dimethylbutyl, 2,3-Dimethylbutyl, 1,3-Dimethylbutyl, or 1,2-Dimethylbutyl, etc.; the term "C1-C6 alkyl" can be understood as referring to alkyl groups having 1, 2, 3, 4, 5, or 6 carbon atoms, specific examples including but not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, neopentyl, hexyl, 2-methylpentyl, etc. The term "C1-C3 alkyl" can be understood as referring to straight-chain or branched saturated alkyl groups having 1, 2, or 3 carbon atoms. The "C1-C6"... 10 "alkyl" can contain "C8-C" 10 The range includes "alkyl", "C1-C6 alkyl" or "C1-C4 alkyl", and the "C1-C6 alkyl" may further include "C1-C4 alkyl".

[0284] The term "alkylene" refers to a divalent group derived from an "alkyl" group as defined herein.

[0285] The term “heteroalkyl” refers to an alkyl group in which one or more -CH2- atoms are replaced by heteroatoms independently selected from NH, O and S, wherein the alkyl group is as defined above.

[0286] The term “heteroalkyl” refers to a divalent group derived from a “heteroalkyl” group as defined herein.

[0287] The term "alkenyl" refers to an unsaturated aliphatic hydrocarbon group consisting of a straight or branched chain of carbon and hydrogen atoms and having at least one double bond. The term "C2-C"... 10"Alkenyl" can be understood as representing a straight-chain or branched unsaturated hydrocarbon group containing one or more double bonds and having 2, 3, 4, 5, 6, 7, 8, 9, or 10 carbon atoms, "C2-C". 10 "Alkenyl" can include "C2-C6 alkenyl", "C8-C6 alkenyl", and "C8-C6 alkenyl". 10 The term "alkenyl" is preferred; more preferably "C2-C6 alkenyl", further preferably "C2-C4 alkenyl", and even more preferably C2 or C3 alkenyl. It is understood that when the alkenyl group contains more than one double bond, the double bonds may be separable or conjugated. Specific examples of the alkenyl group include, but are not limited to, vinyl, allyl, (E)-2-methylvinyl, (Z)-2-methylvinyl, (E)-but-2-enyl, (Z)-but-2-enyl, (E)-but-1-enyl, (Z)-but-1-enyl, isopropenyl, 2-methylprop-2-enyl, 1-methylprop-2-enyl, 2-methylprop-1-enyl, (E)-1-methylprop-1-enyl, or (Z)-1-methylprop-1-enyl, etc.

[0288] The term "alkenyl" refers to a divalent group derived from an "alkenyl" group as defined herein.

[0289] The term "alkynyl" refers to a straight-chain or branched unsaturated aliphatic hydrocarbon group consisting of carbon and hydrogen atoms and having at least one triple bond. The term "C2-C"... 10 "Alkyne" can be understood as representing a straight-chain or branched unsaturated hydrocarbon group containing one or more triple bonds and having 2, 3, 4, 5, 6, 7, 8, 9, or 10 carbon atoms. "C2-C" 10 Examples of "alkynyl" include, but are not limited to, ethynyl (-C≡CH) and propynyl (-C≡CCH). 3、 -CH2C≡CH), but-1-ynyl, but-2-ynyl, or but-3-ynyl. "C2-C 10 "Alynyl" can include "C2-C3 alkynyl", and examples of "C2-C3 alkynyl" include ethynyl (-C≡CH), propynyl-1-alkynyl (-C≡CCH3), and propynyl-2-alkynyl (-CH2C≡CH).

[0290] The term "haloalkyl" is intended to include both monohaloalkyl and polyhaloalkyl. For example, the term "C1-C6 haloalkyl" refers to C1-C6 alkyl groups as defined above that are substituted with one or more halogens, including but not limited to trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, trichloromethyl, pentafluoroethyl, and pentachloroethyl, etc. The term "alkoxy" refers to the substitution of a hydrogen atom on the hydroxyl group of a straight-chain or branched alcohol by an alkyl group, and can be understood as "alkyloxy" or "alkyl-O-".

[0291] The term "C1-C" 10 "Alkoxy" can be understood as "C1-C"10 "alkyloxy" or "C1-C" 10 Alkyl-O-"; the term "C1-C6 alkoxy" can be understood as "C1-C6 alkyloxy" or "C1-C6 alkyl-O-". The "C1-C" 10 "Alkoxy" can include the range of "C1-C6 alkoxy" and "C1-C3 alkoxy", and the "C1-C6 alkoxy" can further include "C1-C3 alkoxy".

[0292] The term "cycloalkyl" refers to a fully saturated carbon ring existing in the form of a monocyclic, fused, bridged, or spirocyclic ring. Unless otherwise indicated, the carbon ring is typically a 3- to 15-membered ring. The term "C3-C" is also used. 15 "Cycloalkyl" can be understood as representing a saturated monocyclic, fused, spirocyclic, or bridged ring having 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 carbon atoms. Specific examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, norbornyl (bicyclo[2.2.1]heptyl), bicyclo[2.2.2]octyl, adamantyl, spiro[4.5]decyl, etc. The term "C3-C" 15 "Cycloalkyl" can contain "C6-C 15 cycloalkyl, C5-C 12 cycloalkyl, C9-C 14 "Cycloalkyl" and "C3-C6 cycloalkyl" are terms that can be understood as indicating a fully saturated monocyclic or bicyclic hydrocarbon ring having 3, 4, 5 or 6 carbon atoms. Specific examples include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.

[0293] The term "cycloalkenyl" refers to a non-aromatic carbon ring that is not fully saturated and exists in the form of a monocyclic, fused, bridged, or spirocyclic ring, having at least one double bond. Unless otherwise indicated, the carbon ring is typically a 5- to 10-membered ring. Specific examples of cycloalkenyl include, but are not limited to, cyclopentenyl, cyclopentadienyl, cyclohexenyl, cyclohexadienyl, cycloheptenyl, or cycloheptadienyl.

[0294] The term "heterocyclic group" or "heterocycle" refers to a fully saturated or partially saturated (not aromatic as a whole) monocyclic, fused, spirocyclic, or bridged ring containing 1, 2, 3, 4, or 5 heteroatoms or heteroatom groups (i.e., groups containing heteroatoms). These "heteratoms or heteroatom groups" include, but are not limited to, nitrogen (N), oxygen (O), sulfur (S), phosphorus (P), boron (B), -S(=O)2-, -S(=O)-, -P(=O)2-, -P(=O)-, -NH-, -S(=O)(=NH)-, -C(=O)NH-, or -NHC(=O)NH-, etc. The term "6-15 membered heterocyclic group" refers to a heterocyclic group with 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ring atoms, and whose ring atoms contain 1, 2, 3, 4, or 5 independently selected heteroatoms or heterogroups as described above. The term "4-12 membered heterocyclic group" refers to a heterocyclic group with 4, 5, 6, 7, 8, 9, 10, 11, or 12 ring atoms, and whose ring atoms contain 1, 2, 3, 4, or 5 independently selected heteroatoms or heterogroups as described above. "3-10 membered heterocyclic groups" include "4-7 membered heterocyclic groups", wherein specific examples of 4 membered heterocyclic groups include, but are not limited to, azirrocyclobutane, thioheterocyclobutane, or oxoheterocyclobutane; specific examples of 5 membered heterocyclic groups include, but are not limited to, tetrahydrofuranyl, dioxacyclopentenyl, pyrrolyl, imidazoalkyl, pyrazolyl, pyrrolinyl, 4,5-dihydrooxazolyl, or 2,5-dihydro-1H-pyrrolyl; specific examples of 6 membered heterocyclic groups include, but are not limited to, tetrahydropyranyl, piperidinyl, morpholinyl, dithiaalkyl, thiomorpholinyl, piperazinyl, trithiaalkyl, tetrahydropyridinyl, or 4H-[1,3,4]thiadiazinyl; and specific examples of 7 membered heterocyclic groups include, but are not limited to, diazacycloheptane. The heterocyclic group can also be a bicyclic group, wherein specific examples of 5,5-membered bicyclic groups include, but are not limited to, hexahydrocyclopentano[c]pyrrolo-2(1H)-yl or; specific examples of 5,6-membered bicyclic groups include, but are not limited to, hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl, 5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazinyl or 5,6,7,8-tetrahydroimidazo[1,5-a]pyrazinyl. Optionally, the heterocyclic group can be a benzofused cyclic group of the above-mentioned 4-7-membered heterocyclic groups, specific examples of which include, but are not limited to, dihydroisoquinolinyl, etc.The term "4-12-membered heterocyclic group" can include the ranges of "4-10-membered heterocyclic group", "5-12-membered heterocyclic group", "5-10-membered heterocyclic group", "4-7-membered heterocyclic group", "5-6-membered heterocyclic group", "6-8-membered heterocyclic group", "4-10-membered heterocyclic alkyl group", "5-10-membered heterocyclic alkyl group", "4-7-membered heterocyclic alkyl group", "5-6-membered heterocyclic alkyl group", and "6-8-membered heterocyclic alkyl group". "4-7-membered heterocyclic group" can further include the ranges of "4-6-membered heterocyclic group", "5-6-membered heterocyclic group", "4-7-membered heterocyclic alkyl group", "4-6-membered heterocyclic alkyl group", and "5-6-membered heterocyclic alkyl group". Although some bicyclic heterocyclic groups in this disclosure partially contain a benzene ring or a heteroaromatic ring, the heterocyclic group as a whole is still non-aromatic.

[0295] The term "aryl" refers to an aromatic ring group consisting of an all-carbon monocyclic or fused polycyclic aromatic cyclic group with a conjugated π-electron system. Aryl groups can have 6-20, 6-14, or 6-12 carbon atoms. The term "C6-C"... 20 "Aryl" can be understood as an aryl group having 6 to 20 carbon atoms. Specifically, it refers to a ring with 6 carbon atoms ("C6 aryl"), such as phenyl; or a ring with 9 carbon atoms ("C9 aryl"), such as indenyl or indenyl; or a ring with 10 carbon atoms ("C9 aryl"). 10 Aryl groups, such as tetrahydronaphthyl, dihydronaphthyl, or naphthyl; or rings having 13 carbon atoms (“C”). 13 Aryl groups, such as fluorene groups; or rings with 14 carbon atoms (“C”). 14 Aryl), for example, anthracene. The term "C6-C" is used. 10 "Aryl" can be understood as an aryl group having 6 to 10 carbon atoms. Specifically, it refers to a ring with 6 carbon atoms ("C6 aryl"), such as phenyl; or a ring with 9 carbon atoms ("C9 aryl"), such as indenyl or indenyl; or a ring with 10 carbon atoms ("C9 aryl"). 10 Aryl), such as tetrahydronaphthyl, dihydronaphthyl, or naphthyl. The term "C6-C" is used. 20 "Aryl" can contain "C6-C 10 Aryl.

[0296] The term "heteroaryl" refers to an aromatic monocyclic or fused polycyclic system containing at least one ring atom selected from N, O, or S, with the remaining ring atoms being C. The term "5-10-membered heteroaryl" can be understood to include monocyclic or bicyclic aromatic ring systems having 5, 6, 7, 8, 9, or 10 ring atoms, particularly 5, 6, 9, or 10 ring atoms, and containing 1, 2, 3, 4, or 5, preferably 1, 2, or 3 heteroatoms independently selected from N, O, and S. Specifically, the heteroaryl group is selected from thienyl, furanyl, pyrroleyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl or thiadiazolyl and their benzo[derivatives], such as benzofuranyl, benzothienyl, benzothiazolyl, benzooxazolyl, benzoisooxazolyl, benzoimidazolyl, benzotriazolyl, indazole, indolyl or isindolyl; or pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl or triazinyl and their benzo[derivatives], such as quinolinyl, quinazolinyl or isoquinolinyl; or acrylinyl, inazinyl, purinyl and their benzo[derivatives]; or cyclolinyl, phthalazinyl, quinazolinyl, quinoxolinyl, naphthidyl, pteridinyl, carbazolyl, acrylinyl, phenazinyl, phenothiazinyl or phenothiazinyl. The term "5-6 heteroaryl" refers to an aromatic ring system having 5 or 6 ring atoms, and containing 1, 2 or 3, preferably 1-2 heteroatoms independently selected from N, O and S.

[0297] The term "halogen" or "halogen" refers to fluorine, chlorine, bromine, or iodine.

[0298] The term "treatment" means administering the compound or preparation described in this application to improve or eliminate a disease or one or more symptoms related to said disease, and includes:

[0299] (i) Suppress the disease or disease state, that is, curb its development;

[0300] (ii) Relieve the disease or disease state, even if the disease or disease state subsides.

[0301] The term “prevention” means administering the compound or formulation described in this application to prevent a disease or one or more symptoms associated with the disease, including preventing the occurrence of a disease or disease state in mammals, particularly when such mammals are susceptible to the disease state but have not yet been diagnosed with the disease state.

[0302] The term "therapeutic effective dose" means:

[0303] The amount of the disclosed compound used to treat a specific disease, condition or symptom, (ii) reduce, improve or eliminate one or more symptoms of a specific disease, condition or symptom, or (iii) delay the onset of one or more symptoms of a specific disease, condition or symptom described herein.

[0304] The amount of the disclosed compound constituting a “therapeutic effective amount” varies depending on the compound, the disease state and its severity, the route of administration, and the age of the mammal to be treated, but may routinely be determined by a person skilled in the art based on their own knowledge and the content of this disclosure.

[0305] The term "pharmaceutical acceptable" refers to compounds, materials, compositions, and / or dosage forms that, within the bounds of reliable medical judgment, are suitable for use in contact with human and animal tissues without excessive toxicity, irritation, allergic reactions, or other problems or complications, in proportion to a reasonable benefit / risk ratio.

[0306] The term "pharmaceutically acceptable salt" refers to a pharmaceutically acceptable salt that has undergone acid or base addition, including salts formed by compounds with inorganic or organic acids, and salts formed by compounds with inorganic or organic bases.

[0307] The term "pharmaceutical composition" refers to a mixture of one or more compounds of the present disclosure or salts thereof with pharmaceutically acceptable excipients. The purpose of a pharmaceutical composition is to facilitate the administration of the disclosed compounds to an organism.

[0308] The term "pharmaceuticalally acceptable excipient" refers to excipients that do not cause significant irritation to the organism and do not impair the biological activity and properties of the active compound. Suitable excipients are well known to those skilled in the art, such as carbohydrates, waxes, water-soluble and / or water-swellable polymers, hydrophilic or hydrophobic materials, gelatin, oils, solvents, water, etc.

[0309] The word “comprise” or “include” and its English variants such as comprises or comprising can be understood as having an open, non-exclusive meaning, that is, “including but not limited to”.

[0310] This disclosure also includes compounds of this disclosure that are identical to those described herein, but in which one or more atoms are labeled with isotopes whose atomic weights or mass numbers differ from those commonly found in nature. Examples of isotopes that can be incorporated into compounds of this disclosure include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, iodine, and chlorine, such as... 2 H, 3 H, 11 C 13 C 14 C 13 N、 15 N、 15 O、 17 O、 18 O、 31 P, 32 P,35 S, 18 F, 123 I, 125 I and 36 Cl, etc.

[0311] Certain isotope-labeled compounds of this disclosure (e.g., using...) 3 H and 14 C-labeling can be used in the analysis of compound and / or substrate tissue distribution. Tritiumization (i.e., 3 H) and carbon-14 (i.e. 14 C) Isotopes are particularly preferred due to their ease of preparation and detectability. Positron-emitting isotopes, such as... 15 O、 13 N、 11 C and 18 F can be used in positron emission tomography (PET) studies to determine substrate occupancy. The isotopically labeled compounds of this disclosure can typically be prepared by replacing the unlabeled reagent with an isotopically labeled reagent using a procedure similar to those disclosed in the schemes and / or examples below.

[0312] The pharmaceutical compositions disclosed herein can be prepared by combining the compounds disclosed herein with suitable pharmaceutically acceptable excipients, for example, in solid, semi-solid, liquid or gaseous formulations, such as tablets, pills, capsules, powders, granules, ointments, emulsions, suspensions, suppositories, injections, inhalers, gels, microspheres and aerosols.

[0313] Typical routes of administration of the disclosed compounds or their pharmaceutically acceptable salts or pharmaceutical compositions thereof include, but are not limited to, oral, rectal, topical, inhalation, parenteral, sublingual, vaginal, intranasal, intraocular, intraperitoneal, intramuscular, subcutaneous, and intravenous administration.

[0314] The pharmaceutical compositions disclosed herein can be manufactured using methods well known in the art, such as conventional mixing, dissolving, granulation, emulsification, freeze drying, etc.

[0315] In some embodiments, the pharmaceutical composition is in an oral form. For oral administration, the pharmaceutical composition can be formulated by mixing the active compound with pharmaceutically acceptable excipients well known in the art. These excipients enable the compounds of this disclosure to be formulated into tablets, pills, lozenges, sugar-coated tablets, capsules, liquids, gels, pastes, suspensions, etc., for oral administration to patients.

[0316] Solid oral compositions can be prepared using conventional mixing, filling, or tableting methods. For example, they can be obtained by mixing the active compound with solid excipients, optionally milling the resulting mixture, adding other suitable excipients if necessary, and then processing the mixture into granules to obtain the core of a tablet or sugar-coated formulation. Suitable excipients include, but are not limited to, binders, diluents, disintegrants, lubricants, flow aids, or flavoring agents.

[0317] The pharmaceutical composition may also be suitable for parenteral administration, such as in suitable unit dosage forms of sterile solutions, suspensions or lyophilized products.

[0318] In all methods of administration of the compounds of general formula (I) or formula (Ia) or formula (Ia-1) or formula (Ib) or formula (Ib-1) or formula (Ic) or formula (Ic-X) or formula (II) or formula (III) or their stereoisomers or pharmaceutically acceptable salts thereof, the daily dose is from 0.01 mg / kg to 1000 mg / kg body weight, in the form of single or separate doses. Detailed Implementation

[0319] The invention will now be described in detail with reference to embodiments, but this does not imply any adverse limitation of the present disclosure. The present disclosure has been described in detail herein, including specific embodiments thereof. It will be apparent to those skilled in the art that various changes and modifications can be made to the specific embodiments of the present disclosure without departing from the spirit and scope thereof.

[0320] Unless otherwise specified, all reagents used in this disclosure are commercially available and can be used without further purification.

[0321] Unless otherwise stated, the proportions expressed for mixed solvents are volume-based.

[0322] Unless otherwise stated, % refers to wt%.

[0323] Compounds are processed manually or Software naming conventions are used; commercially available compounds use supplier catalog names.

[0324] The structure of the compound was determined by nuclear magnetic resonance (NMR) and / or mass spectrometry (MS). NMR shifts are measured in units of 10⁻⁶. -6 (ppm). The solvents used for NMR determination included deuterated dimethyl sulfoxide, deuterated chloroform, and deuterated methanol, with tetramethylsilane (TMS) as the internal standard. "IC 50 "Half-inhibition concentration" refers to the concentration at which half of the maximum inhibitory effect is achieved.

[0325] The eluent described below can be a mixture of two or more solvents, with the ratio being the volume ratio of each solvent. For example, in a mixed eluent, dichloromethane / methanol = 20 / 1 indicates that the volume ratio of dichloromethane to methanol is 20:1.

[0326] Abbreviations:

[0327] THF: Tetrahydrofuran; n-BuL: n-Butyllithium; 1,4-Dioxane: 1,4-Dioxane; FmocOSU: 9-fluorenylmethyl-N-succinimide carbonate; POM: Paraformaldehyde; TFA: Trifluoroacetic acid; Toluene: Toluene; TES: Triethylsilane; DCM: Dichloromethane; HATU: 2-(7-azabenzotriazolyl)-N,N,N',N'-Tetramethylurea hexafluorophosphate; DIPEA Or DIEA: N,N-diisopropylethylamine; EA: ethyl acetate; DCE: 1,2-dichloroethane; TCFH: N,N,N',N'-tetramethylchloroformamidin hexafluorophosphate; NMI: N-methylimidazolium; ACN: acetonitrile; DMF: N,N-dimethylformamide; Pd(dppf)Cl2: [1'1-bis(diphenylphosphine)ferrocene]palladium dichloride; TsOH: p-toluenesulfonic acid; Piperidine: piperidine; TBDPSC l: tert-butyldiphenylchlorosilane; imidazole; EDCl: 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride; DMAP: 4-dimethylaminopyridine; LDA: lithium diisopropylamino; TPAP: tetrapropylammonium perruthenate; NMO: N-methylmorpholine oxide; NsCl: 4-nitrobenzenesulfonyl chloride; NMP: N-methylpyrrolidone; DBU: 1,8-diazabicyclo[5,4,0]undec-7-ene ; 2,6-Lutidine: 2,6-dimethylpyridine; (Bpin)2: pinacol diboronate; NCS: N-chlorosuccinimide; Py: pyridine; DMA: N,N-dimethylacetamide; Tf2O: trifluoromethanesulfonic anhydride; Xantphos: 4,5-bis(diphenylphosphine-9,9-dimethyloxanthracene; Pd2(dba)3: tris(dibenzylideneacetone)dipalladium; TBAF: tetrabutylammonium fluoride; Dess-Martin Periodiane: DAST: Diethylaminosulfur trifluoride; Piperidine: Piperidine; Ns: p-Nitrobenzenesulfonyl; Zhan catalyst-1B: Zhan catalyst; BOPCl or BOP-Cl: Bis(2-oxo-3-oxazolyl)phosphine chloride; NsCl: p-Nitrobenzenesulfonyl chloride; Oxone: Potassium peroxymonosulfonate; DABCO: 1,4-Dazabicyclo[2,2,2]octane; TBAI: Tetrabutylammonium iodide; PCC: Pyridinium chlorochromate; TMSI: Trimethyliodosilane; HOBt: 1-Hydroxybenzotriazole; TEA: Triethylamine; CuBr-DMS: Cuprous dimethyl sulfide bromide; Boc2O: Ditert-butyl dicarbonate; BnOH: Benzyl alcohol; t-BuOK: Potassium tert-butoxide; Et2NH: Diethylamine; Hoveyda-Grubbs 2 nd HG 2 nd; Benzaldehyde; Cbz-Cl: benzyl chloroformate; Cbz: benzyloxycarbonyl; KHMDS: potassium bis(trimethylsilylamino)amino; TMSCH2N2: trimethylsilyldiazomethane; KOsO4.2H2O: potassium osmium dihydrate.

[0328] Synthesis of Int 1

[0329] Step 1: Synthesis of intermediate Int1-1

[0330] (R)-2,5-dihydro-3,6-dimethoxy-2-isopropylpyrazine (13.0 g, 70.56 mmol) was dissolved in tetrahydrofuran (200 mL). Under nitrogen protection, n-butyllithium (2.5 M, 36.69 mL) was slowly added at -78 °C, and the mixture was stirred at -78 °C for 30 min. Then, a tetrahydrofuran solution (120 mL) of 2-bromo-4-chlorobenzyl bromide (22.1 g, 77.62 mmol) was slowly added, and the reaction was continued at -78 °C for 3 h. The reaction was quenched by adding saturated ammonium chloride solution (100 mL), and the layers were separated. The aqueous phase was extracted twice with ethyl acetate (60 mL x 2). The organic phases were combined, concentrated under reduced pressure to remove the solvent, and the residue was purified by column chromatography with gradient elution (petroleum ether / ethyl acetate = 5 / 1) to give compound Int 1-1 (22.0 g).

[0331] Step 2: Synthesis of intermediate Int 1-2

[0332] Intermediate Int 1-1 (20.0 g, 51.59 mmol) was dissolved in tetrahydrofuran (300 mL), and 2N HCl (2 M, 300 mL) was added under ice bath conditions. The mixture was stirred for 30 min under ice bath conditions, and the reaction was continued at room temperature for 2 h. The reaction was stopped by LC-MS. The pH of the system was adjusted to 7-8 with concentrated ammonia, and the layers were separated. The aqueous phase was extracted twice with ethyl acetate (100 mL x 2). The organic phases were combined, concentrated under reduced pressure to remove the solvent, and the residue was purified by column chromatography with gradient elution (petroleum ether / ethyl acetate = 5 / 1) to give compound Int 1-2 (13.0 g).

[0333] Step 3: Synthesis of intermediates Int 1-3

[0334] Intermediate Int 1-2 (13.0 g, 44.44 mmol) was dissolved in 1,4-dioxane (150 mL), followed by the addition of an aqueous solution of lithium hydroxide monohydrate (3.73 g, 88.87 mmol) (120 mL). The mixture was stirred at room temperature for 2 h. The system was then cooled in an ice bath, and the pH was adjusted to 4-5 with 2N dilute hydrochloric acid. Water (150 mL) and 1,4-dioxane (150 mL) were added, followed by sodium bicarbonate solid (14.9 g, 177.74 mmol) and 9-fluorenylmethyl-N-succinimide carbonate (16.5 g, 48.88 mmol). The mixture was slowly heated to room temperature and stirred for 16 h. The mixture was cooled in an ice bath, and the pH was adjusted to 2-3 with 2N dilute hydrochloric acid. The phases were separated into two layers. The aqueous phase was extracted twice with ethyl acetate (150 mL x 2). The organic phases were combined and washed once with saturated brine (100 mL x 1). The organic phase was dried with anhydrous sodium sulfate and concentrated to dryness under reduced pressure to obtain compound Int 1-3 (20.0 g).

[0335] Step 4: Synthesis of intermediates Int 1-4

[0336] Intermediate Int 1-3 (1.0 g, 2.00 mmol) and paraformaldehyde (395.4 mg, 11.98 mmol) were dissolved in toluene (10 mL), followed by the addition of trifluoroacetic acid (2.28 g, 19.97 mmol). The mixture was stirred at room temperature for 12 h under nitrogen protection. The solvent was removed by concentration under reduced pressure, and the residue was purified by column chromatography with gradient elution (petroleum ether / ethyl acetate = 5 / 1) to give compound Int 1-4 (800.0 mg).

[0337] Step 5: Synthesis of Int 1

[0338] Intermediate Int 1-4 (800.0 mg, 1.56 mmol) was dissolved in dichloromethane (15 mL), followed by the addition of boron trifluoride diethyl ether (2.22 g, 15.60 mmol) and triethylsilane (1.45 g, 12.48 mmol). The reaction was stirred at room temperature for 20 h under nitrogen protection. The reaction was quenched with water (20 mL), and the mixture was separated into two phases. The aqueous phase was extracted twice with dichloromethane (10 mL x 2). The organic phases were combined, concentrated under reduced pressure to remove the solvent, and the residue was purified by column chromatography with gradient elution (dichloromethane / methanol = 20 / 1) to give the title compound Int 1 (600.0 mg).

[0339] Synthesis of Int 2a and Int 2b

[0340] Step 1: Synthesis of intermediates Int 2a-1 and Int 2b-1

[0341] 2-(trifluoromethyl)tetrahydropyran-2-carboxylic acid (180.0 mg, 908.45 μmol) was added to a 50 mL reaction flask, followed by dichloromethane (20 mL). The mixture was cooled to 0 °C and stirred. Then, bis(2-oxo-3-oxazolyl)phosphine chloride (104.94 mg, 1.09 mmol) and N,N-diisopropylethylamine (352.23 mg, 2.73 mmol) were added, and the mixture was stirred for 10 min. Next, (2S,4R)-4-fluoropyrrolidine-2-carboxylic acid benzyl ester hydrochloride (377.49 mg, 1.45 mmol) was added, and the mixture was reacted at 25 °C for 6 h. The reaction was then analyzed by LC-MS, and the reaction was considered complete. Dilute with dichloromethane (30 mL), wash once with saturated sodium bicarbonate aqueous solution (10 mL x 1), wash once with water (20 mL x 1), dry with anhydrous sodium sulfate, filter, concentrate under reduced pressure to remove solvent, purify the residue by column chromatography with gradient elution (0-30% ethyl acetate), collect the product to give intermediates Int 2a-1 (140.0 mg) and Int 2b-1 (135.0 mg).

[0342] Step 2: Synthesis of Int 2a and Int 2b

[0343] Intermediate Int 2a-1 (140.0 mg, 347.08 μmol) was added to a 100 mL reaction flask, followed by tetrahydrofuran (2 mL) and methanol (4 mL). Palladium on carbon (22.0 mg, 10% m / m) was then added. The mixture was purged with hydrogen three times. The reaction was carried out at 25 °C for 3 h under a hydrogen atmosphere. The reaction was then monitored by LC-MS, and the reaction was considered complete. The mixture was filtered, and the filter cake was washed with methanol (10 mL). The filtrates were combined and concentrated to dryness under reduced pressure to obtain the title compound Int 2a (100.0 mg).

[0344] Intermediate Int 2b-1 (135.0 mg, 334.68 μmol) was added to a 100 mL reaction flask, followed by tetrahydrofuran (2 mL) and methanol (4 mL). Palladium on carbon (22.0 mg, 10% m / m) was then added. The mixture was purged with hydrogen three times. The reaction was carried out at 25 °C for 3 h under a hydrogen atmosphere. The reaction was then monitored by LC-MS, and the reaction was considered complete. The mixture was filtered, and the filter cake was washed with methanol (10 mL). The filtrates were combined and concentrated to dryness under reduced pressure to obtain the title compound Int 2b (90.0 mg).

[0345] LC-MS (ESI): m / z = 313.9 [M+H] +

[0346] The two isomers were analyzed by chromatographic methods: Int 2a (Rt: 7.385 min), Int 2b (Rt: 7.363 min). LC-MS (ESI): m / z = 313.9 [M+H] +

[0347] Synthesis of Int 3

[0348] Step 1: Synthesis of intermediate Int 3-2

[0349] (2S,4R)-1-(tert-Butoxycarbonyl)-4-fluoropyrrolidine-2-carboxylic acid (500.0 mg, 2.14 mmol) was added to a 50 mL reaction flask, followed by N,N-dimethylformamide (10 mL). The mixture was stirred, and then benzyl bromide (476.6 mg, 2.79 mmol) and sodium bicarbonate (540.3 mg, 6.43 mmol) were added. The reaction was allowed to proceed at room temperature for 24 h. The reaction was confirmed by LC-MS. The mixture was diluted with ethyl acetate (100 mL), washed twice with water (20 mL x 2), and twice with saturated brine (20 mL x 2). The solvent was removed by concentration under reduced pressure. The residue was mixed with silica gel and purified by column chromatography using a gradient elution (0-50% ethyl acetate). The product was collected to give compound Int 3-2 (690.0 mg).

[0350] Step 2: Synthesis of intermediate Int 3-3

[0351] Intermediate Int 3-2 (690.0 mg, 2.16 mmol) was added to a 50 mL reaction flask, followed by 1,4-dioxane (10 mL). The mixture was stirred, and then 10.82 mmol (2.7 mL) of 4 M HCl in 1,4-dioxane was added. The reaction was allowed to proceed at room temperature for 16 h. LC-MS analysis indicated the reaction was complete. The mixture was then concentrated to dryness under reduced pressure to obtain crude compound Int 3-3 (560.0 mg), which was used directly in the next reaction step.

[0352] Step 3: Synthesis of intermediate Int 3-4

[0353] Intermediate Int 3-3 (560.0 mg) and 3,3-difluoro-1-(trifluoromethyl)cyclobutane-1-carboxylic acid (274.3 mg, 1.34 mmol) were added to a 50 mL reaction flask, followed by N,N-dimethylformamide (8 mL). The mixture was stirred and reacted under argon protection. Then, 2-(7-azabenzotriazolyl)-N,N,N',N'-tetramethylurea hexafluorophosphate (766.5 mg, 2.02 mmol) and N,N-diisopropylethylamine (694.7 mg, 5.38 mmol) were added, and the reaction was carried out at room temperature for 4 h. Samples were taken and analyzed by LC-MS; the reaction was considered complete at this point. The system was diluted with ethyl acetate (60 mL), then washed twice with water (15 mL x 2), and once with saturated saline (15 mL x 1). The solvent was removed by concentration under reduced pressure, and the residue was mixed with silica gel and purified by column chromatography with gradient elution (0-50% ethyl acetate). The product was collected to give compound Int 3-4 (440.0 mg).

[0354] Step 4: Synthesis of intermediate Int 3

[0355] Intermediate Int 3-4 (440.0 mg, 1.07 mmol) was added to a 50 mL reaction flask, followed by methanol (3 mL) and tetrahydrofuran (6 mL). The mixture was stirred, and then 10% Pd / C (44.0 mg, 10% m / m) was added. The system was purged with hydrogen three times, and the reaction was carried out at room temperature for 16 h. A sample was taken, and the reaction was detected by LC-MS. The reaction was then considered complete. The system was directly filtered through a diatomaceous earth filter, and the filter cake was washed with an appropriate amount of ethyl acetate. The filtrate was concentrated to dryness under reduced pressure to obtain the title compound Int 3 (330.0 mg).

[0356] Synthesis of Int 4

[0357] Step 1: Synthesis of intermediate Int 4-2

[0358] (S)-2-((tert-Butoxycarbonyl)amino)-2-cyclopropylacetic acid (4.0 g, 18.58 mmol) was added to a 250 mL reaction flask, followed by sodium bicarbonate solid (3.12 g, 37.17 mmol) and N,N-dimethylformamide (40 mL). Under argon protection, benzyl bromide (3.66 g, 21.37 mmol) was added with stirring. After the addition was complete, the system was reacted at room temperature for 16 h. The system was diluted with water (100 mL), then washed twice with ethyl acetate (150 mL x 2). The organic phase was washed twice with saturated brine (100 mL x 2). The solvent was removed by concentration under reduced pressure. The residue was mixed with silica gel and purified by column chromatography with gradient elution (0-20% ethyl acetate). The product was collected and concentrated to dryness under reduced pressure to give compound Int4-2 (2.43 g).

[0359] Step 2: Synthesis of intermediate Int 4-3

[0360] Intermediate Int 4-2 (2.43 g, 7.96 mmol) was added to a 100 mL reaction flask, followed by 1,4-dioxane (10 mL). Then, a 4 M dioxane chloride solution (10 mL) was added with stirring. After the addition was complete, the reaction mixture was allowed to react at room temperature for 3 h. The reaction solution was then concentrated to dryness under reduced pressure to obtain compound Int 4-3 (1.69 g), which was used in the next reaction step.

[0361] Step 3: Synthesis of intermediate Int 4-4

[0362] Intermediate Int 4-3 (1.69 g, 6.99 mmol), (2S,4R)-1-(tert-butoxycarbonyl)-4-fluoropyrrolidine-2-carboxylic acid (1.96 g, 8.39 mmol), and 2-(7-azobenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (3.46 g, 9.09 mmol) were added to a 100 mL reaction flask. N,N-dimethylformamide (20 mL) was added, followed by N,N-diisopropylethylamine (2.71 g, 20.98 mmol) with stirring. After the addition was complete, the system was reacted at room temperature for 16 h under argon protection. The system was diluted with water (100 mL), extracted twice with ethyl acetate (100 mL x 2), washed twice with saturated saline (60 mL x 2), concentrated under reduced pressure to remove the solvent, mixed the residue with silica gel, purified by column chromatography, eluted with gradient (0-50% ethyl acetate), the product was collected, concentrated under reduced pressure to dryness, and compound Int4-4 (2.89 g) was obtained.

[0363] Step 4: Synthesis of intermediate Int 4-5

[0364] Intermediate Int 4-4 (2.89 g, 6.87 mmol) was added to a 100 mL reaction flask, followed by 1,4-dioxane (10 mL). Then, a 4 M dioxane chloride solution (10 mL) was added with stirring. After the addition was complete, the system was allowed to react at room temperature for 3 h. The reaction solution was then concentrated to dryness under reduced pressure to obtain crude compound Int 4-5 (2.2 g), which was used in the next reaction step.

[0365] Step 5: Synthesis of intermediate Int 4-6

[0366] Int 4-5 (2.0 g, 6.24 mmol), 3,3-difluoro-1-(trifluoromethyl)cyclobutane-1-carboxylic acid (1.53 g, 7.49 mmol), and N,N,N',N'-tetramethylchloroformamidine hexafluorophosphate (2.63 g, 9.36 mmol) were added to a 100 mL reaction flask, followed by acetonitrile (5 mL). The mixture was stirred, and then N-methylimidazole (1.28 g, 15.61 mmol) was added. After the addition was complete, the mixture was reacted at room temperature for 16 h under argon protection. The reaction solution was concentrated under reduced pressure to remove the solvent. The residue was mixed with silica gel and purified by column chromatography with gradient elution (0-30% ethyl acetate). The product was collected and concentrated to dryness under reduced pressure to give compound Int 4-6 (2.75 g).

[0367] Step 6: Synthesis of Int 4

[0368] Int 4-6 (4.2 g, 8.29 mmol) was dissolved in a mixed solvent of tetrahydrofuran (50 mL) and ethyl acetate (50 mL), and then palladium on carbon (88.32 mg, 0.83 mmol) was added. The mixture was purged with hydrogen three times and stirred at room temperature for 2 h. The mixture was filtered, and the filtrate was concentrated directly to dryness to give the title compound Int 4 (2.65 g).

[0369] 1 H NMR(400MHz,Chloroform-d)δ7.23(d,J=7.0Hz,1H),5.36-5.51(m,1H),4.90(t,J=7.8Hz 1H),4.36(t,J=7.0Hz 1H),3.94(t,J=7.7Hz,1H),3.85-3.77(m,1H),3.57-3.35(m,2H),3.20-3.09(m,2H),2.79 -2.61(m,1H),2.49-2.38(m,1H),2.38-2.18(m,1H),0.75-0.40(m,3H),0.39-0.33(m,1H).

[0370] Synthesis of Int 5

[0371] Step 1: Synthesis of intermediate Int 5-1

[0372] Ethyl 3,3,3-trifluoro-2-oxopropionate (2.18 g, 12.82 mmol) was added to a 100 mL reaction flask, followed by the addition of tetrahydrofuran (40 mL). The mixture was purged with argon three times and stirred at -78 °C. Then, a tetrahydrofuran solution of allyl magnesium bromide (1 M, 12.82 mmol, 12.82 mL) was added, and the mixture was kept at -78 °C for 2 h. The reaction was monitored by LC-MS, and the reaction was considered complete. The reaction was quenched by the addition of saturated ammonium chloride solution (30 mL), followed by the addition of methyl tert-butyl ether (200 mL) and saturated brine (80 mL). The mixture was stirred, and the layers were separated. The aqueous layer was extracted once with methyl tert-butyl ether (100 mL x 1). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to remove the solvent. The residue was purified by column chromatography with gradient elution (ethyl acetate / petroleum ether = 0-20%) to give intermediate Int 5-1 (1.8 g).

[0373] Step 2: Synthesis of intermediate Int 5-2

[0374] Intermediate Int 5-1 (1.8 g, 8.48 mmol) was added to a 100 mL reaction flask, followed by the addition of N,N-dimethylformamide (50 mL). The mixture was purged with argon three times, cooled to 0 °C, and stirred. Then, sodium hydride (542.92 mg, 13.57 mmol, 60% purity) was added, and the mixture was stirred at 0 °C for 30 min. Finally, 3-iodopropene (2.14 g, 12.73 mmol) and tetrabutylammonium iodide (783.43 mg, 2.12 mmol) were added. The mixture was allowed to react at room temperature for 2 h, and the reaction was completed by LC-MS analysis. The reaction was quenched by adding saturated ammonium chloride solution (30 mL), followed by the addition of methyl tert-butyl ether (200 mL) and saturated brine (80 mL). The mixture was stirred and separated into layers. The aqueous layer was extracted once with methyl tert-butyl ether (100 mL x 1). The organic phases were combined and washed twice with water (50 mL x 2) and once with saturated brine (50 mL x 1). The mixture was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to remove the solvent. The residue was purified by column chromatography with gradient elution (ethyl acetate / petroleum ether = 0-20%) to give intermediate Int 5-2 (1.6 g).

[0375] Step 3: Synthesis of intermediate Int 5-3

[0376] Intermediate Int 5-2 (566.0 mg, 2.24 mmol) was added to a 40 mL reaction flask, followed by the addition of dichloromethane (15 mL) and purging with argon three times. Then, Hoveyda-Grubbs second-generation catalyst (210.92 mg, 336.60 μmol) was added. The system was refluxed and stirred for 16 h. The reaction was monitored by TLC, indicating completion of the reaction. The reaction solution was directly concentrated under reduced pressure to remove the solvent. The residue was purified by column chromatography using a gradient elution (ethyl acetate / petroleum ether = 0-20%) to obtain intermediate Int 5-3 (300.0 mg).

[0377] Step 4: Synthesis of intermediate Int 5-4

[0378] Intermediate Int 5-3 (500.0 mg, 2.23 mmol) was added to a 100 mL reaction flask, along with methanol (5 mL) and tetrahydrofuran (10 mL). The system was stirred at 0 °C, and sodium hydroxide aqueous solution (2 M, 8.92 mmol, 4.5 mL) was added. The reaction mixture was slowly heated to room temperature and stirred for 2 h. The reaction was then monitored by TLC, indicating completion. The system was cooled to 0 °C and stirred, followed by slow addition of 2 M hydrochloric acid aqueous solution until the pH reached 3-4. Ethyl acetate (50 mL) and saturated saline solution (20 mL) were added, and the mixture was stirred to separate the layers. The aqueous phase was extracted once with ethyl acetate (20 mL x 1). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to dryness to obtain crude intermediate Int 5-4 (430.0 mg), which was directly used in the next reaction step.

[0379] Step 5: Synthesis of intermediate Int 5-5

[0380] Intermediate Int 5-4 (480.0 mg, 2.45 mmol) was added to a 50 mL reaction flask, followed by dichloromethane (20 mL). The mixture was stirred at 0 °C, and then bis(2-oxo-3-oxazolyl)phosphine chloride (685.32 mg, 2.69 mmol) and N,N-diisopropylethylamine (506.1 mg, 3.92 mmol) were added. The mixture was stirred for 10 min, and then (2S,4R)-4-fluoropyrrolidine-2-carboxylic acid benzyl ester hydrochloride (889.85 mg, 3.43 mmol) was added. The reaction mixture was incubated at 25 °C for 6 h, and the reaction was completed by LC-MS analysis. Dilute with 50 mL of dichloromethane, cool to 0 °C, add 10 mL of saturated sodium bicarbonate aqueous solution, stir, separate into layers, wash the organic phase once with 20 mL of water, dry to anhydrous sodium sulfate, filter, concentrate under reduced pressure to remove solvent, purify the residue by column chromatography with gradient elution (0-35% ethyl acetate), collect the product, and obtain intermediates Int 5-5a (380.0 mg, Rt: 10.162 min) and Int 5-5b (330.0 mg, Rt: 10.088 min). The two isomers were analyzed by chromatographic methods.

[0381] Step 6: Synthesis of intermediate Int 5-6

[0382] Intermediate Int 5-5b (300.0 mg, 747.47 μmol) was added to a 50 mL reaction flask, along with ethanol (10 mL) and water (1 mL). The mixture was stirred at room temperature, followed by the addition of 1,8-diazabicyclo[5.4.0]undec-7-ene (685.32 mg, 2.69 mmol) and rhodium tris(triphenylphosphine)chloride (34.58 mg, 37.37 μmol). The reaction mixture was stirred at 60 °C for 3 h, and the reaction was analyzed by LC-MS. The reaction was then considered complete. The system was cooled to room temperature, diluted with dichloromethane (50 mL), and then water (20 mL) was added. The mixture was stirred, and the layers were separated. The organic phase was washed once with water (20 mL), dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure to remove the solvent, and the residue was purified by column chromatography with gradient elution (0-35% ethyl acetate). The product was collected to obtain intermediate Int 5-6 (200.0 mg).

[0383] Step 7: Synthesis of intermediate Int 5-7

[0384] Intermediate Int 5-6 (200.0 mg, 498.32 μmol) was added to a 50 mL reaction flask, followed by 10 mL of tetrahydrofuran. The mixture was stirred at 0 °C, and argon gas was purged three times. A toluene solution of borane dimethyl sulfide (2 M, 498.32 μmol, 249.2 μL) was added, and the mixture was stirred at room temperature for 3 h. The mixture was then cooled and stirred at 0 °C, and 1 mL of an aqueous solution of sodium acetate (61.32 mg, 747.47 μmol) was slowly added. The mixture was stirred at room temperature for 0.5 h, and then stirred at 0 °C. Hydrogen peroxide (169.50 mg, 1.74 mmol, 35% purity) was slowly added. The mixture was stirred at room temperature for 16 h, and the reaction was considered complete by LC-MS. Dilute with ethyl acetate (50 mL), stir at 0 °C, add 10% sodium thiosulfate aqueous solution (20 mL), stir for 20 min, separate into layers, wash the organic phase once with water (20 mL), dry with anhydrous sodium sulfate, filter, concentrate under reduced pressure to remove solvent, purify the residue by column chromatography, elute with gradient (0-50% ethyl acetate), collect the product, and give intermediate Int 5-7 (180.0 mg).

[0385] Step 8: Synthesis of intermediate Int 5-8

[0386] Intermediate Int 5-7 (120.00 mg, 286.15 μmol) was added to a 50 mL reaction flask, followed by 6 mL of dichloromethane. The mixture was stirred at 0 °C, and then 85.0 mg of 4A molecular sieve and pyridinium chlorochromate (92.52 mg, 429.22 μmol) were added sequentially. The mixture was stirred at room temperature for 16 h, and the reaction was completed by LC-MS. The mixture was diluted with 30 mL of dichloromethane, filtered, and the filtrate was concentrated under reduced pressure to remove the solvent. The residue was purified by column chromatography with gradient elution (0-40% ethyl acetate). The product was collected to obtain intermediate Int 5-8 (100.0 mg).

[0387] Step 9: Synthesis of intermediate Int 5-9

[0388] Intermediate Int 5-8 (57.0 mg, 136.58 μmol) was added to a 50 mL reaction flask, followed by the addition of N,N-dimethylacetamide (6 mL) to replace the argon atmosphere. Difluoromethyl (2-pyridyl) sulfone (31.66 mg, 163.89 μmol) was then added, and the mixture was stirred at -20 °C. A solution of potassium tert-butoxide (27.59 mg, 245.84 μmol) in N,N-dimethylacetamide (2 mL) was then added, and the mixture was stirred at -15 °C for 2 h. Subsequently, saturated ammonium chloride aqueous solution (0.5 mL) and hydrochloric acid aqueous solution (3 M, 0.5 mL) were added, and the mixture was stirred at -15 °C for another 2 h. The reaction was then analyzed by LC-MS, indicating the end of the reaction. Add methyl tert-butyl ether (40 mL) and water (15 mL), stir, separate into layers, wash the organic phase once with water (20 mL), dry with anhydrous sodium sulfate, filter, concentrate under reduced pressure to remove solvent, purify the residue by column chromatography, elute with gradient (0-40% ethyl acetate), collect the product, and give intermediate Int 5-9 (20.0 mg).

[0389] Step 10: Synthesis of intermediate Int 5

[0390] Intermediate Int 5-9 (20.09 mg, 44.51 μmol) was added to an 8 mL reaction flask, followed by the addition of dichloromethane (2 mL) to replace the argon atmosphere. Trimethyliodosilane (89.01 mg, 445.05 μmol) was then added, and the mixture was heated under reflux and stirred for 16 h. The reaction was confirmed by LC-MS. After cooling to room temperature, the solvent was removed by concentration under reduced pressure. The residue was dissolved in a small amount of acetonitrile and water, and then lyophilized to obtain the title compound Int 5 (12.0 mg).

[0391] Synthesis of Int 7

[0392] Step 1: Synthesis of intermediate Int 7-1

[0393] Intermediate Int 1 (600.0 mg, 1.55 mmol), N-methylhexyl-5-en-1-amine (211.0 mg, 1.86 mmol), and 2-(7-azobenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (649.0 mg, 1.71 mmol) were dissolved in N,N-dimethylformamide (10 mL), followed by the addition of N,N-diisopropylethylamine (702.0 mg, 5.44 mmol). The mixture was stirred at room temperature for 3 h. The system was diluted with water (50 mL), extracted twice with ethyl acetate (50 mL x 2), and the organic phases were combined. The mixture was washed twice with saturated sodium chloride solution (20 mL x 2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to dryness to obtain crude compound Int 7-1 (600.0 mg), which was used directly in the next reaction.

[0394] Step 2: Synthesis of intermediate Int 7-2

[0395] Intermediate Int 7-1 (600.0 mg, 983.64 μmol) was dissolved in a 20% piperidine solution in dichloromethane (10 mL), and the mixture was stirred at room temperature for 1 h. The system was diluted with dichloromethane (60 mL), washed twice with saturated ammonium chloride solution (20 mL x 2), the organic phase was concentrated under reduced pressure to remove the solvent, and the residue was purified by column chromatography with gradient elution (dichloromethane / methanol = 20 / 1) to give compound Int 7-2 (300.0 mg).

[0396] Step 3: Synthesis of intermediate Int 7-3

[0397] Intermediate Int 7-2 (300.0 mg, 773.71 μmol), (S)-2-((tert-butoxycarbonyl)amino)-4-methylpentanoic acid (233.0 mg, 1.01 mmol), and 2-(7-azobenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (324.0 mg, 851.08 μmol) were dissolved in N,N-dimethylformamide (15 mL), followed by the addition of N,N-diisopropylethylamine (350.0 mg, 2.71 mmol). The mixture was stirred at room temperature for 2 h. The solution was diluted with water (80 mL), extracted twice with ethyl acetate (50 mL x 2), and the organic phases were combined. The mixture was washed twice with saturated sodium chloride solution (20 mL x 2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to dryness to give crude compound Int 7-3 (400.0 mg). This crude compound was used directly in the next reaction.

[0398] Step 4: Synthesis of intermediate Int 7-4

[0399] Intermediate Int 7-3 (400.0 mg, 665.54 μmol) was dissolved in dichloromethane (15 mL), followed by the addition of trifluoroacetic acid (3 mL). The mixture was stirred at room temperature for 2 h. The reaction was confirmed to be complete by LC-MS. The reaction solution was directly concentrated under reduced pressure to remove the solvent. The residue was then rotary evaporated twice under reduced pressure with dichloromethane (20 mL) to obtain crude compound Int 7-4 (300.0 mg), which was then directly proceeded to the next step.

[0400] Step 5: Synthesis of intermediate Int 7-5

[0401] Intermediate Int 7-4 (300.0 mg, 698.74 μmol), (S)-2-((tert-butoxycarbonyl)(methyl)amino)pent-4-enoic acid, and N,N-diisopropylethylamine (451.0 mg, 3.49 mmol) were dissolved in N,N-dimethylformamide (15 mL), followed by the addition of 2-(7-azobenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (292.0 mg, 768.62 μmol). The mixture was stirred at room temperature for 2 h. The solution was diluted with water (70 mL), extracted twice with ethyl acetate (50 mL x 2), and the organic phases were combined. The mixture was washed twice with saturated sodium chloride solution (20 mL x 2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to dryness to obtain crude compound Int 7-5 (500.0 mg), which was used directly in the next reaction.

[0402] Step 6: Synthesis of intermediate Int 7-6

[0403] Intermediate Int 7-5 (500.0 mg, 702.09 μmol) was dissolved in dichloromethane (10 mL), and trifluoroacetic acid (2 mL) was added. The mixture was stirred at room temperature for 2 h. The reaction solution was concentrated under reduced pressure to remove the solvent. The residue was dissolved in dichloromethane (40 mL), washed twice with saturated sodium carbonate solution (15 mL x 2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to dryness to obtain crude compound Int 7-6 (400.0 mg), which was directly used in the next reaction.

[0404] Step 7: Synthesis of intermediate Int 7-7

[0405] Intermediate Int 7-6 (350.0 mg, 698.74 μmol), (S)-2-((tert-butoxycarbonyl)amino)-2-cyclopropylacetic acid (209.0 mg, 908.37 μmol), and 2-(7-azobenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (292.0 mg, 768.62 μmol) were dissolved in N,N-dimethylformamide (15 mL), followed by the addition of N,N-diisopropylethylamine (451.0 mg, 3.49 mmol). The mixture was stirred at room temperature for 2 h. The solution was diluted with water (70 mL), extracted twice with ethyl acetate (50 mL x 2), and the organic phases were combined. The mixture was washed twice with saturated sodium chloride solution (20 mL x 2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to dryness to obtain crude compound Int 7-7 (490.0 mg), which was used directly in the next reaction.

[0406] Step 8: Synthesis of intermediate Int 7-8

[0407] Intermediate Int 7-7 (450.0 mg, 556.06 μmol) was dissolved in 1,2-dichloroethane (100 mL), and then Howeyda-Grubbs-2nd (52.0 mg, 83.41 μmol) was added. The mixture was heated at 70 °C for 5 h under nitrogen protection. The solvent was removed by direct concentration under reduced pressure. The residue was mixed with silica gel and purified by column chromatography using a gradient elution (dichloromethane / methanol = 20 / 1) to give compound Int 7-8 (420.0 mg).

[0408] Step 9: Synthesis of intermediate Int 7-9

[0409] Intermediate Int 7-8 (450.0 mg, 576.02 μmol) was dissolved in ethyl acetate (10 mL), and platinum dioxide (26.0 mg, 115.20 μmol) was added. The mixture was purged with hydrogen three times, and the mixture was stirred at room temperature for 2 h. The mixture was filtered, and the filtrate was concentrated to dryness under reduced pressure to obtain crude compound Int 7-9 (450.0 mg), which was used directly in the next reaction.

[0410] Step 10: Synthesis of Int 7-10

[0411] Intermediate Int 7-9 (200.0 mg, 255.35 μmol), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxapentylborane-2-yl)-1H-pyrazole (79.0 mg, 383.03 μmol), [1,1-bis(diphenylphosphine)ferrocene]palladium dichloride (37.0 mg, 51.07 μmol), and N,N-diisopropylethylamine (519.0 mg, 4.02 mmol) were dissolved in 1,4-dioxane (8 mL) and water (2 mL). The reaction mixture was stirred at 85 °C for 12 h under nitrogen protection. The reaction solution was directly separated, and the organic phase was concentrated under reduced pressure to remove the solvent. The residue was purified by column chromatography (gradient elution, methanol / dichloromethane = 0-10%) to give the title compound Int 7-10 (190.0 mg).

[0412] Step 11: Synthesis of Int 7

[0413] Intermediate Int 7-10 (160.0 mg, 203.97 μmol) was dissolved in dichloromethane (10 mL), and trifluoroacetic acid (2 mL) was added. The mixture was stirred at room temperature for 2 h. The reaction solution was concentrated under reduced pressure to remove the solvent. The residue was dissolved in dichloromethane (40 mL), washed twice with saturated sodium carbonate solution (15 mL x 2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to dryness to obtain crude Int7 (140.0 mg).

[0414] Synthesis of Int 8

[0415] Step 1: Synthesis of intermediate Int8-1

[0416] Intermediate Int1 (6.0 g, 15.28 mmol), N-methylhexyl-5-en-1-amine (211.0 mg, 1.86 mmol), and 2-(7-azobenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (6.39 g, 16.81 mmol) were dissolved in N,N-dimethylformamide (50 mL). Under argon protection, N,N-diisopropylethylamine (5.92 g, 45.84 mmol, 8.0 mL) was added, and the reaction was carried out at room temperature for 16 h. Samples were taken, and LC-MS analysis was performed to determine the reaction was complete. Water (100 mL) was added to the system, and the mixture was extracted twice with ethyl acetate (100 mL x 2). The organic phases were combined, washed twice with saturated brine (40 mL x 2), concentrated under reduced pressure to remove the solvent, and the residue was mixed with silica gel for purification by column chromatography with gradient elution (0-3% MeOH). The product was collected and concentrated to dryness under reduced pressure to obtain the title compound (4.6 g).

[0417] Step 2: Synthesis of intermediate Int8-2

[0418] Intermediate Int8-1 (5.0 g, 10.25 mmol) was dissolved in dichloromethane (80 mL), and trifluoroacetic acid (20 mL) was added. The mixture was stirred at room temperature for 4 h, and the reaction was monitored by LC-MS until completion. The solvent was removed by concentration under reduced pressure. The residue was dissolved in dichloromethane (50 mL), washed twice with saturated sodium bicarbonate aqueous solution (20 mL x 2), washed once with saturated brine (50 mL x 1), dried over anhydrous sodium sulfate, and concentrated to dryness under reduced pressure to obtain the crude title compound (3.5 g), which was directly used in the next reaction.

[0419] Step 3: Synthesis of intermediate Int8-3

[0420] Intermediate Int8-2 (4.0 g, 10.32 mmol), (2S)-2-(tert-butoxycarbonylamino)-4-methylpentanoic acid (2.86 g, 12.38 mmol), and 2-(7-azobenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (4.71 g, 12.38 mmol) were dissolved in N,N-dimethylformamide (50 mL), followed by the addition of N,N-diisopropylethylamine (4.00 g, 30.95 mmol, 5.41 mL). The reaction was carried out at room temperature for 16 h under argon protection. Samples were taken and analyzed by LC-MS, indicating the reaction was complete. Water (100 mL) was added to the system, and the mixture was extracted twice with ethyl acetate (100 mL x 2). The organic phases were combined, washed twice with saturated brine (40 mL x 2), concentrated under reduced pressure to remove the solvent, and the residue was mixed with silica gel for purification by column chromatography with gradient elution (0-5% MeOH). The product was collected and concentrated to dryness under reduced pressure to obtain the title compound (5.68 g).

[0421] Step 4: Synthesis of intermediate Int8-4

[0422] Intermediate Int8-3 (5.68 g, 9.45 mmol) was dissolved in dichloromethane (80 mL), and trifluoroacetic acid (20 mL) was added. The mixture was stirred at room temperature for 2 h, and the reaction was monitored by LC-MS until completion. The solvent was removed by concentration under reduced pressure. The residue was dissolved in dichloromethane (50 mL), washed twice with saturated sodium bicarbonate aqueous solution (20 mL x 2), washed once with saturated brine (50 mL x 1), dried over anhydrous sodium sulfate, and concentrated to dryness under reduced pressure to obtain the crude title compound (4.0 g), which was directly used in the next reaction.

[0423] Step 5: Synthesis of intermediate Int8-5

[0424] (2S)-2-[tert-Butoxycarbonyl(methyl)amino]pent-4-enoic acid (2.20 g, 9.58 mmol), N,N-diisopropylethylamine (3.10 g, 23.96 mmol, 4.18 mL), and 2-(7-azobenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (3.64 g, 9.58 mmol) were added to a 100 mL reaction flask, followed by 50 mL of N,N-dimethylformamide. The mixture was stirred for 30 min under argon protection, then intermediate Int8-4 (4.0 g, 7.99 mmol) was added, and the reaction was allowed to proceed at room temperature for 16 h. Samples were taken and analyzed by LC-MS; the reaction was considered complete at this point. Water (100 mL) was added to the system, and the mixture was extracted twice with ethyl acetate (100 mL x 2). The organic phases were combined, washed twice with saturated brine (50 mL x 2), concentrated under reduced pressure to remove the solvent, and the residue was mixed with silica gel for purification by column chromatography with gradient elution (0-30% EA). The product was collected and concentrated to dryness under reduced pressure to obtain the title compound (5.69 g).

[0425] Step 6: Synthesis of intermediate Int8-6

[0426] Intermediate Int8-5 (4.72 g, 5.84 mmol) was dissolved in 1,2-dichloroethane (500 mL), followed by the addition of Howeyda-Grubbs second-generation catalyst (547.0 mg, 876.0 μmol). The reaction was carried out under argon protection at 70 °C for 5 h. The solvent was removed by direct concentration under reduced pressure, and the residue was mixed with silica gel and purified by column chromatography (dichloromethane:methanol = 20:1). The product was collected to give the title compound (3.7 g).

[0427] Step 7: Synthesis of Int 8

[0428] Intermediate Int8-6 (1.3 g, 1.66 mmol) was dissolved in ethyl acetate (30 mL), followed by the addition of platinum dioxide (75.58 mg, 332.81 μmol). The mixture was purged with hydrogen three times, stirred at room temperature for 2 h, and the reaction was stopped by LC-MS. The solution was filtered directly, and the filtrate was concentrated to dryness under reduced pressure to obtain the crude title compound (1.3 g), which was used directly in the next reaction.

[0429] Int10 synthesis

[0430] Step 1: Synthesis of intermediate Int10-2

[0431] 2,2-Difluoropent-4-en-1-ol (200.0 mg, 1.64 mmol) was added to a 50 mL reaction flask, followed by 10 mL of dichloromethane and stirring. Then, pyridine (181.37 mg, 2.29 mmol, 185.07 μL) was added, and the mixture was reacted at 0 °C for 5 min. Next, trifluoromethanesulfonic anhydride (555.0 mg, 1.97 mmol) was added, and the mixture was reacted at room temperature for 30 min. The reaction was then analyzed by TLC, indicating completion. The mixture was used directly in the next reaction without any post-treatment purification.

[0432] Step 2: Synthesis of intermediate Int10-3

[0433] To the crude product obtained in the previous step, a methanol solution of ammonia (7M, 81.83 mmol, 11.69 mL) was added, and the mixture was stirred at 45 °C for 14 h. The reaction was confirmed by TLC, indicating completion. The solvent was removed by vacuum concentration, and the residue was reconstituted with dichloromethane (10 mL). Di-tert-butyl dicarbonate (1.79 g, 8.18 mmol) was added, and the reaction was confirmed by LC-MS, indicating completion. The solvent was removed by vacuum concentration, and the residue was purified by column chromatography with gradient elution (0-30% ethyl acetate). The product was collected to give compound Int10⁻³ (200.0 mg).

[0434] Step 3: Synthesis of intermediate Int10-4

[0435] Intermediate Int10-3 (265.0 mg, 1.20 mmol) was added to a 100 mL reaction flask, followed by N,N-dimethylformamide (10 mL). The mixture was stirred at 0 °C under argon protection. Then, sodium hydride (115.0 mg, 2.87 mmol, 60% purity) was added, and the reaction was maintained at 0 °C for 30 min. Iodimethane (680.04 mg, 4.79 mmol, 298.26 μL) was added, and the reaction was continued at room temperature for 16 h. The reaction was confirmed by LC-MS. The reaction solution was quenched in ice water (20 mL) and extracted three times with methyl tert-butyl ether (20 mL x 3). The organic phases were combined, washed twice with saturated brine (20 mL x 2), dried over anhydrous sodium sulfate, and concentrated to dryness under reduced pressure to obtain crude Int10-4 (270.0 mg), which was directly used in the next reaction step.

[0436] Step 4: Synthesis of intermediate Int10-5

[0437] Intermediate Int10-4 (180.0 mg, 765.08 μmol) was added to a 50 mL reaction flask, followed by acetonitrile (5 mL), and then p-toluenesulfonic acid (526.99 mg, 3.06 mmol). The reaction was carried out at 25 °C for 6 h, and the reaction was stopped by LC-MS. The solution was then concentrated to dryness under reduced pressure to obtain crude Int10-5 (180 mg), which was used directly in the next step.

[0438] Step 5: Synthesis of intermediate Int10-6

[0439] Intermediate Int10-5 (368.0 mg, 1.20 mmol) was added to a 50 mL reaction flask, followed by N,N-dimethylformamide (8 mL). The mixture was stirred, then intermediate Int1 (465 mg, 1.18 mmol) was added, along with 2-(7-azabenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (450 mg, 1.18 mmol) and N,N-diisopropylethylamine (1.07 g, 8.29 mmol, 1.45 mL). The reaction was allowed to proceed at room temperature for 6 h, and the reaction was confirmed by LC-MS. The mixture was then diluted with ethyl acetate (60 mL), washed once with water (20 mL x 1), washed once with saturated brine (20 mL x 1), dried over anhydrous sodium sulfate, concentrated under reduced pressure to remove the solvent, and purified by column chromatography with gradient elution (0-50% ethyl acetate). The product was collected to give compound Int10-6 (400.0 mg).

[0440] Step 6: Synthesis of intermediate Int10-7

[0441] Intermediate Int10-6 (330.0 mg, 647.30 μmol) was added to a 50 mL reaction flask, followed by dichloromethane (5 mL) and stirring. Then, trifluoroacetic acid (1 mL) was added, and the reaction was allowed to proceed at room temperature for 2 h. The reaction was then monitored by LC-MS, indicating completion. The solvent was removed by concentration under reduced pressure. The residue was reconstituted with ethyl acetate (60 mL), washed once with 10% sodium carbonate aqueous solution (20 mL x 1), and the aqueous layer was extracted once with ethyl acetate (20 mL x 1). The combined organic phases were dried over anhydrous sodium sulfate and concentrated under reduced pressure to dryness, yielding crude Int10-7 (250.0 mg), which was directly used in the next reaction step.

[0442] Step 7: Synthesis of intermediate Int10-8

[0443] Intermediate Int10-7 (125.0 mg, 305.10 μmol) was added to a 50 mL reaction flask, followed by N,N-dimethylformamide (5 mL). The mixture was stirred, then (tert-butoxycarbonyl)-L-leucine (105.85 mg, 457.66 μmol), 2-(7-azabenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (150.81 mg, 396.64 μmol), and N,N-diisopropylethylamine (118.30 mg, 915.31 μmol). The reaction was carried out at room temperature for 6 h, and the reaction was stopped by LC-MS. The system was diluted with methyl tert-butyl ether (60 mL), then washed once with water (20 mL x 1), washed once with saturated brine (20 mL x 1), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to dryness to obtain crude compound Int10-8 (180.0 mg), which was directly used in the next reaction.

[0444] Step 8: Synthesis of intermediate Int10-9

[0445] Intermediate Int10-8 (1.2 g, 1.96 mmol) was added to a 100 mL reaction flask, followed by dichloromethane (30 mL) and stirring. Trifluoroacetic acid (6 mL) was then added, and the reaction was allowed to proceed at room temperature for 2 h. The reaction was then monitored by LC-MS, indicating completion. The solvent was removed by concentration under reduced pressure. The residue was redissolved in ethyl acetate (60 mL), washed once with 10% sodium carbonate aqueous solution (20 mL x 1), and the aqueous layer was extracted once with ethyl acetate (20 mL x 1). The combined organic phases were dried over anhydrous sodium sulfate and concentrated under reduced pressure to dryness, yielding crude compound Int10-9 (1.0 g), which was directly used in the next reaction.

[0446] Step 9: Synthesis of intermediate Int10-10

[0447] Intermediate Int10-9 (230.0 mg, 439.89 μmol) was added to a 100 mL reaction flask, followed by N,N-dimethylformamide (10 mL). The mixture was stirred, and then (S)-2-((tert-butoxycarbonyl)(methyl)amino)hex-5-enoic acid (160.54 mg, 659.84 μmol), 2-(7-azabenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (217.44 mg, 571.86 μmol), and N,N-diisopropylethylamine (170.56 mg, 1.32 mmol) were added. The mixture was allowed to react at room temperature for 2 h, and the reaction was stopped by LC-MS. The system was diluted with methyl tert-butyl ether (60 mL), then washed once with water (20 mL x 1), once with saturated brine (20 mL x 1), dried over anhydrous sodium sulfate, concentrated under reduced pressure to remove the solvent, and the residue was purified by column chromatography with gradient elution (0-50% ethyl acetate). The product was collected to give compound Int10-10 (200.0 mg).

[0448] Step 10: Synthesis of intermediate Int10

[0449] Intermediate Int10-10 (600.0 mg, 801.99 μmol) was added to a 250 mL heating flask, followed by 60 mL of 1,2-dichloroethane. Under argon protection, Hoveyda-Grubbs second-generation catalyst (50.25 mg, 80.20 μmol) was added, and the reaction was carried out at 70 °C for 6 h. The reaction was detected by LC-MS, and the reaction was considered complete. The system was concentrated under reduced pressure to remove the solvent, and the residue was purified by column chromatography with gradient elution (0-60% ethyl acetate). The product was collected to give compound Int10 (400.0 mg).

[0450] Among them, the synthesis of Int1a

[0451] Step 1: Synthesis of intermediate Int1a-3

[0452] (R)-2,5-dihydro-3,6-dimethyl-2-isopropylpyrazine (13.0 g, 70.56 mmol) was dissolved in tetrahydrofuran (200 mL). Under nitrogen protection, n-butyllithium (2.5 M, 36.69 mL) was slowly added at -78 °C, and the mixture was stirred at -78 °C for 30 min. Then, a tetrahydrofuran solution (100 mL) of 2-bromo-4-chlorobenzyl bromide (22.07 g, 77.62 mmol) was slowly added. The reaction was carried out at -78 °C for 3 h, and the reaction was stopped by LC-MS. The reaction was quenched by adding saturated ammonium chloride solution (100 mL), and the layers were separated. The aqueous phase was extracted twice with ethyl acetate (60 mL x 2). The organic phases were combined, concentrated under reduced pressure to remove the solvent, and the residue was purified by column chromatography with gradient elution (0-15% EA). The product was collected to give the title compound Int1a-3 (22.0 g).

[0453] Step 2: Synthesis of intermediate Int1a-4

[0454] Intermediate Int1a-3 (20.0 g, 51.59 mmol) was dissolved in tetrahydrofuran (300 mL), cooled in an ice bath, and 2N dilute hydrochloric acid (300 mL) was added dropwise. The reaction was allowed to proceed at room temperature for 2 h, and the reaction was confirmed by LC-MS. The pH was adjusted to weakly alkaline by adding ammonia, and the mixture was stirred and allowed to separate into layers. The aqueous phase was extracted twice with ethyl acetate (100 mL x 2). The organic phases were combined, concentrated under reduced pressure to remove the solvent, and the residue was purified by column chromatography with gradient elution (0-10% MeOH). The product was collected to give the title compound Int1a-4 (13.0 g).

[0455] Step 3: Synthesis of intermediate Int1a-5

[0456] Intermediate Int1a-4 (6.0 g, 20.50 mmol) was dissolved in dichloromethane (120 mL), followed by the sequential addition of N,N-diisopropylethylamine (6.23 g, 8.52 mmol) and di-tert-butyl dicarbonate (11.90 g, 51.27 mmol). The reaction was carried out at room temperature for 18 h, and the reaction was detected by LC-MS. The system was then diluted with dichloromethane (100 mL), washed once with water (50 mL x 1) and once with saturated brine (50 mL x 1), and the organic phase was concentrated under reduced pressure to remove the solvent. The residue was purified by column chromatography with gradient elution (0-50% EA), and the product was collected to give the title compound Int1a-5 (3.0 g).

[0457] Step 4: Synthesis of intermediate Int1a-6

[0458] Intermediate Int1a-5 (1.0 g, 2.55 mmol) was dissolved in tetrahydrofuran (20 mL), followed by the addition of an aqueous solution of lithium hydroxide (243.9 mg, 10.19 mmol) (10 mL). The reaction was allowed to proceed at room temperature for 4 h, and the reaction was confirmed by LC-MS. The system was then diluted with ethyl acetate (50 mL) and washed once each with water (20 mL x 1) and saturated brine (20 mL x 1). The organic phase was concentrated under reduced pressure to remove the solvent, and the residue was purified by column chromatography with gradient elution (0-10% MeOH). The product was collected to give the title compound Int1a-6 (931.0 mg).

[0459] Step 5: Synthesis of Int1a

[0460] Intermediate Int1a-6 (800.0 mg, 2.11 mmol) was dissolved in tetrahydrofuran (20 mL). Under nitrogen protection, the system was cooled to 0 °C and stirred. Then, sodium hydride (506.0 mg, 13.20 mmol, 60% purity) was added in portions. After the addition was complete, the system was kept at 0 °C and stirred for 1 h. Then, iodomethane (5.62 g, 39.61 mmol) was added, and the reaction was carried out at room temperature for 20 h. The reaction was detected by LC-MS and the reaction was considered complete. The system was quenched in ice water (30 mL), and the layers were separated. The aqueous phase was extracted with ethyl acetate (30 mL x 2). The organic phases were combined, concentrated under reduced pressure to remove the solvent, and the residue was purified by column chromatography with gradient elution (0-10% methanol). The product was collected to give the title compound Int1a (805.0 mg).

[0461] Synthesis of Int 11

[0462] Step 1: Synthesis of intermediate Int 11-1

[0463] Compound 8-1 (0.45 g, 623.18 μmol) was dissolved in dioxane hydrochloride solution (4 M, 16 mL), stirred at room temperature for 1 h, and the reaction was complete as monitored by LC-MS. The system was then concentrated to dryness under reduced pressure to obtain crude intermediate Int 11-1 (380.0 mg), which was directly used in the next reaction step.

[0464] Step 2: Synthesis of Int 11

[0465] (2S)-2-(tert-Butoxycarbonylamino)-2-cyclopropylacetic acid (176.53 mg, 820.11 μmol), N,N-diisopropylethylamine (264.99 mg, 2.05 mmol), and 2-(7-azobenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (311.83 mg, 820.11 μmol) were added to a 100 mL reaction flask. N,N-dimethylformamide (10 mL) was added, and the mixture was stirred under argon protection. Then, intermediate Int 11-1 (0.38 g, 577.08 μmol) was added. The reaction was allowed to proceed at room temperature for 1 h. Samples were taken and analyzed by LC-MS. The reaction was considered complete. Water (100 mL) was added to the mixture, and the mixture was extracted three times with ethyl acetate (60 mL x 3). The organic phases were combined and then subjected to saturated brine (40 mL). x2) Wash twice, concentrate under reduced pressure to remove solvent, mix the residue with silica gel, purify by column chromatography, gradient elution (0-30% EA), collect the product, concentrate under reduced pressure to dryness, and obtain the title compound Int 11 (0.48 g).

[0466] 1 H NMR(400MHz,Chloroform-d)δ7.48(d,J=8.4Hz,1H),7.17-7.12(m,2H),6.27(d,J=6.7H z,1H),5.35-5.30(m,1H),4.77-4.66(m,2H),4.50-4.45(m,1H),4.21(s,1H),3.49-3.3 6(m,2H),3.26(d,J=8.3Hz,1H),3.18-3.16(m,1H),3.12(s,3H),3.06(s,3H),2.72(s,3 H),2.12-1.95(m,3H),1.63(s,11H),1.43(s,9H),0.89-0.84(m,6H),0.44-0.31(m,4H).

[0467] Synthesis of Int 12

[0468] Step 1: Synthesis of intermediate Int 12-1

[0469] But-3-ene-2-amine hydrochloride (400.0 mg, 3.72 mmol) was dissolved in dichloromethane (10 mL), followed by the addition of di-tert-butyl dicarbonate (1.22 g, 5.58 mmol) and N,N-diisopropylethylamine (1.43 g, 11.15 mmol). The reaction was carried out at room temperature for 2 h, and the reaction was detected by LC-MS. The reaction was then terminated. The system was diluted with dichloromethane (50 mL), washed once with water (15 mL x 1) and once with saturated saline (15 mL x 1), and the organic phase was concentrated under reduced pressure to remove the solvent. The residue was mixed with silica gel and purified by column chromatography with gradient elution (0-20% EA). The product was collected and concentrated under reduced pressure to give compound Int 12-1 (514.0 mg).

[0470] Step 2: Synthesis of intermediate Int 12-2

[0471] Intermediate Int 12-1 (514.0 mg, 3.00 mmol) was dissolved in N,N-dimethylformamide (10 mL). Under nitrogen protection, the mixture was cooled in an ice bath, and then sodium hydride (481.16 g, 12.03 mmol) was added. After the addition was complete, the mixture was kept at 0-5 °C and stirred for 1 h. Then iodomethane (4.27 g, 30.08 mmol) was added, and the reaction was carried out at room temperature for 18 h. The reaction was detected by LC-MS, and the reaction was considered complete. The system was diluted with ethyl acetate (60 mL) and washed once each with water (20 mL x 1) and saturated brine (20 mL x 1). The organic phase was concentrated under reduced pressure to remove the solvent. The residue was mixed with silica gel and purified by column chromatography with gradient elution (0-10% EA). The product was collected and concentrated under reduced pressure to obtain compound Int 12-2 (347.0 mg).

[0472] Step 3: Synthesis of intermediate Int 12-3

[0473] Intermediate Int 12-2 (347.0 mg, 1.87 mmol) was dissolved in dichloromethane (5 mL), followed by the addition of a dioxane solution of hydrogen chloride (2.5 M, 18.7 mmol). The reaction was carried out at room temperature for 10 h, and the reaction was confirmed by LC-MS. The reaction solution was then concentrated to dryness under reduced pressure to obtain the crude title compound Int 12-3 (153.0 mg), which was used directly in the next step.

[0474] Step 4: Synthesis of intermediate Int 12-4

[0475] Intermediate Int 1a (2.65 g, 6.75 mmol) and potassium carbonate (2.80 g, 20.25 mmol) were dissolved in acetonitrile (100 mL). Under nitrogen protection, iodomethane (9.58 g, 67.49 mmol) was added, and the reaction was carried out at room temperature for 18 h. The reaction was detected by LC-MS, and the reaction was considered complete. The reaction solution was concentrated under reduced pressure to remove the solvent. The residue was diluted with ethyl acetate (100 mL), washed once with water (20 mL x 1) and once with saturated brine (20 mL x 1), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to dryness to obtain the crude title compound Int12-4 (2.7 g), which was directly used in the next reaction.

[0476] Step 5: Synthesis of intermediate Int 12-5

[0477] Intermediate Int 12-4 (2.7 g, 6.64 mmol) was dissolved in dichloromethane (40 mL), followed by the addition of a dioxane solution of hydrogen chloride (2.5 M, 70 mmol). The reaction was allowed to proceed at room temperature for 2 h, and the reaction was confirmed by LC-MS. The reaction solution was then concentrated to dryness under reduced pressure to obtain crude compound Int 12-5 (2.1 g), which was used directly in the next reaction step.

[0478] Step 6: Synthesis of intermediate Int 12-6

[0479] Intermediate Int 12-5 (1.18 g, 4.04 mmol), (tert-butoxycarbonyl)-L-leucine (1.12 g, 4.84 mmol), and 2-(7-azobenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (1.84 g, 4.84 mmol) were dissolved in N,N-dimethylformamide (10 mL), and finally N,N-diisopropylethylamine (1.56 g, 12.12 mmol) was added. The reaction was carried out at room temperature for 2 h under nitrogen protection, and the reaction was stopped by LC-MS. The system was diluted with ethyl acetate (100 mL), washed once with water (20 mL x 1) and once with saturated brine (20 mL x 1), and the organic phase was concentrated under reduced pressure to remove the solvent. The residue was mixed with silica gel and purified by column chromatography with gradient elution (0-10% MeOH). The product was collected and concentrated under reduced pressure to give compound Int 12-6 (1.71 g).

[0480] Step 7: Synthesis of intermediate Int 12-7

[0481] Intermediate Int 12-6 (1.71 g, 3.33 mmol) was dissolved in tetrahydrofuran (20 mL) and water (10 mL), and lithium hydroxide (239.3 mg, 9.99 mmol) was added. The reaction was carried out at room temperature for 2 h, and the reaction was detected by LC-MS. The system was concentrated under reduced pressure to remove some tetrahydrofuran. The residue was added to water (10 mL), and the pH was adjusted to about 3-4 with 2N hydrochloric acid. The mixture was extracted twice with ethyl acetate (20 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure to remove the solvent, and the residue was mixed with silica gel for column chromatography purification with gradient elution (0-10% MeOH). The product was collected and concentrated under reduced pressure to give compound Int 12-7 (1.22 g).

[0482] Step 8: Synthesis of intermediate Int 12-8

[0483] Intermediate Int 12-7 (732.0 mg, 1.45 mmol), intermediate Int 12-3 (147.86 mg, 1.74 mmol), and 2-(7-azobenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (660.29 mg, 4.84 mmol) were dissolved in N,N-dimethylformamide (10 mL). Finally, N,N-diisopropylethylamine (740.93 mg, 5.79 mmol) was added. The reaction was carried out at room temperature for 2 h under nitrogen protection, and the reaction was completed by LC-MS. The system was diluted with ethyl acetate (60 mL) and washed once each with water (20 mL x 1) and saturated brine (20 mL x 1). The organic phase was concentrated under reduced pressure to remove the solvent. The residue was mixed with silica gel and purified by column chromatography with gradient elution (0-10% MeOH). The product was collected and concentrated under reduced pressure to obtain compound Int 12-8 (781.0 mg).

[0484] Step 9: Synthesis of intermediate Int 12-9

[0485] Intermediate Int 12-8 (200.0 mg, 349.06 μmol) was dissolved in dichloromethane (10 mL), followed by the addition of a dioxane solution of hydrogen chloride (2.5 M, 3.49 mmol). The reaction was allowed to proceed at room temperature for 2 h, and the reaction was confirmed by LC-MS. The mixture was then concentrated to dryness under reduced pressure to obtain crude Int 12-9 (150.0 mg), which was used directly in the next reaction step.

[0486] Step 10: Synthesis of intermediate Int 12-10

[0487] Intermediate Int 12-9 (150.0 mg, 317.22 μmol), (2S)-2-[tert-butoxycarbonyl(methyl)amino]oct-7-enoic acid (94.69 mg, 317.22 μmol), and 2-(7-azobenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (159.22 mg, 418.74 μmol) were dissolved in N,N-dimethylformamide (10 mL). Finally, N,N-diisopropylethylamine (178.66 mg, 1.40 mmol) was added. The reaction was carried out at room temperature for 2 h under nitrogen protection. The reaction was completed by LC-MS. The system was diluted with ethyl acetate (50 mL) and washed once each with water (20 mL x 1) and saturated saline (20 mL x 1). The organic phase was concentrated under reduced pressure to remove the solvent. The residue was mixed with silica gel and purified by column chromatography with gradient elution (0-100% EA). The product was collected and concentrated under reduced pressure to give compound Int 12-10 (159.0 mg).

[0488] Step 11: Synthesis of Int12

[0489] The intermediate Int 12-10 (200.0 mg, 275.41 μmol) was dissolved in 1,2-dichloroethane (20 mL), and then Howeyda-Grubbs-2 was added. nd Catalyst (70.15 mg, 82.62 μmol), under nitrogen protection, the system was reacted at 70 °C for 2 h, and the reaction was completed by LC-MS. The reaction solution was directly concentrated to dryness under reduced pressure to obtain crude title compound Int12 (180.0 mg), which was directly used in the next reaction.

[0490] Synthesis of Int 13

[0491] Step 1: Synthesis of intermediate Int 13-1

[0492] Cuprous dimethyl sulfide bromide (20.94 g, 101.86 mmol) was added to a 250 mL reaction flask, followed by tetrahydrofuran (100 mL). The system was cooled to -78 °C and stirred. Then, a tetrahydrofuran solution of allyl magnesium bromide (1 M, 101.87 mmol, 101.87 mL) was slowly added dropwise. After the addition was complete, the system was kept at -78 °C and stirred for 30 min. Next, methyl (R)-2,3-epoxypropionate (8.0 g, 78.36 mmol) in tetrahydrofuran (10 mL) was added, and the system was kept at -78 °C for 1 h. The reaction was monitored by LC-MS until it was complete. Quenching was performed by adding saturated ammonium chloride aqueous solution (100 mL), stirring, and separating the layers. The aqueous phase was extracted twice with ethyl acetate (100 mL x 2). The organic phases were combined and washed once with saturated sodium chloride solution (80 mL x 1). The mixture was dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure to remove the solvent, and the residue was purified by column chromatography with gradient elution (0-30% EA). The product was collected to give intermediate Int 13-1 (4.7 g).

[0493] Step 2: Synthesis of intermediate Int 13-2

[0494] Intermediate Int 13-1 (3.4 g, 23.58 mmol) was dissolved in dichloromethane (60 mL), and the system was cooled in an ice bath. Then, pyridine (2.80 g, 35.38 mmol) was added, followed by trifluoromethanesulfonic anhydride (9.98 g, 35.38 mmol). The mixture was stirred at room temperature for 1 h. The reaction was monitored by TLC until completion. The system was quenched with saturated ammonium chloride aqueous solution (60 mL), stirred, and the layers were separated. The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to dryness under reduced pressure to obtain crude intermediate Int 13-2 (6.5 g), which was directly used in the next reaction step.

[0495] Step 3: Synthesis of intermediate Int 13-3

[0496] 3-Aminopyridine-2(1H)-one (3.0 g, 27.24 mmol) and di-tert-butyl dicarbonate (11.89 g, 54.49 mmol) were dissolved in tetrahydrofuran (80 mL), and the mixture was heated at 60 °C for 18 h. The reaction was stopped by LC-MS. The reaction solution was directly concentrated under reduced pressure to remove the solvent, and the residue was purified by column chromatography with gradient elution (0-50% EA). The product was collected to give intermediate Int 13-3 (2.0 g).

[0497] Step 4: Synthesis of intermediate Int 13-4

[0498] Intermediate Int 13-2 (3.42 g, 12.37 mmol), intermediate Int 13-3 (2.6 g, 12.37 mmol), and potassium carbonate (1.71 g, 12.37 mmol) were dissolved in tetrahydrofuran (80 mL), and the mixture was stirred at room temperature for 16 h. The reaction was monitored by LC-MS until it was complete. The reaction solution was directly filtered and washed with an appropriate amount of ethyl acetate. The filtrates were combined, concentrated under reduced pressure to remove the solvent, and the residue was purified by column chromatography with gradient elution (0-30% EA). The product was collected to give intermediate Int 13-4 (1.0 g).

[0499] Step 5: Synthesis of Int 13

[0500] Intermediate Int 13-4 (1.0 g, 2.97 mmol) and trimethyltin hydroxide (1.61 g, 8.92 mmol) were dissolved in 1,2-dichloroethane (30 mL), and the mixture was stirred at 60 °C for 4 h. The reaction was monitored by LC-MS until completion. The reaction solution was directly concentrated under reduced pressure to remove the solvent. The residue was dissolved in ethyl acetate (20 mL), and the pH was adjusted to 1-2 with 1 M hydrochloric acid. The mixture was separated into layers, and the organic phase was washed once with saturated saline solution (10 mL x 1), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to dryness to obtain crude intermediate Int13 (950.0 mg), which was directly used in the next reaction.

[0501] Synthesis of Int 14

[0502] Step 1: Synthesis of intermediate Int 14-2

[0503] 1.0 g (5.34 mmol) of N-methyl-N-(3-oxopropyl)carbamate tert-butyl ester was added to a 250 mL reaction flask, followed by the addition of tetrahydrofuran (25 mL). The mixture was purged with argon three times and stirred at -78 °C. Then, allyl magnesium bromide (1 M, 6.94 mmol, 6.94 mL) was added, and the reaction was carried out at -78 °C for 1 h. The reaction was then quenched by adding ammonium chloride aqueous solution (20 mL), and the mixture was stirred at 0 °C for 10 min. Ethyl acetate (60 mL) was added, and the mixture was stirred and separated into layers. The organic phase was washed twice with water (20 mL x 2) and twice with saturated brine (20 mL x 2). The mixture was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to remove the solvent. The residue was purified by column chromatography with gradient elution (0-50% ethyl acetate). The product was collected and concentrated under reduced pressure to give intermediate Int 14-2 (1.1 g).

[0504] Step 2: Synthesis of intermediate Int 14-3

[0505] Intermediate Int 14-2 (1.51 g, 6.58 mmol) was added to a 250 mL reaction flask, followed by 50 mL of dichloromethane. The mixture was stirred at 0 °C, then 5.59 g (13.17 mmol) of Dys-Martin oxidant was added. Under argon protection, the reaction was carried out at 0 °C for 10 min, then cooled to room temperature and stirred for 1 h. The reaction was then monitored by LC-MS, indicating completion. The mixture was stirred at 0 °C for 10 min, diluted with 50 mL of dichloromethane, and then 30 mL each of 10% sodium thiosulfate aqueous solution and saturated sodium bicarbonate aqueous solution were added. The mixture was stirred at 0 °C for 30 min, and the layers were separated. The organic phase was washed once with water (30 mL x 1) and once with saturated brine (30 mL x 1). The mixture was dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the residue was purified by column chromatography with gradient elution (0-30% ethyl acetate). The product was collected and concentrated under reduced pressure to obtain intermediate Int 14-3 (1.1 g).

[0506] Step 3: Synthesis of intermediate Int 14-4

[0507] Intermediate Int 14-3 (750.0 mg, 3.30 mmol) was added to a 100 mL reaction flask, followed by 10 mL of dichloromethane. The mixture was stirred at 0 °C under argon protection. Then, diethylaminosulfur trifluoride (15.96 g, 98.99 mmol, 13.08 mL) was added, and the mixture was stirred at 0 °C for 10 min. The reaction was then carried out at room temperature for 18 h. The reaction was analyzed by LC-MS, and the reaction was considered complete. The reaction solution was cooled to 0 °C and diluted with 300 mL of dichloromethane. The reaction was quenched with 150 mL of saturated sodium bicarbonate solution, and the layers were separated. The organic phase was washed twice with 50 mL of water (2 times) and once with 50 mL of saturated brine (1 time). The mixture was dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the residue was purified by column chromatography with gradient elution (0-30% ethyl acetate). The product was collected and concentrated under reduced pressure to obtain intermediate Int 14-4 (380.0 mg).

[0508] Step 4: Synthesis of intermediate Int 14-5

[0509] Intermediate Int 14-4 (200.0 mg, 802.26 μmol) was added to a 50 mL reaction flask, followed by acetonitrile (5 mL), and then p-toluenesulfonic acid (551.95 mg, 3.21 mmol). The reaction was carried out at 25 °C for 6 h, and the reaction was stopped by LC-MS. The reaction solution was then concentrated to dryness under reduced pressure to obtain crude compound Int 14-5 p-toluenesulfonate (700.0 mg), which was used directly in the next step.

[0510] Step 5: Synthesis of intermediate Int 14-6

[0511] Intermediate Int 14-5 (700.0 mg, 802.0 μmol) was added to a 50 mL reaction flask, followed by N,N-dimethylformamide (8 mL). The mixture was stirred, then intermediate Int 1 (420.0 mg, 815.86 μmol) and 2-(7-azabenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (310.21 mg, 815.86 μmol) were added. Finally, N,N-diisopropylethylamine (632.67 mg, 4.90 mmol) was added. The reaction was carried out at room temperature for 6 h under argon protection. The reaction was then analyzed by LC-MS, indicating the reaction was complete. The system was diluted with ethyl acetate (60 mL), then washed once with water (20 mL x 1) and once with saturated saline (20 mL x 1), dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure to remove the solvent, purified by column chromatography with gradient elution (0-50% ethyl acetate), collected the product, and concentrated under reduced pressure to dryness to obtain intermediate Int 14-6 (490.0 mg).

[0512] Step 6: Synthesis of intermediate Int 14-7

[0513] Intermediate Int 14-6 (500.0 mg, 774.04 μmol) was added to a 50 mL reaction flask, followed by 5 mL of dichloromethane and stirring. Then, diethylamine (1.70 g, 23.22 mmol) was added, and the mixture was reacted at room temperature for 16 h. The reaction was then analyzed by LC-MS, indicating the reaction was complete. The reaction solution was directly concentrated under reduced pressure to remove the solvent. The residue was mixed with silica gel and purified by column chromatography with gradient elution (0-5% methanol). The product was collected and concentrated under reduced pressure to obtain intermediate Int 14-7 (300.0 mg).

[0514] Step 7: Synthesis of intermediate Int 14-8

[0515] Intermediate Int 14-7 (125.0 mg, 305.10 μmol) was added to a 50 mL reaction flask, followed by N,N-dimethylformamide (5 mL). The mixture was stirred, then (tert-butoxycarbonyl)-L-leucine (105.85 mg, 457.66 μmol) and 2-(7-azabenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (150.81 mg, 396.64 μmol) were added. Finally, N,N-diisopropylethylamine (118.30 mg, 915.31 μmol) was added. The reaction was carried out at room temperature for 6 h under argon protection. The reaction was then analyzed by LC-MS, and the reaction was considered complete. The system was diluted with methyl tert-butyl ether (60 mL), then washed once with water (20 mL x 1) and once with saturated brine (20 mL x 1), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to dryness to obtain crude compound Int 14-8 (180.0 mg), which was directly used in the next reaction.

[0516] Step 8: Synthesis of intermediate Int 14-9

[0517] Intermediate Int 14-8 (1.2 g, 1.96 mmol) was added to a 100 mL reaction flask, followed by dichloromethane (30 mL) and stirring. Trifluoroacetic acid (6 mL) was then added, and the reaction was allowed to proceed at room temperature for 2 h. The reaction was then monitored by LC-MS, indicating completion of the reaction. The reaction solution was directly concentrated under reduced pressure to remove the solvent. The residue was redissolved in ethyl acetate (60 mL), washed once with 10% sodium carbonate aqueous solution (20 mL x 1), and the aqueous layer was extracted once with ethyl acetate (20 mL x 1). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to dryness to obtain crude compound Int 14-9 (1.0 g), which was directly used in the next reaction step.

[0518] Step 9: Synthesis of intermediate Int 14-10

[0519] Intermediate Int 14-9 (230.0 mg, 439.89 μmol) was added to a 100 mL reaction flask, followed by N,N-dimethylformamide (10 mL). The mixture was stirred, then N-tert-butyl formate-N-methyl-(S)-2-allylglycine (160.54 mg, 659.84 μmol) and 2-(7-azabenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (217.44 mg, 571.86 μmol) were added. Finally, N,N-diisopropylethylamine (170.56 mg, 1.32 mmol) was added. The reaction was carried out at room temperature for 2 h under argon protection. The reaction was then analyzed by LC-MS, indicating the reaction was complete. The system was diluted with methyl tert-butyl ether (60 mL), then washed once with water (20 mL x 1), once with saturated brine (20 mL x 1), dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure to remove the solvent, and the residue was purified by column chromatography with gradient elution (0-50% ethyl acetate). The product was collected and concentrated under reduced pressure to dryness to give compound Int 14-10 (200.0 mg).

[0520] Step 10: Synthesis of Int 14

[0521] Intermediate Int 14-10 (600.0 mg, 801.99 μmol) was added to a 250 mL heating flask, followed by the addition of 60 mL of 1,2-dichloroethane. Under argon protection, Hoveyda Grubbs-2 was then added. ndThe catalyst (50.25 mg, 80.20 μmol) was used in the reaction at 70 °C for 6 h. The reaction was stopped by LC-MS. The solvent was removed by concentration under reduced pressure, and the residue was purified by column chromatography with gradient elution (0-60% ethyl acetate). The product was collected and concentrated under reduced pressure to give the title compound Int 14 (400.0 mg).

[0522] Synthesis of Int 15

[0523] Step 1: Synthesis of intermediate Int 15-1

[0524] Compound 18-8 (450.0 mg, 898.19 μmol) was added to a 100 mL reaction flask, followed by N,N-dimethylformamide (10 mL). The mixture was stirred, then (2S)-2-(tert-butoxycarbonylamino)hex-5-enoic acid (308.89 mg, 1.35 mmol) and 2-(7-azabenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (443.97 mg, 1.17 mmol) were added. Finally, N,N-diisopropylethylamine (464.34 mg, 3.59 mmol) was added. The reaction was carried out under argon protection at room temperature for 2 h. The reaction was monitored by LC-MS, indicating completion of the reaction. The system was diluted with methyl tert-butyl ether (60 mL), washed once with water (20 mL x 1), and then rinsed with saturated saline solution (20 mL). x1) Wash once, dry with anhydrous sodium sulfate, filter, concentrate under reduced pressure to remove solvent, purify the residue by column chromatography, elute with gradient (0-50% ethyl acetate), collect the product, concentrate to dryness, and give intermediate Int 15-1 (420.0 mg).

[0525] Step 2: Synthesis of intermediate Int 15-2

[0526] Intermediate Int 15-1 (500.0 mg, 701.99 μmol) was added to a 250 mL heating flask, followed by the addition of 1,2-dichloroethane (50 mL). The mixture was kept under argon protection, and Hoveyda-grubbs II catalyst (65.98 mg, 105.30 μmol) was added. The reaction was carried out at 70 °C for 6 h, and the reaction was confirmed by LC-MS. The solvent was removed by concentration under reduced pressure, and the residue was purified by column chromatography with gradient elution (0-50% ethyl acetate). The product was collected to give intermediate Int 15-2 (280.0 mg).

[0527] Step 3: Synthesis of intermediate Int 15-3

[0528] Intermediate Int 15-2 (280.0 mg, 409.23 μmol) was added to a 100 mL reaction flask, followed by 15 mL of ethyl acetate. The mixture was stirred, and then platinum dioxide (92.93 mg, 409.23 μmol) was added. The system was purged with hydrogen three times, and the reaction was allowed to proceed at room temperature for 0.5 h. The reaction was then monitored by LC-MS, indicating completion. The mixture was directly filtered, and the filtrate was concentrated to dryness under reduced pressure to obtain intermediate Int 15-3 (260.0 mg).

[0529] Step 4: Synthesis of intermediate Int 15-4

[0530] Intermediate Int 15-3 (280.0 mg, 408.03 μmol) was added to a 100 mL reaction flask, followed by dichloromethane (5 mL) and stirring. Then, trifluoroacetic acid (1 mL) was added, and the reaction was allowed to proceed at room temperature for 2 h. The reaction was then monitored by LC-MS, indicating completion of the reaction. The system was concentrated under reduced pressure at room temperature to remove the solvent. The residue was dissolved in ethyl acetate (60 mL), washed once with 10% sodium carbonate aqueous solution (15 mL x 1), and the aqueous layer was extracted once with ethyl acetate (20 mL x 1). The combined organic phases were dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure to remove the solvent, and the residue was purified by column chromatography with gradient elution (0-50% ethyl acetate). The product was collected to give intermediate Int 15-4 (200.0 mg).

[0531] Step 5: Synthesis of intermediate Int 15-5

[0532] Intermediate Int 15-4 (220.0 mg, 375.35 μmol) was added to a 100 mL reaction flask, followed by 8 mL of dichloromethane. The mixture was cooled to 0 °C and stirred. N,N-diisopropylethylamine (243.0 mg, 1.88 mmol) and p-nitrobenzenesulfonyl chloride (415.93 mg, 1.88 mmol) were then added. The mixture was heated to room temperature and reacted for 12 h. The reaction was then analyzed by LC-MS, indicating the end of the reaction. The solvent was removed by direct concentration under reduced pressure. The residue was purified by column chromatography with gradient elution (0-50% ethyl acetate). The product was collected to obtain intermediate Int 15-5 (200.0 mg).

[0533] Step 6: Synthesis of intermediate Int 15-6

[0534] Intermediate Int 15-5 (40.0 mg, 51.86 μmol) was added to a 100 mL reaction flask, followed by N,N-dimethylacetamide (3 mL). The mixture was cooled to 0 °C and stirred. Cesium carbonate (50.69 mg, 155.59 μmol) and iodoethane (16.18 mg, 103.73 μmol) were then added. The reaction was carried out at room temperature for 5 h, and the reaction was monitored by LC-MS until completion. The system was diluted with methyl tert-butyl ether (30 mL), then washed once with saturated ammonium chloride aqueous solution (10 mL x 1), once with water (10 mL x 1), and once with saturated brine (20 mL x 1). The mixture was dried over anhydrous sodium sulfate, filtered, and concentrated to dryness under reduced pressure to obtain crude intermediate Int 15-6 (40.0 mg), which was directly used in the next reaction step.

[0535] Step 7: Synthesis of intermediate 15-7

[0536] Intermediate Int 15-6 (50.0 mg, 62.55 μmol) was added to a 100 mL reaction flask, followed by N,N-dimethylacetamide (3 mL). The mixture was cooled to 0 °C and stirred. Then, 2-mercaptoethanol (25.40 mg, 325.65 μmol) and 1,8-diazabicyclo[5.4.0]undec-7-ene (49.50 mg, 325.65 μmol) were added. The reaction was carried out at room temperature for 3 h, and the reaction was stopped by LC-MS. The system was directly purified by reverse-phase chromatography (acetonitrile / water = 0-60%), and the product was collected to obtain intermediate Int 15-7 (40.0 mg).

[0537] Step 8: Synthesis of intermediate Int 15

[0538] Intermediate 15-7 (30.0 mg, 48.85 μmol) was added to a 100 mL reaction flask, followed by N,N-dimethylformamide (3 mL). The mixture was stirred, then (S)-2-((tert-butoxycarbonyl)amino)-2-cyclopropylacetic acid (21.03 mg, 97.69 μmol) and 2-(7-azabenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (27.86 mg, 73.27 μmol). Finally, N,N-diisopropylethylamine (50.50 mg, 390.77 μmol, 68.25 μL) was added. The mixture was allowed to react at room temperature for 2 h. The reaction was then analyzed by LC-MS, and the reaction was considered complete. The system was diluted with methyl tert-butyl ether (60 mL), then washed once with water (20 mL x 1), washed once with saturated brine (20 mL x 1), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to dryness to obtain crude intermediate Int 15 (40.0 mg), which was directly used in the next reaction.

[0539] Synthesis of Int 17

[0540] Step 1: Synthesis of intermediate Int17-1

[0541] Intermediate Int 1 (600.0 mg, 1.16 mmol), N-methylhexyl-5-en-1-amine (211.0 mg, 1.86 mmol), and 2-(7-azabenzotriazolyl)-N,N,N',N'-tetramethylurea hexafluorophosphate (649.0 mg, 1.71 mmol) were dissolved in N,N-dimethylformamide (10 mL), followed by the addition of N,N-diisopropylethylamine (702.0 mg, 5.44 mmol). The mixture was stirred at room temperature for 3 h. The system was diluted with water (50 mL), extracted twice with ethyl acetate (50 mL x 2), and the organic phases were combined. The mixture was washed twice with saturated sodium chloride solution (20 mL x 2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to dryness to obtain the crude title compound (600.0 mg), which was used directly in the next reaction.

[0542] Step 2: Synthesis of intermediate Int17-2

[0543] Intermediate 17-1 (600.0 mg, 983.64 μmol) was dissolved in 20% piperidine in dichloromethane (10 mL), and the mixture was stirred at room temperature for 1 h. The system was diluted with dichloromethane (60 mL), washed twice with saturated ammonium chloride solution (20 mL x 2), the organic phase was concentrated under reduced pressure to remove the solvent, and the residue was purified by column chromatography with gradient elution (dichloromethane / methanol = 20 / 1) to give the title compound (300.0 mg).

[0544] Step 3: Synthesis of intermediate Int17-3

[0545] Intermediate 17-2 (300.0 mg, 773.71 μmol), (S)-2-((tert-butoxycarbonyl)amino)-4-methylpentanoic acid (233.0 mg, 1.01 mmol), and 2-(7-azabenzotriazolyl)-N,N,N',N'-tetramethylurea hexafluorophosphate (324.0 mg, 851.08 μmol) were dissolved in N,N-dimethylformamide (15 mL), followed by the addition of N,N-diisopropylethylamine (350.0 mg, 2.71 mmol). The mixture was stirred at room temperature for 2 h. The solution was diluted with water (80 mL), extracted twice with ethyl acetate (50 mL x 2), and the organic phases were combined. The mixture was washed twice with saturated sodium chloride solution (20 mL x 2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to dryness to give the crude compound (400.0 mg). This crude compound was used directly in the next reaction.

[0546] Step 4: Synthesis of intermediate Int17-4

[0547] Intermediate 17-3 (400.0 mg, 665.54 μmol) was dissolved in dichloromethane (15 mL), and then trifluoroacetic acid (3 mL) was added. The mixture was stirred at room temperature for 2 h. The reaction was stopped by LC-MS. The reaction solution was directly concentrated under reduced pressure to remove the solvent. The residue was then rotary evaporated once under reduced pressure with dichloromethane (20 mL) to obtain the crude title compound (300.0 mg), which was then directly proceeded to the next step.

[0548] Step 5: Synthesis of intermediate Int17-5

[0549] Intermediate Int17-4 (300.0 mg, 598.91 μmol), (S)-2-((tert-butoxycarbonyl)(methyl)amino)pent-4-enoic acid (137.3 mg, 598.91 μmol), and N,N-diisopropylethylamine (451.0 mg, 4.46 mmol) were dissolved in N,N-dimethylformamide (15 mL), followed by the addition of 2-(7-azabenzotriazolyl)-N,N,N',N'-tetramethylurea hexafluorophosphate (292.0 mg, 768.62 μmol). The mixture was stirred at room temperature for 2 h. The solution was diluted with water (70 mL), extracted twice with ethyl acetate (50 mL x 2), and the organic phases were combined. The mixture was washed twice with saturated sodium chloride solution (20 mL x 2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to dryness to obtain the crude title compound (500.0 mg), which was used directly in the next reaction.

[0550] Step 6: Synthesis of intermediate Int17-6

[0551] Intermediate Int17-5 (500.0 mg, 702.09 μmol) was dissolved in dichloromethane (10 mL), and trifluoroacetic acid (2 mL) was added. The mixture was stirred at room temperature for 2 h. The reaction solution was concentrated under reduced pressure to remove the solvent. The residue was dissolved in dichloromethane (40 mL), washed twice with saturated sodium carbonate solution (15 mL x 2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to dryness to obtain the crude title compound (400.0 mg), which was used directly in the next reaction.

[0552] Step 7: Synthesis of intermediate Int17-7

[0553] Intermediate Int17-6 (350.0 mg, 571.85 μmol), (S)-2-((tert-butoxycarbonyl)amino)-2-cyclopropylacetic acid (209.0 mg, 970.96 μmol), and 2-(7-azabenzotriazolyl)-N,N,N',N'-tetramethylurea hexafluorophosphate (292.0 mg, 768.62 μmol) were dissolved in N,N-dimethylformamide (15 mL), followed by the addition of N,N-diisopropylethylamine (451.0 mg, 3.49 mmol). The mixture was stirred at room temperature for 2 h. The solution was diluted with water (70 mL), extracted twice with ethyl acetate (50 mL x 2), and the organic phases were combined. The mixture was washed twice with saturated sodium chloride solution (20 mL x 2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to dryness to obtain the crude title compound (490.0 mg), which was used directly in the next reaction.

[0554] Step 8: Synthesis of intermediate Int17-8

[0555] Intermediate Int17-7 (450.0 mg, 556.06 μmol) was dissolved in dichloroethane (100 mL), followed by the addition of Howeyda-Grubbs second-generation catalyst (52.0 mg, 83.41 μmol). The reaction was carried out under nitrogen protection at 70 °C for 5 h. The solvent was removed by direct concentration under reduced pressure. The residue was mixed with silica gel and purified by column chromatography using a gradient elution (dichloromethane / methanol = 20 / 1) to obtain the title compound Int17-8 (420.0 mg).

[0556] Step 9: Synthesis of intermediate Int17-9

[0557] Intermediate Int17-8 (450.0 mg, 576.02 μmol) was dissolved in ethyl acetate (10 mL), and platinum dioxide (26.0 mg, 115.20 μmol) was added. The mixture was purged with hydrogen three times, and the mixture was stirred at room temperature for 2 h. The mixture was filtered, and the filtrate was concentrated to dryness under reduced pressure to obtain crude title compound Int17-9 (450.0 mg), which was used directly in the next step of the reaction.

[0558] Step 10: Synthesis of Int 17

[0559] Intermediate Int17-9 (450.0 mg, 574.53 μmol) was dissolved in dichloromethane (10 mL), and trifluoroacetic acid (2 mL) was added. The mixture was stirred at room temperature for 2 h. The reaction solution was concentrated under reduced pressure to remove the solvent. The residue was dissolved in dichloromethane (40 mL), washed twice with saturated sodium carbonate solution (15 mL x 2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to dryness to obtain crude Int17 (300.0 mg), which was directly used in the next reaction.

[0560] Example 1: (2S,4R)-N-((S)-2-(((3S,6S,9S)-3-(5-chloro-2-(1-methyl-1H-pyrazole-4-yl)benzyl)-6-isobutyl-1,4-dimethyl-2,5,8-trioxo-1,4,7-triazacyclohexadecane-9-yl)(methyl)amino)-1-cyclopropyl-2-oxoethyl)-1-(3,3-difluoro-1-(trifluoromethyl)cyclobutane-1-carbonyl)-4-(trifluoromethane)pyrrolidine-2-carboxamide (Compound 1)

[0561] Step 1: Synthesis of Intermediate 1-1

[0562] (2S,4R)-1-(tert-butoxycarbonyl)-4-(trifluoromethyl)pyrrolidine-2-carboxylic acid (27.32 mg, 96.45 μmol), N,N-diisopropylethylamine (34.0 mg, 263.04 μmol), and 2-(7-azobenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (40.0 mg, 105.22 μmol) were added to a 100 mL reaction flask. N,N-dimethylformamide (2 mL) was added, and the mixture was stirred for 0.5 h. Then, intermediate Int 7 (60.0 mg, 87.68 μmol) was added, and the reaction was allowed to proceed at room temperature for 2 h. The reaction was considered complete by LC-MS. The system was diluted with water (10 mL), extracted three times with ethyl acetate (10 mL x 2), the organic phases were combined, washed twice with saturated brine (10 mL x 2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to dryness to obtain crude compound 1-1 (80.0 mg), which was used directly in the next step.

[0563] Step 2: Synthesis of intermediates 1-2

[0564] Intermediate 1-1 (80.0 mg, 84.25 μmol) was dissolved in dichloromethane (4 mL), and trifluoroacetic acid (1 mL) was added. The mixture was stirred at room temperature for 2 h. The reaction was stopped by LC-MS. The solvent was removed by direct concentration under reduced pressure. The residue was redissolved in dichloromethane (30 mL), washed twice with saturated sodium bicarbonate aqueous solution (10 mL x 2), washed once with saturated brine (10 mL x 1), dried over anhydrous sodium sulfate, and concentrated to dryness under reduced pressure to obtain crude compound 1-2 (70.0 mg), which was directly used in the next reaction.

[0565] Step 3: Synthesis of Compound 1

[0566] 3,3-Difluoro-1-(trifluoromethyl)cyclobutane-1-carboxylic acid (14.4 mg, 70.64 μmol), N,N,N',N'-tetramethylchloromethanemidazone hexafluorophosphate (24.8 mg, 88.30 μmol), and intermediates 1-2 (50.0 mg, 58.86 μmol) were added to a 50 mL reaction flask, followed by acetonitrile (4 mL). The mixture was stirred, and then N-methylimidazole (12.0 mg, 147.16 μmol) was added. The reaction was allowed to proceed at room temperature for 2 h. The reaction was confirmed to be complete by LC-MS. The solvent was removed by concentration under reduced pressure, and the residue was preparatively separated (column: YMC C18; mobile phase A: 0.7% sodium bicarbonate; mobile phase B: acetonitrile, mobile phase B: 40%–95%, 25 mL / min) to obtain title compound 1 (9.3 mg).

[0567] LC-MS (ESI): m / z = 1035.4 [M+H] +

[0568] 1 H NMR(400MHz,DMSO-d6)δ8.50-8.10(m,2H),7.89(s,1H),7.57(s,1H),7.26-7.19(m,3H),5.3 5-5.27(m,1H),4.86-4.39(m,4H),4.14(t,J=11.8Hz,1H),3.88(s,3H),3.75(s,1H),3.68(s ,1H),3.25-3.02(m,6H),2.95(s,3H),2.76-2.63(m,6H),2.50-2.40(m,3H),2.33-2.30(m,2 H),2.03-1.99(m,3H),1.59-1.42(m,4H),1.24(s,8H),0.89-0.80(m,6H),0.70-0.63(m,4H).

[0569] Example 2: (2S,4S)-N-((S)-2-(((3S,6S,9S)-3-(5-chloro-2-(1-methyl-1H-pyrazole-4-yl)benzyl)-6-isobutyl-1,4-dimethyl-2,5,8-trioxo-1,4,7-triazacyclohexadecane-9-yl)(methyl)amino)-1-cyclopropyl-2-oxoethyl)-1-(3,3-difluoro-1-(trifluoromethyl)cyclobutane-1-carbonyl)-4-(trifluoromethane)pyrrolidine-2-carboxamide (Compound 2)

[0570] Step 1: Synthesis of intermediate 2-1

[0571] Intermediate Int 7 (45.0 mg, 65.76 μmol), (2S,4S)-1-(tert-butoxycarbonyl)-4-(trifluoromethyl)pyrrolidine-2-carboxylic acid (28.0 mg, 98.64 μmol), and 2-(7-azobenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (28.0 mg, 72.34 μmol) were dissolved in N,N-dimethylformamide (2 mL), followed by the addition of N,N-diisopropylethylamine (42.0 mg, 328.80 μmol). The reaction was carried out under nitrogen protection and stirred at room temperature for 16 h. The mixture was diluted with water (20 mL), extracted twice with ethyl acetate (20 mL x 2), and the organic phases were combined. The mixture was washed twice with saturated sodium chloride solution (10 mL x 2), dried over anhydrous sodium sulfate, and concentrated to dryness under reduced pressure to give compound 2-1 (60.0 mg), which was used directly in the next reaction.

[0572] Step 2: Synthesis of intermediate 2-2

[0573] Intermediate 2-1 (60.0 mg, 63.19 μmol) was dissolved in dichloromethane (2 mL), and then trifluoroacetic acid (0.4 mL) was added. The mixture was stirred at room temperature for 2 h under nitrogen protection. The solvent was removed by direct concentration under reduced pressure. The residue was redissolved in dichloromethane (30 mL), washed twice with saturated sodium bicarbonate aqueous solution (10 mL x 2), washed once with saturated brine (10 mL x 1), dried over anhydrous sodium sulfate, and concentrated to dryness under reduced pressure to obtain crude compound 2-2 (50.0 mg), which was directly used in the next reaction.

[0574] Step 3: Synthesis of Compound 2

[0575] Intermediate 2-2 (50.0 mg, 58.86 μmol), 3,3-difluoro-1-(trifluoromethyl)cyclobutane-1-carboxylic acid (18.0 mg, 88.30 μmol), and N,N,N',N'-tetramethylchloromethanemidazone hexafluorophosphate (24.0 mg, 87.45 μmol) were dissolved in acetonitrile (2 mL), followed by the addition of N-methylimidazole (25.0 mg, 312.26 μmol). The mixture was stirred at room temperature for 3 h under nitrogen protection. The system was directly filtered, and the filtrate was purified by preparative chromatography (column: YMC C18; mobile phase A: 0.7% sodium bicarbonate; mobile phase B: acetonitrile, mobile phase B: 35%–95%, 25 mL / min) to give title compound 2 (13.0 mg).

[0576] LC-MS (ESI): m / z = 1035.3 [M+H] +

[0577] 1H NMR (400MHz, Chloroform-d) δ8.81(s,1H),7.75(s,1H),7.54(s,1H),7.46(s,1H),7.25-7.19(m,2H),7.14(d,J=8. 0Hz,1H),5.65-5.38(m,1H),5.23-5.03(m,1H),4.96(s,1H),4.51(s,1H),4.33-4.20(m,1H),3.94(s,3H),3.80-3. 71(m,1H),3.64-3.52(m,1H),3.29-3.12(m,7H),3.05-2.93(m,1H),2.77(s,3H),2.57-2.47(m,3H),2.35(s,1H),1 .65-1.56(m,6H),1.44-1.17(m,12H),1.15-1.04(m,3H),0.96-0.91(m,3H),0.81-0.74(m,3H),0.54-0.42(m,4H).

[0578] Example 3: (2S,4R)-N-((S)-2-(((3S,6S,9S)-3-(5-chloro-2-(1-methyl-1H-pyrazol-4-yl)benzyl)-6-isobutyl-4-methyl-2,5,8-trioxo-1,4,7-triazabicyclo[13.1.1]heptadecane-9-yl)(methyl)amino)-1-cyclopropyl-2-oxoethyl)-1-(3,3-difluoro-1-(trifluoromethyl)cyclobutane-1-carbonyl)-4-fluoropyrrolidine-2-carboxamide (Compound 3)

[0579] Step 1: Synthesis of intermediate 3-2

[0580] (S)-2-((tert-Butoxycarbonyl)amino)hex-5-enoic acid (900.0 mg, 3.93 mmol) was dissolved in tetrahydrofuran (30 mL). Sodium hydride (628.0 mg, 15.70 mmol, 60% dispersed in mineral oil) was added under ice bath conditions. The mixture was stirred under ice bath conditions for 30 minutes. Iodomethane (4.46 g, 31.40 mmol) was added, and the mixture was slowly heated to room temperature and stirred for 16 hours. The reaction was quenched with water (10 mL), and the pH was adjusted to 2-3 with 2N HCl. The mixture was separated into layers, and the aqueous phase was extracted twice with ethyl acetate (15 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to dryness to give compound 3-2 (900.0 mg), which was used directly in the next reaction.

[0581] Step 2: Synthesis of intermediates 3-4

[0582] 3-Allylazine-1-carboxylic acid tert-butyl ester (compound 3-3, 700.0 mg, 3.55 mmol) was dissolved in acetonitrile (20 mL), and then p-toluenesulfonic acid (2.44 g, 14.19 mmol) was added. The mixture was stirred at room temperature for 16 h, and the reaction was stopped by TLC. The system was then directly concentrated to dryness under reduced pressure to give crude compound 3-4 (700.0 mg), which was not further purified and proceeded directly to the next step.

[0583] Step 3: Synthesis of intermediates 3-5

[0584] Intermediate 3-4 (700.0 mg), intermediate Int 1 (741.0 mg, 1.44 mmol), and 2-(7-azobenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (684.0 mg, 1.80 mmol) were dissolved in N,N-dimethylformamide (20 mL), followed by the addition of N,N-diisopropylethylamine (2.79 g, 21.61 mmol). The mixture was stirred at room temperature for 16 h. The solution was diluted with water (100 mL), extracted twice with ethyl acetate (60 mL x 2), and the organic phases were combined. The mixture was washed twice with saturated brine (30 mL x 2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to dryness to give crude compound 3-5 (700.0 mg), which was then directly proceeded to the next step.

[0585] Step 4: Synthesis of intermediates 3-6

[0586] Intermediate 3-5 (600.0 mg, 1.01 mmol) was dissolved in dichloromethane (10 mL), and then piperidine (2 mL) was added. The mixture was stirred at room temperature for 2 h. After dilution with saturated ammonium chloride (20 mL), the layers were separated. The aqueous phase was extracted twice with dichloromethane (15 mL x 2). The organic phases were combined, concentrated under reduced pressure to remove the solvent, and the residue was purified by column chromatography with gradient elution (dichloromethane / methanol = 20 / 1 to 10 / 1) to finally give compound 3-6 (300.0 mg).

[0587] Step 5: Synthesis of intermediates 3-7

[0588] Intermediate 3-6 (250.0 mg, 672.59 μmol), (tert-butoxycarbonyl)-L-leucine (202.0 mg, 874.36 μmol), and 2-(7-azobenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (281 mg, 739.85 μmol) were dissolved in N,N-dimethylformamide (8 mL), followed by the addition of N,N-diisopropylethylamine (260 mg, 2.02 mmol). The mixture was stirred at room temperature for 2 h. The solution was diluted with water (50 mL), extracted twice with ethyl acetate (40 mL x 2), and the organic phases were combined. The mixture was washed twice with saturated brine (20 mL x 2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to dryness to give crude compound 3-7 (350.0 mg), which was used directly in the next reaction.

[0589] Step 6: Synthesis of intermediates 3-8

[0590] Intermediate 3-7 (350.0 mg, 598.32 μmol) was dissolved in dichloromethane (15 mL), and then trifluoroacetic acid (3 mL) was added. The mixture was stirred at room temperature for 2 h under nitrogen protection. The solvent was removed by direct concentration under reduced pressure. The residue was diluted with ethyl acetate (60 mL), washed twice with saturated sodium carbonate solution (20 mL x 2), dried over anhydrous sodium sulfate, and the organic phase was concentrated to dryness under reduced pressure to give crude compound 3-8 (290.0 mg), which was directly used in the next reaction.

[0591] Step 7: Synthesis of intermediates 3-9

[0592] Intermediate 3-8 (250.0 mg, 515.62 μmol), intermediate 3-2 (188.0 mg, 773.43 μmol), and 2-(7-azobenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (215.0 mg, 567.18 μmol) were dissolved in N,N-dimethylformamide (10 mL), followed by the addition of N,N-diisopropylethylamine (266 mg, 2.06 mmol). The mixture was stirred at room temperature for 16 h. The system was diluted with water (50 mL), extracted twice with ethyl acetate (40 mL x 2), and the organic phases were combined. The mixture was washed twice with saturated brine (20 mL x 2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to dryness to give crude compound 3-9 (350.0 mg), which was used directly in the next reaction.

[0593] Step 8: Synthesis of intermediates 3-10

[0594] Intermediate 3-9 (330.0 mg, 464.70 μmol) was dissolved in dichloroethane (30 mL), and then Howeyda-Grubbs-2nd (29.0 mg, 46.47 μmol) was added. The mixture was stirred at 70 °C for 6 h under nitrogen protection. The solvent was removed by direct concentration under reduced pressure. The residue was mixed with silica gel and purified by column chromatography with gradient elution (dichloromethane / methanol = 20 / 1-10 / 1) to give compound 3-10 (200.0 mg).

[0595] Step 9: Synthesis of intermediate 3-11

[0596] Intermediate 3-10 (200.0 mg, 293.22 μmol) was dissolved in ethyl acetate (10 mL), then platinum dioxide (71.0 mg, 293.22 μmol) was added. The mixture was purged with hydrogen three times and stirred at room temperature for 2 h. The mixture was then filtered directly, and the filtrate was concentrated to dryness under reduced pressure to obtain crude compound 3-11 (200.0 mg), which was used directly in the next reaction.

[0597] Step 10: Synthesis of intermediates 3-12

[0598] Intermediate 3-11 (200.0 mg, 292.35 μmol), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxapentoborane-2-yl)-1H-pyrazole (121.0 mg, 584.71 μmol), and [1,1-bis(diphenylphosphine)ferrocene]palladium dichloride (42.0 mg, 58.47 μmol) were dissolved in dioxane (6 mL) and water (2 mL), and then N,N-diisopropylethylamine (445.0 mg, 3.44 mmol) was added. The system was protected under nitrogen and stirred at 85 °C for 6 h. The system was diluted with ethyl acetate (60 mL) and washed twice with water (20 mL x 2). The organic phase was concentrated under reduced pressure to remove the solvent. The residue was purified by column chromatography with gradient elution (dichloromethane / methanol = 20 / 1 to 10 / 1) to give compound 3-12 (120.0 mg).

[0599] Step 11: Synthesis of intermediates 3-13

[0600] Intermediate 3-12 (120.0 mg, 175.10 μmol) was dissolved in dichloromethane (10 mL), and then trifluoroacetic acid (2 mL) was added. The mixture was stirred at room temperature for 2 h under nitrogen protection. The solvent was removed by direct concentration under reduced pressure. The residue was diluted with ethyl acetate (50 mL), washed twice with saturated sodium carbonate solution (20 mL x 2), dried over anhydrous sodium sulfate, and the organic phase was concentrated to dryness under reduced pressure to give crude compound 3-13 (110.0 mg), which was directly used in the next reaction.

[0601] Step 12: Synthesis of Compound 3

[0602] Intermediate Int 4 (136.0 mg, 326.67 μmol), intermediate 3-13 (110.0 mg, 187.97 μmol), and 2-(7-azobenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (101.0 mg, 266.59 μmol) were dissolved in N,N-dimethylformamide (4 mL), followed by the addition of N,N-diisopropylethylamine (132 mg, 1.03 mmol). The mixture was stirred at room temperature for 12 h. The solution was diluted with water (20 mL), extracted twice with ethyl acetate (20 mL x 2), and the organic phases were combined. The solvent was removed by concentration under reduced pressure. The crude residue was purified by preparative chromatography (column: YMC C18; mobile phase A: 0.7% sodium bicarbonate; mobile phase B: acetonitrile, mobile phase B: 50%–95%, 25 mL / min) to give title compound 3 (15.0 mg).

[0603] LC-MS (ESI): m / z = 983.3 [M+H] +

[0604] 1 H NMR(400MHz,Chloroform-d)δ7.62-7.56(m,1H),7.52-7.37(m,1H),7.25-7.19(m,1H),7.17-7.02(m,1H),6 .70-6.49(m,1H),5.41-5.18(m,2H),4.93-4.72(m,2H),4.69-4.46(m,2H),4.14-4.03(m,1H),3.90-3.72(m ,3H),3.71-3.58(m,2H),3.52-3.37(m,2H),3.24-2.84(m,8H),2.79-2.57(m,4H),2.53-2.27(m,3H),1.76- 1.58(m,4H),1.57-1.41(m,8H),1.37-1.09(m,6H),1.06-0.96(m,1H),0.93-0.76(m,2H),0.65-0.27(m,6H).

[0605] Example 4: (3S,8aR)-N-((S)-2-(((3S,6S,9S)-3-(5-chloro-2-(1-methyl-1H-pyrazol-4-yl)benzyl)-6-isobutyl-1,4-dimethyl-2,5,8-trioxo-1,4,7-triazacyclohexadecane-9-yl)(methyl)amino)-1-cyclopropyl-2-oxoethyl)-6,6-dimethyl-5-oxooctahydroindoleazine-3-carboxamide (Compound 4)

[0606] Step 1: Synthesis of Compound 4-1

[0607] Boc-L-pyroglutamic acid methyl ester (10.0 g, 41.11 mmol) was dissolved in tetrahydrofuran (100 mL). Under nitrogen protection, lithium triethoxyborohydride (1 M, 49.33 mmol, 49.33 mL) was slowly added dropwise at -78 °C. After the addition was complete, the system was kept at -78 °C with stirring for 2 h. The reaction was then terminated. Saturated ammonium chloride (60 mL) was added to quench the reaction. The mixture was stirred and the layers were separated. The aqueous phase was extracted twice with ethyl acetate (50 mL x 2). The organic phases were combined, concentrated under reduced pressure to remove the solvent, and the residue was purified by column chromatography with gradient elution (dichloromethane:methanol = 20:1) to give compound 4-1 (8.0 g).

[0608] Step 2: Synthesis of compound 4-2

[0609] Compound 4-1 (8.0 g, 32.62 mmol) and p-toluenesulfonic acid monohydrate (631.0 mg, 3.67 mmol) were dissolved in methanol (60 mL). The mixture was stirred at room temperature for 16 h until the reaction was complete. The solvent was removed by direct concentration under reduced pressure, and the residue was purified by column chromatography with gradient elution (0-50% ethyl acetate) to give compound 4-2 (8.0 g).

[0610] Step 3: Synthesis of compound 4-3

[0611] Dissolve cuprous dimethyl sulfide (6.05 g, 28.92 mmol) in tetrahydrofuran (55 mL). Slowly add 1-allyl magnesium bromide (0.5 M, 23.14 mmol, 46.28 mL) dropwise at -50 °C. After the addition is complete, maintain the temperature at -50 °C and stir for 30 min. Then cool to -78 °C and slowly add boron trifluoride diethyl ether (4.93 g, 34.71 mmol, 4.29 mL) dropwise. Stir for 10 min. Slowly add a tetrahydrofuran solution (4 mL) of compound 4-2 (3.0 g, 11.57 mmol). Maintain the temperature at -78 °C and stir for 30 min. Then heat to room temperature and stir for 5 h. The reaction is complete. The mixture was cooled to -78°C, and saturated ammonium chloride solution (80 mL) was added to quench the reaction. The mixture was stirred and separated into layers. The aqueous phase was extracted twice with ethyl acetate (80 mL x 2). The organic phases were combined, concentrated under reduced pressure to remove the solvent, and the residue was purified by column chromatography with gradient elution (0-50% ethyl acetate) to give compound 4-3 (800.0 mg).

[0612] Step 4: Synthesis of compound 4-4

[0613] Compound 4-3 (570.0 mg, 2.12 mmol) was dissolved in tetrahydrofuran (20 mL), and lithium borohydride (139.0 mg, 6.35 mmol) was added at -20 °C. The system was heated to room temperature and reacted for 4 h until the reaction was complete. The reaction was quenched with water (20 mL), and the layers were separated. The aqueous phase was extracted twice with ethyl acetate (15 mL x 2). The organic phases were combined, concentrated under reduced pressure to remove the solvent, and the residue was purified by column chromatography with gradient elution (0-50% ethyl acetate) to give compound 4-4 (430.0 mg).

[0614] Step 5: Synthesis of compounds 4-5

[0615] Compound 4-4 (430.0 mg, 1.78 mmol) was dissolved in N,N-dimethylformamide (10 mL), followed by the addition of tert-butyldiphenylchlorosilane (735.0 mg, 2.67 mmol) and imidazole (485.0 mg, 7.13 mmol). The reaction was carried out under nitrogen protection and stirred at room temperature for 16 h until the reaction was complete. The solution was diluted with water (50 mL), extracted twice with ethyl acetate (20 mL x 2), and the organic phases were combined. The solution was washed once with saturated brine (15 mL x 1), concentrated under reduced pressure to remove the solvent, and purified by column chromatography with gradient elution (0-20% ethyl acetate) to give compound 4-5 (700.0 mg).

[0616] Step 6: Synthesis of compounds 4-6

[0617] Compounds 4-5 (700.0 mg, 1.46 mmol) were dissolved in dichloromethane (20 mL), and trifluoroacetic acid (2 mL) was added. The mixture was stirred at room temperature for 2 h under nitrogen protection. The solvent was removed by concentration under reduced pressure. The residue was dissolved in dichloromethane (30 mL), washed twice with saturated sodium carbonate solution (15 mL x 2), dried over anhydrous sodium sulfate, filtered, and concentrated to dryness under reduced pressure to obtain the crude product of the title compound (550.0 mg), which was used directly in the next reaction.

[0618] Step 7: Synthesis of compounds 4-7

[0619] Compounds 4-6 (550.0 mg, 1.45 mmol) were dissolved in dichloromethane (15 mL), and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (275.0 mg, 1.45 mmol), 4-dimethylaminopyridine (177.0 mg, 1.45 mmol), vinylacetic acid (187.0 mg, 2.17 mmol, 185.24 μL), and N,N-diisopropylethylamine (749.0 mg, 5.80 mmol, 1.01 mL) were added. The mixture was stirred at room temperature for 16 h until the reaction was complete. The reaction solution was diluted with dichloromethane (60 mL), washed twice with sodium bicarbonate solution (20 mL x 2), concentrated under reduced pressure to remove the solvent, and the residue was purified by column chromatography with gradient elution (0-60% ethyl acetate) to give compounds 4-7 (300.0 mg).

[0620] Step 8: Synthesis of compounds 4-8

[0621] Compound 4-7 (300.0 mg, 670.12 μmol) and Howeyda-Grubbs second-generation catalyst (42.0 mg, 67.01 μmol) were dissolved in 1,2-dichloroethane (25 mL). The reaction was carried out under nitrogen protection and heated at 70 °C for 2 h. The solvent was removed by direct concentration under reduced pressure to obtain crude compound 4-8 (270.0 mg), which was directly used in the next reaction.

[0622] Step 9: Synthesis of compounds 4-9

[0623] Compounds 4-8 (270.0 mg, 662.36 μmol) were dissolved in methanol (10 mL), then palladium / carbon (179.0 mg, 1.48 mmol) was added, and the mixture was purged with hydrogen three times. The reaction was carried out at room temperature for 2 h, and the reaction was terminated. The mixture was filtered, the filtrate was concentrated under reduced pressure, and the residue was purified by column chromatography with gradient elution (0-70% ethyl acetate) to give compounds 4-9 (200.0 mg).

[0624] Step 10: Synthesis of compounds 4-10

[0625] Compound 4-9 (200.0 mg, 490.65 μmol) was dissolved in tetrahydrofuran (7 mL). Under nitrogen protection, diisopropylaminolithium (2 M, 3.93 mmol, 1.96 mL) was slowly added dropwise at -78 °C. The mixture was stirred at -78 °C for 30 min, followed by the addition of iodomethane (1.04 g, 7.36 mmol, 458.18 μL). The system was slowly heated to room temperature and reacted for 24 h until the reaction was complete. The reaction was quenched with water (20 mL), and the mixture was extracted twice with ethyl acetate (15 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated to dryness under reduced pressure to obtain crude compound 4-10 (200.0 mg), which was used directly in the next reaction.

[0626] Step 11: Synthesis of compound 4-11

[0627] Compound 4-10 (180.0 mg, 413.15 μmol) was dissolved in tetrahydrofuran (10 mL), and tetrabutylammonium fluoride tetrahydrofuran solution (1 M, 1.24 mmol, 1.24 mL) was added. The mixture was stirred at room temperature for 16 h. The solvent was removed by direct concentration under reduced pressure, and the residue was purified by column chromatography with gradient elution (0-60% ethyl acetate) to give compound 4-11 (60.0 mg).

[0628] Step 12: Synthesis of Compounds 4-12

[0629] Compound 4-11 (60.0 mg, 304.15 μmol) and N-methylmorpholine oxide (142.0 mg, 1.22 mmol) were dissolved in acetonitrile (4 mL), and then tetrapropylammonium perruthenate (43.0 mg, 121.66 μmol) was added. The mixture was stirred at room temperature for 2 h under nitrogen protection. The solution was diluted with water (10 mL), and the pH was adjusted to approximately 3-4 with 2N dilute hydrochloric acid. The mixture was extracted three times with ethyl acetate (20 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated to dryness under reduced pressure to obtain the crude title compound 4-12 (40.0 mg), which was used directly in the next reaction.

[0630] Step 13: Synthesis of Compound 4

[0631] Intermediate Int7 (40.0 mg, 58.45 μmol), compound 4-12 (24.0 mg, 113.60 μmol), and 2-(7-azobenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (22.0 mg, 58.45 μmol) were dissolved in N,N-dimethylformamide (3 mL), followed by the addition of N,N-diisopropylethylamine (22.0 mg, 175.36 μmol, 30.63 μL). The mixture was reacted at room temperature for 2 h. The solution was diluted with water (20 mL), extracted three times with ethyl acetate (30 mL x 3), and the organic phases were combined. The solvent was removed by concentration under reduced pressure. The residue was purified by preparative chromatography (column: YMC C18; mobile phase A: 0.7% sodium bicarbonate aqueous solution; mobile phase B: acetonitrile, B%: 35%–95%, 25 mL / min) to give title compound 4 (20.0 mg).

[0632] LC-MS (ESI): m / z = 877.5 [M+H] +

[0633] 1H NMR(400MHz,Chloroform-d)δ7.66-7.55(m,3H),7.23-7.11(m,3H),6.39(s,1H),4.80-4.55(m,4H),4.39-4.20(m,3 H),3.98-3.90(m,3H),3.61-3.52(m,1H),3.42-3.12(m,3H),3.04(s,2H),2.81(t,J=17.6Hz,5H),2.69(s,2H),2.50 (d,J=13.1Hz,1H),2.32-2.22(m,1H),2.16-1.93(m,4H),1.78-1.65(m,3H),1.47-1.30(m,9H),1.28-1.17(m,9H),0 .98-0.93(m,2H),0.91-0.83(m,2H),0.79-0.71(m,3H),0.41(d,J=8.5Hz,2H),0.34-0.23(m,2H),0.22-0.18(m,1H).

[0634] Example 5: (2S,4R)-N-((S)-2-(((3S,6S,9S)-3-(5-chloro-2-(1-methyl-1H-pyrazol-4-yl)benzyl)-6-isobutyl-1,4-dimethyl-2,5,8-trioxo-1,4,7-triazacyclohexadecane-9-yl)(2-fluoroethyl)amino)-1-cyclopropyl-2-oxoethyl)-1-(3,3-difluoro-1-(trifluoromethyl)cyclobutane-1-carbonyl)-4-fluoropyrrolidine-2-carboxamide (Compound 5)

[0635] Step 1: Synthesis of Compound 5-1

[0636] Intermediate Int 7-4 (500.0 mg, 998.21 μmol), Boc-L-allylglycine (257.0 mg, 1.20 mmol), and 2-(7-azobenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (379.0 mg, 998.21 μmol) were dissolved in N,N-dimethylformamide (10 mL), followed by the addition of N,N-diisopropylethylamine (387.0 mg, 2.99 mmol, 523.02 μL). The reaction mixture was stirred at room temperature for 16 h under nitrogen protection. The mixture was diluted with water (50 mL), extracted twice with ethyl acetate (50 mL x 2), and the organic phases were combined. The mixture was washed once with saturated sodium chloride solution (30 mL x 1), dried over anhydrous sodium sulfate, and concentrated to dryness under reduced pressure to give crude compound 5-1 (680.0 mg), which was used directly in the next reaction.

[0637] Step 2: Synthesis of Compound 5-2

[0638] Compound 5-1 (600.0 mg, 859.44 μmol) and Howeyda-Grubbs second-generation catalyst (80.8 mg, 128.92 μmol) were dissolved in 1,2-dichloroethane (60 mL) and reacted at 70 °C for 4 h under nitrogen protection. The system was directly concentrated under reduced pressure to remove the solvent, and the residue was purified by column chromatography with gradient elution (0-10% methanol) to obtain crude compound 5-2 (250.0 mg), which was directly used in the next reaction.

[0639] Step 3: Synthesis of compound 5-3

[0640] Compound 5-2 (250.0 mg, 373.09 μmol) was dissolved in ethyl acetate (5 mL), and platinum dioxide (18.0 mg, 74.62 μmol) was added. The mixture was purged with hydrogen three times and reacted at room temperature for 2 h. LC-MS showed complete substrate conversion. The mixture was filtered, the filter cake was washed with ethyl acetate, and the filtrate was concentrated to dryness under reduced pressure to give crude compound 5-3 (250.0 mg), which was used directly in the next reaction.

[0641] Step 4: Synthesis of compound 5-4

[0642] Compound 5-3 (200.0 mg, 297.58 μmol), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxapentylborane-2-yl)-1H-pyrazole (92.0 mg, 446.37 μmol), [1,1'-bis(diphenylphosphine)ferrocene]palladium dichloride (32.63 mg, 44.64 μmol), and N,N-diisopropylethylamine (444.0 mg, 3.44 mmol, 0.6 mL) were dissolved in dioxane (6 mL) and water (1.5 mL). The mixture was heated and stirred at 85 °C for 8 h under nitrogen protection. The reaction solution was diluted with ethyl acetate (50 mL), washed twice with water (15 mL x 2), the organic phase was concentrated to remove the solvent, and the residue was purified by column chromatography with gradient elution (0-10% methanol) to give compound 5-4 (100.0 mg).

[0643] Step 5: Synthesis of compound 5-5

[0644] Compound 5-4 (90.0 mg, 133.67 μmol) was dissolved in dichloromethane (5 mL), and then trifluoroacetic acid (1 mL) was added. The mixture was stirred at room temperature for 2 h under nitrogen protection. The solvent was removed by direct concentration under reduced pressure. The residue was dissolved in dichloromethane (20 mL), washed twice with saturated sodium carbonate solution (10 mL x 2), dried over anhydrous sodium sulfate, and concentrated to dryness under reduced pressure to obtain crude compound 5-5 (75.0 mg), which was directly used in the next reaction.

[0645] Step 6: Synthesis of compounds 5-6

[0646] Compound 5-5 (75.0 mg, 130.85 μmol) and 4-nitrobenzenesulfonyl chloride (173.0 mg, 785.11 μmol) were dissolved in N-methylpyrrolidone (4 mL), followed by the addition of 2,6-dimethylpyridine (168.0 mg, 1.57 mmol, 182.88 μL). The reaction was carried out under nitrogen protection at room temperature for 3 h. The mixture was diluted with water (20 mL), extracted three times with ethyl acetate (15 mL x 3), and the organic phases were combined. The solvent was removed by concentration under reduced pressure, and the residue was purified by column chromatography with gradient elution (0-10% methanol) to give compound 5-6 (70.0 mg).

[0647] Step 7: Synthesis of compounds 5-7

[0648] Compounds 5-6 (60.0 mg, 79.12 μmol) and 1-fluoro-2-iodoethane (18.0 mg, 102.86 μmol) were dissolved in N,N-dimethylformamide (6 mL), followed by the addition of cesium carbonate (51.0 mg, 158.24 μmol). The mixture was stirred at room temperature for 16 h under nitrogen protection. The solution was diluted with water (40 mL), extracted twice with ethyl acetate (40 mL x 2), and the organic phases were combined. The mixture was washed once with saturated brine (20 mL x 1), concentrated under reduced pressure to remove the solvent, and purified by column chromatography with gradient elution (0-10% methanol) to give compound 5-7 (50.0 mg).

[0649] Step 8: Synthesis of compounds 5-8

[0650] Compound 5-7 (60.0 mg, 74.59 μmol) was dissolved in N-methylpyrrolidone (3 mL), followed by the addition of 1,8-diazabicyclo[5,4,0]undec-7-ene (56.0 mg, 372.96 μmol) and 2-mercaptoethanol (46.0 mg, 596.74 μmol, 42.00 μL). The mixture was stirred at room temperature for 2 h under nitrogen protection. The solution was diluted with water (15 mL), extracted twice with ethyl acetate (15 mL x 2), and the organic phases were combined. The solvent was removed by concentration under reduced pressure, and the residue was purified by column chromatography with gradient elution (0-10% methanol) to give compound 5-8 (30.0 mg).

[0651] Step 9: Synthesis of compounds 5-9

[0652] Compounds 5-8 (30.0 mg, 48.45 μmol), Boc-L-cyclopropylglycine (41.0 mg, 193.79 μmol), 2-(7-azobenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (27.0 mg, 72.67 μmol), and N,N-diisopropylethylamine (31.0 mg, 242.24 μmol, 42.31 μL) were dissolved in N,N-dimethylformamide (1.5 mL) and stirred at room temperature for 48 h under nitrogen protection. The solution was diluted with water (8 mL), extracted twice with ethyl acetate (10 mL x 2), and the organic phases were combined, dried over anhydrous sodium sulfate, concentrated under reduced pressure to remove the solvent, and purified by column chromatography with gradient elution (0-10% methanol) to give compounds 5-9 (13.0 mg).

[0653] Step 10: Synthesis of compounds 5-10

[0654] Compound 5-9 (12.0 mg, 14.70 μmol) was dissolved in dichloromethane (2 mL), and then trifluoroacetic acid (0.4 mL) was added. The mixture was stirred at room temperature for 2 h under nitrogen protection. The reaction solution was directly concentrated under reduced pressure to remove the solvent. The residue was dissolved in dichloromethane (10 mL), washed twice with saturated sodium carbonate solution (5 mL x 2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to dryness to obtain crude compound 5-10 (10.0 mg), which was directly used in the next reaction.

[0655] Step 11: Synthesis of Compound 5

[0656] Intermediate Int3 (9.8 mg, 30.71 μmol), compound 5-10 (10.0 mg, 13.96 μmol), and 2-(7-azobenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (5.84 mg, 15.36 μmol) were dissolved in N,N-dimethylformamide (1 mL), followed by the addition of N,N-diisopropylethylamine (6.0 mg, 46.07 μmol, 8.05 μL). The reaction was carried out at room temperature for 2 h. The mixture was diluted with water (5 mL), extracted three times with ethyl acetate (10 mL x 3), and the organic phases were combined. The solvent was removed by concentration under reduced pressure. The residue was purified by preparative chromatography (column: YMC C18; mobile phase A: 0.7% sodium bicarbonate; mobile phase B: acetonitrile, B%: 35%–95%, 25 mL / min) to give title compound 5 (1.5 mg).

[0657] LC-MS (ESI): m / z = 1017.5 [M+H] +

[0658] Example 6: (2S,4R)-N-((1S)-2-((3S,6S,9S)-3-((4-chloro-4'-(N,S-dimethylsulfonylimino)-[1,1'-biphenyl]-2-yl)methyl)-6-isobutyl-1,4-dimethyl-2,5,8-trioxo-1,4,7-triazacyclohexadecane-9-yl)(methyl)amino)-1-cyclopropyl-2-oxoethyl)-1-(3,3-difluoro-1-(trifluoromethyl)cyclobutane-1-carbonyl)-4-fluoropyrrolidine-2-carboxamide (Compound 6)

[0659] Step 1: Synthesis of Compound 6-2

[0660] (4-Bromophenyl)-iminomethyloxothione (50.0 mg, 213.57 μmol) was added to a 10 mL reaction flask, followed by N,N-dimethylformamide (2 mL). Sodium hydride (12.8 mg, 320.36 μmol, 60% purity) was added at 0 °C, and the mixture was stirred for 10 minutes. Then, iodomethane (60.6 mg, 427.14 μmol) was added, and the reaction was carried out at 25 °C for 3 hours. The reaction was sampled and monitored by LC-MS until completion. The reaction was quenched with saturated ammonium chloride aqueous solution (5 mL), and extracted twice with ethyl acetate (5 mL x 2). The organic phases were combined, washed once with saturated sodium chloride (5 mL x 1), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to dryness to obtain crude compound 6-2 (50.0 mg), which was directly used in the next reaction.

[0661] Step 2: Synthesis of Compound 6-3

[0662] Compound 6-2 (50.0 mg, 201.50 μmol) and pinacol diborate (76.7 mg, 302.25 μmol) were added to a 10 mL reaction flask, followed by 1,4-dioxane (2 mL), then potassium acetate (51.8 mg, 528.09 μmol) and [1,1'-bis(diphenylphosphine)ferrocene]palladium dichloride (14.7 mg, 20.15 μmol). The reaction was carried out at 90 °C for 4 h under an argon atmosphere. Samples were taken and monitored by LC-MS; the reaction was complete. The crude product was used directly in the next reaction without any further processing.

[0663] Step 3: Synthesis of Compound 6-4

[0664] Intermediate Int8 (200.0 mg, 291.49 μmol) was added to a 100 mL reaction flask, followed by 8 mL of dichloromethane and then 2 mL of trifluoroacetic acid. The reaction was allowed to proceed at room temperature for 2 h. A sample was taken, and the reaction was monitored by LC-MS until completion. The reaction solvent was removed by concentration under reduced pressure. The residue was dissolved in 20 mL of dichloromethane and washed three times with saturated sodium bicarbonate aqueous solution (5 mL x 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to dryness under reduced pressure to give compound 6-4 (165.0 mg), which was used directly in the next reaction step.

[0665] Step 4: Synthesis of compounds 6-5

[0666] (2S)-2-(tert-Butoxycarbonylamino)-2-cyclopropylacetic acid (72.7 mg, 337.88 μmol), 2-(7-azobenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (128.5 mg, 337.88 μmol), and N,N-diisopropylethylamine (109.2 mg, 844.71 μmol, 147.5 μL) were added to a 25 mL reaction flask, followed by 5 mL of N,N-dimethylformamide. The mixture was stirred for 30 min under argon protection, then compound 6-4 (165.0 mg, 281.57 μmol) was added. The reaction was allowed to proceed at room temperature for 16 h. Samples were taken and analyzed by LC-MS, indicating the reaction was complete. Water (20 mL) was added to the system, and the mixture was extracted three times with ethyl acetate (10 mL x 3). The organic phases were combined, washed twice with saturated brine (10 mL x 2), dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure to remove the solvent, and the residue was mixed with silica gel for purification by column chromatography with gradient elution (0-3% MeOH). The product was collected and concentrated to dryness under reduced pressure to give compound 6-5 (195.0 mg).

[0667] Step 5: Synthesis of Compound 6-6

[0668] Compound 6-5 (100.0 mg, 127.68 μmol) was dissolved in dichloromethane (4 mL), and trifluoroacetic acid (1 mL) was added. The mixture was stirred at room temperature for 2 h. LC-MS showed that the reaction was complete. The solvent was removed by direct concentration under reduced pressure. The residue was dissolved in dichloromethane (30 mL), washed twice with saturated sodium bicarbonate aqueous solution (10 mL x 2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to dryness to give compound 6-6 (75.0 mg), which was directly used in the next reaction.

[0669] Step 6: Synthesis of compounds 6-7

[0670] Intermediate Int3 (28.0 mg, 87.83 μmol), N,N,N',N'-tetramethylchloromethamidine hexafluorophosphate (24.6 mg, 87.83 μmol), N-methylimidazole (18.0 mg, 219.58 μmol), and compound 6-6 (50.0 mg, 73.19 μmol) were added to a 10 mL reaction flask, and acetonitrile (2 mL) was added. The system was reacted at room temperature for 1 h. Samples were taken, and LC-MS analysis was performed. The reaction was considered complete. Water (10 mL) was added to the system, and the mixture was extracted twice with ethyl acetate (10 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to remove the solvent. The residue was loaded onto a wet plate and eluted with a gradient (0-5% MeOH). The product was collected to give compound 6-7 (55.0 mg).

[0671] Step 7: Synthesis of Compound 6

[0672] Compounds 6-3 (10.8 mg, 36.57 μmol), 6-7 (30.0 mg, 30.48 μmol), potassium phosphate (19.4 mg, 91.44 μmol), and [1,1'-bis(diphenylphosphine)ferrocene]palladium dichloride (2.2 mg, 3.05 μmol) were added to a 10 mL reaction flask, along with 1,4-dioxane (2.5 mL) and water (0.5 mL). The reaction was carried out at 90 °C for 4 h under an argon atmosphere. Samples were taken, and the reaction was monitored by LC-MS, indicating complete reaction. The solvent was removed by direct concentration under reduced pressure, and the residue was preparatively separated by liquid chromatography (column: Ultimate C18, 5 μm 150 mm; flow rate: 20 mL / min, mobile phase A: water (0.05% NH3), mobile phase B: acetonitrile, acetonitrile gradient 45-75%), yielding the title compound 6 (7.07 mg).

[0673] LC-MS (ESI): m / z = 1072.7 [M+H] +

[0674] 1H NMR(400MHz,DMSO d6)δ8.37-8.23(m,2H),7.90(d,J=8.2Hz,2H),7.72-7.63(m,2H),7.40-7.35(m,2H),7.20-7.18(m,1H), 5.44-5.27(m,2H),4.64-4.39(m,4H),4.05-4.01(m,2H),3.87-3.55(m,3H),3.18(s,3H),3.10-2.99(m,3 H),2.92(s,3H),2.77-2.67(m,4H),2.58(s,3H),2.48-2.44(d,J=2.9Hz,3H),2.03-1.86(m,4H),1.63-1. 43(m,3H),1.42-1.29(m,5H),1.14-0.93(m,5H),0.92-0.80(m,4H),0.7-0.63(m,4H),0.53-0.31(m,4H).

[0675] Example 7: (2S,4R)-N-((S)-2-(((3S,6S,9S)-3-(5-chloro-2-(dimethylamino)benzyl)-6-isobutyl-1,4-dimethyl-2,5,8-trioxo-1,4,7-triazacyclohexadecane-9-yl)(methyl)amino)-1-cyclopropyl-2-oxoethyl)-1-(3,3-difluoro-1-(trifluoromethyl)cyclobutane-1-carbonyl)-4-fluoropyrrolidine-2-carboxamide (Compound 7)

[0676] Step 1: Synthesis of Compound 7-1

[0677] The starting material, 5-chloro-2-fluorobenzaldehyde (10.0 g, 63.07 mmol), was dissolved in N,N-dimethylformamide (100 mL), and dimethylamine hydrochloride (6.7 g, 81.99 mmol) and potassium carbonate (17.4 g, 126.14 mmol) were added. The system was heated to 100 °C and reacted for 5 h. The system was allowed to cool naturally, quenched in ice water (200 mL), and extracted four times with ethyl acetate (100 mL x 4). The organic phases were combined, washed once with saturated sodium chloride aqueous solution (80 mL x 1), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to remove the solvent. The residue was purified by column chromatography with gradient elution (petroleum ether:ethyl acetate = 5:1), and the product was collected to give compound 7-1 (8.8 g).

[0678] Step 2: Synthesis of Compound 7-2

[0679] Compound 7-1 (8.70 g, 47.38 mmol) was dissolved in methanol (40 mL), cooled in an ice bath, and sodium borohydride (2.63 g, 71.07 mmol) was added. The reaction was carried out at room temperature for 3 h, and the reaction was monitored by LC-MS until completion. The system was quenched with ammonium chloride aqueous solution (20 mL), and the system was concentrated under reduced pressure to remove some methanol. Then, water (80 mL) was added, the pH was adjusted to neutral with 2N dilute hydrochloric acid, and the mixture was extracted three times with dichloromethane (60 mL x 3). The organic phases were combined, washed once with saturated sodium chloride aqueous solution (30 mL x 1), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to remove the solvent, yielding crude compound 7-2 (8.44 g), which was directly used in the next reaction.

[0680] Step 3: Synthesis of Compound 7-3

[0681] Compound 7-2 (7.90 g, 42.55 mmol) was dissolved in dichloromethane (50 mL). Under argon protection, the mixture was cooled in an ice bath. Phosphorus tribromide (34.60 g, 127.66 mmol) was added at 0 °C, and the reaction was maintained at 0 °C for 3 h. The reaction was monitored by LC-MS until completion. The system was quenched in ice water (100 mL), stirred, and separated into layers. The aqueous phase was extracted three times with 30 mL x 3 liters of water. The organic phases were combined, washed once with saturated sodium chloride aqueous solution (30 mL x 1 liter), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to remove the solvent, yielding crude compound 7-3 (10.50 g), which was directly used in the next reaction.

[0682] Step 4: Synthesis of Compound 7-4

[0683] The starting material (R)-2,5-dihydro-3,6-dimethoxy-2-isopropylpyrazine (7.08 g, 38.41 mmol) was dissolved in tetrahydrofuran (80 mL), purged three times with argon, and the system was cooled to -78 °C. Then, n-butyllithium (2.5 M, 38.41 mmol, 15.4 mL) was added, and the mixture was stirred at -78 °C for 30 min. Then, compound 7-3 (10.50 g, 42.25 mmol) was added, and the mixture was kept at -78 °C on ice for 3 h. The reaction was monitored by LC-MS until it ended. The system was quenched with saturated ammonium chloride aqueous solution (30 mL), and water (30 mL) and ethyl acetate (30 mL) were added. The layers were separated, and the aqueous phase was extracted three times with ethyl acetate (25 mL x 3). The organic phases were combined, washed once with saturated sodium chloride aqueous solution (40 mL x 1), dried over anhydrous sodium sulfate, concentrated under reduced pressure to remove the solvent, and the residue was purified by column chromatography with gradient elution (petroleum ether: ethyl acetate = 8:1) to give compound 7-4 (8.75 g).

[0684] Step 5: Synthesis of Compounds 7-5

[0685] Compound 7-4 (8.75 g, 24.87 mmol) was dissolved in acetonitrile (30 mL), cooled in an ice bath with stirring, and 2N hydrochloric acid (18.7 mL) was added. The mixture was heated to room temperature and reacted for 6 h. The reaction was monitored by LC-MS until completion. The system was concentrated under reduced pressure to remove acetonitrile. The residue was diluted with water (50 mL) and the pH was adjusted to weakly alkaline with triethylamine. The mixture was extracted three times with ethyl acetate (50 mL x 3), and the organic phases were combined. The mixture was washed once with saturated sodium chloride aqueous solution (50 mL x 1), dried over anhydrous sodium sulfate, concentrated under reduced pressure to remove the solvent, and the residue was purified by column chromatography with gradient elution (using dichloromethane:methanol = 50:1) to give compound 7-5 (3.47 g).

[0686] Step Six: Synthesis of Compounds 7-6

[0687] Compound 7-5 (2.40 g, 9.35 mmol) was dissolved in tetrahydrofuran (15 mL), and an aqueous solution of lithium hydroxide (1.12 g, 46.74 mmol) (5 mL) was added. The mixture was stirred at room temperature for 15 h, and the reaction was monitored for completion by LC-MS. The system was concentrated under reduced pressure to remove tetrahydrofuran, and 1,4-dioxane (15 mL) was added. The pH was adjusted to weakly acidic with 2N dilute hydrochloric acid. An aqueous solution of sodium bicarbonate (3.14 g, 37.39 mmol) (5 mL) was added, followed by 9-fluorenylmethyl-N-succinimide carbonate (3.78 g, 11.22 mmol). The reaction was carried out at room temperature for 5 h. The reaction was monitored for completion by LC-MS. The pH of the system was adjusted to acidic with 2N dilute hydrochloric acid. Water (20 mL) was added to the system, and the mixture was extracted three times with ethyl acetate (40 mL x 3). The organic phases were combined, washed once with saturated sodium chloride aqueous solution (50 mL x 1), dried over anhydrous sodium sulfate, concentrated under reduced pressure to remove the solvent, and the residue was purified by column chromatography with gradient elution (dichloromethane:methanol = 50:1) to give compound 7-6 (3.50 g).

[0688] Step 7: Synthesis of Compound 7-7

[0689] Compound 7-6 (3.73 g, 8.02 mmol) was dissolved in toluene (20 mL), and formaldehyde aqueous solution (3.45 g, 42.52 mmol, 37% purity) was added. Under argon protection, p-toluenesulfonic acid (138.15 mg, 802.25 μmol) was added, and the reaction was heated at 100 °C for 15 h. The reaction was monitored by LC-MS until the reaction was complete. The system was directly concentrated under reduced pressure to remove the reaction solvent. The residue was added to water (20 mL), and the pH was adjusted to 8-9 with saturated sodium bicarbonate aqueous solution. The mixture was extracted three times with ethyl acetate (30 mL x 3), and the organic phases were combined. The mixture was washed once with saturated sodium chloride aqueous solution (30 mL x 1), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to remove the solvent. The residue was purified by column chromatography with gradient elution (petroleum ether: ethyl acetate = 5:1) to give compound 7-7 (2.18 g).

[0690] Step 8: Synthesis of Compounds 7-8

[0691] Compound 7-7 (2.18 g, 4.57 mmol) was dissolved in dichloromethane (40 mL). Under argon protection, triethylsilane (4.24 g, 36.57 mmol) and boron trifluoride diethyl ether (6.49 g, 45.71 mmol) were added, and the reaction was carried out at room temperature for 15 h. The reaction was monitored by LC-MS until the reaction was complete. The system was quenched with water (40 mL), and the layers were separated. The aqueous phase was extracted three times with dichloromethane (30 mL x 3). The organic phases were combined, washed twice with saturated sodium bicarbonate solution (20 mL x 2), and once with saturated sodium chloride aqueous solution (30 mL x 1). The mixture was dried over anhydrous sodium sulfate, concentrated under reduced pressure to remove the solvent, and the residue was purified by column chromatography with gradient elution (dichloromethane:methanol = 20:1) to give compound 7-8 (1.2 g).

[0692] Step Nine: Synthesis of Compounds 7-9

[0693] Compounds 7-8 (1.20 g, 2.51 mmol) were dissolved in N,N-dimethylformamide (15 mL), and N-methyl-5-hexen-1-amine (311.97 mg, 2.76 mmol), 2-(7-azobenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (1.43 g, 3.76 mmol), and N,N-diisopropylethylamine (971.42 mg, 7.52 mmol, 1.3 mL) were added. The mixture was reacted at room temperature for 2 h, and the reaction was monitored by LC-MS until completion. Water (50 mL) was added to the system, and the mixture was extracted three times with ethyl acetate (30 mL x 3). The organic phases were combined, washed once with saturated sodium chloride aqueous solution (30 mL x 1), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to dryness to obtain crude compound 7-9 (1.44 g), which was used directly in the next reaction.

[0694] Step 10: Synthesis of Compounds 7-10

[0695] Compound 7-9 (1.44 g, 2.51 mmol) was dissolved in dichloromethane (15 mL), and piperidine (1.07 g, 12.54 mmol) was added. The reaction was carried out at room temperature for 5 h, and the reaction was monitored by LC-MS until completion. The system was concentrated under reduced pressure to remove the solvent, and the residue was purified by column chromatography with gradient elution (dichloromethane:methanol = 50:1) to give compound 7-10 (1.2 g).

[0696] Step 11: Synthesis of Compounds 7-11

[0697] Compound 7-10 (1.10 g, 3.13 mmol) was dissolved in N,N-dimethylformamide (15 mL), and tert-butoxycarbonyl-L-leucine (795.25 mg, 3.44 mmol), 2-(7-azobenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (1.78 g, 4.69 mmol), and N,N-diisopropylethylamine (1.21 g, 9.38 mmol, 1.64 mL) were added. The reaction was carried out at room temperature for 2 h, and the reaction was monitored by LC-MS until the end of the reaction. Water (50 mL) was added to the system, and the mixture was extracted three times with ethyl acetate (40 mL x 3). The organic phases were combined, washed once with saturated sodium chloride aqueous solution (30 mL x 1), dried over anhydrous sodium sulfate, concentrated under reduced pressure to remove the solvent, and purified by column chromatography with gradient elution (petroleum ether:ethyl acetate = 5:1) to give compound 7-11 (990.0 mg).

[0698] Step Twelve: Synthesis of Compounds 7-12

[0699] Compound 7-11 (990.0 mg, 1.75 mmol) was dissolved in dichloromethane (10 mL), and trifluoroacetic acid (2 mL) was added. The reaction was carried out at room temperature for 2 h, and the reaction was monitored by LC-MS until completion. The system was directly concentrated to dryness under reduced pressure to obtain crude compound 7-12 (814.0 mg), which was used directly in the next reaction.

[0700] Step Thirteen: Synthesis of Compounds 7-13

[0701] Compound 7-12 (814.0 mg, 1.75 mmol) was dissolved in N,N-dimethylformamide (10 mL), and (S)-2-((tert-butoxycarbonyl)(methyl)amino)pent-4-enoic acid (481.55 mg, 2.10 mmol), 2-(7-azobenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (1.33 g, 3.50 mmol) and N,N-diisopropylethylamine (1.13 g, 8.75 mmol, 1.53 mL) were added. The reaction was carried out at room temperature for 2 h, and the reaction was monitored by LC-MS until it ended. Water (30 mL) was added to the system, and the mixture was extracted three times with ethyl acetate (30 mL x 3). The organic phases were combined, washed once with saturated sodium chloride aqueous solution (30 mL x 1), dried over anhydrous sodium sulfate, concentrated under reduced pressure to remove the solvent, and purified by column chromatography with gradient elution (petroleum ether: ethyl acetate = 5:1) to give compound 7-13 (1.04 g).

[0702] Step Fourteen: Synthesis of Compounds 7-14

[0703] Compound 7-13 (940.0 mg, 1.39 mmol) was dissolved in 1,2-dichloroethane (10 mL), and Hoveyda-Grubbs second-generation catalyst (87.0 mg, 138.99 μmol) was added. The reaction was carried out under argon protection at 70 °C for 2 h, and the reaction was monitored by LC-MS until the reaction was complete. The system was concentrated under reduced pressure to remove the solvent, and the residue was purified by column chromatography with gradient elution (dichloromethane:methanol = 50:1) to give compound 7-14 (880.0 mg).

[0704] Step 15: Synthesis of Compounds 7-15

[0705] Compound 7-14 (400.0 mg, 617.02 μmol) was dissolved in ethyl acetate (8 mL), and platinum dioxide (28.0 mg, 123.40 μmol) was added. The mixture was purged with hydrogen three times, and the reaction was carried out at room temperature for 2 h. The reaction was monitored by LC-MS until it was complete. The system was filtered through a diatomaceous earth liner, and the filtrate was concentrated to dryness under reduced pressure to obtain crude compound 7-15 (400.0 mg), which was used directly in the next reaction.

[0706] Step Sixteen: Synthesis of Compounds 7-16

[0707] Compound 7-15 (450.0 mg, 692.00 μmol) was dissolved in dichloromethane (5 mL), and trifluoroacetic acid (1 mL) was added. The reaction was carried out at room temperature for 1 h, and the reaction was monitored by LC-MS until completion. The system was directly concentrated to dryness under reduced pressure to obtain crude compound 7-16 (380.0 mg), which was directly used in the next reaction.

[0708] Step 17: Synthesis of Compounds 7-17

[0709] Compound 7-16 (300.0 mg, 545.28 μmol) was dissolved in N,N-dimethylformamide (5 mL), and (S)-2-(tert-butoxycarbonyl)amino)-2-cyclopropylacetic acid (140.84 mg, 654.34 μmol), 2-(7-azobenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (415.0 mg, 1.09 mmol) and N,N-diisopropylethylamine (353.0 mg, 2.73 mmol, 476.18 μL) were added. The reaction was carried out at room temperature for 1 h, and the reaction was monitored by LC-MS until it ended. Water (20 mL) was added to the system, and the mixture was extracted three times with ethyl acetate (20 mL x 3). The organic phases were combined, washed once with saturated sodium chloride aqueous solution (20 mL x 1), dried over anhydrous sodium sulfate, concentrated under reduced pressure to remove the solvent, and the residue was purified by column chromatography with gradient elution (dichloromethane:methanol = 50:1) to give compound 7-17 (400.0 mg).

[0710] Step 18: Synthesis of Compounds 7-18

[0711] Compound 7-17 (480.0 mg, 642.22 μmol) was dissolved in dichloromethane (10 mL), and trifluoroacetic acid (2 mL) was added. The reaction was carried out at room temperature for 2 h, and the reaction was monitored by LC-MS until completion. The system was directly concentrated to dryness under reduced pressure to obtain crude compound 7-18 (415.0 mg), which was directly used in the next reaction.

[0712] Step Nineteen: Synthesis of Compound 7

[0713] Compound 7-18 (415.0 mg, 641.14 μmol) was dissolved in N,N-dimethylformamide (10 mL), and intermediate Int3 (246.0 mg, 769.36 μmol), 2-(7-azobenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (488.0 mg, 1.28 mmol) and N,N-diisopropylethylamine (415.0 mg, 3.21 mmol, 559.88 μL) were added. The reaction was carried out at room temperature for 2 h, and the reaction was monitored by LC-MS until it ended. Water (20 mL) was added to the system, and the mixture was extracted three times with ethyl acetate (15 mL x 3). The organic phases were combined, washed once with saturated sodium chloride aqueous solution (15 mL x 1), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to remove the solvent. The residue was then subjected to preparative separation (chromatographic column: Waters Xbridge Prep C18 5um OBD, 19*150 mm; flow rate 15 mL / min, mobile phase A: water (0.05% NH3), mobile phase B: acetonitrile, acetonitrile gradient 55%-80%), finally yielding the title compound 7 (17.5 mg).

[0714] LC-MS (ESI): m / z = 948.73 [M+H] +

[0715] 1 H NMR(400MHz,Chloroform-d)δ7.16(m,1H),7.05-7.00(m,2H),6.33(d,J=6.4Hz,1H),5.34(s,1H),5.21(s,1H),4.89-4.72(m,4H),4.54-4.32(m,3H), 3.80(m,2H),3.58-3.41(m,3H),3.25-3.06(m,9H),2.93(m,3H),2.66(m,9 H),2.56(m,1H),2.45-2.31(m,2H),1.40-1.28(m,8H),0.94(m,3H),0.83(m 2H),0.75(m,3H),0.41(m,2H),0.30(m,2H),0.20(m,1H).

[0716] Example 8: (2S,4R)-N-((S)-2-(((3S,6S,9S)-3-(5-chloro-2-(1-methyl-1H-pyrazol-4-yl)benzyl)-15,15-difluoro-6-isobutyl-1,4-dimethyl-2,5,8-trioxo-1,4,7-triazacyclohexadecane-9-yl)(methyl)amino)-1-cyclopropyl-2-oxoethyl)-1-(3,3-difluoro-1-(trifluoromethyl)cyclobutane-1-carbonyl)-4-fluoropyrrolidine-2-carboxamide (Compound 8)

[0717] Step 1: Synthesis of Compound 8-1

[0718] Intermediate Int10 (112.0 mg, 155.54 μmol) was added to a 100 mL reaction flask, followed by 10 mL of ethyl acetate. The mixture was stirred, and then platinum dioxide (35.0 mg, 10% m / m) was added. The system was purged with hydrogen three times, and the reaction was allowed to proceed at room temperature for 0.5 h. The reaction was then confirmed by LC-MS. The mixture was directly filtered, and the filtrate was concentrated to dryness under reduced pressure to obtain crude compound 8-1 (110.0 mg), which was used directly in the next reaction step.

[0719] Step 2: Synthesis of Compound 8-2

[0720] Compound 8-1 (100.0 mg, 138.49 μmol) and 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborhexacyclopentan-2-yl)-1H-pyrazole (57.63 mg, 276.97 μmol) were added to a 50 mL reaction flask, along with 1,4-dioxane (5 mL) and water (0.5 mL). The mixture was stirred, and then potassium phosphate (117.58 mg, 553.94 μmol) and [1,1'-bis(diphenylphosphine)ferrocene]palladium dichloride (16.95 mg, 20.77 μmol) were added. The system was purged with argon three times, and the reaction was carried out at 90 °C for 8 h. The reaction was then analyzed by LC-MS, and the reaction was considered complete. Cool to room temperature, dilute with ethyl acetate (30 mL), wash once with saturated sodium chloride aqueous solution (10 mL x 1), concentrate under reduced pressure to remove solvent, purify the residue by column chromatography with gradient elution (0-100% ethyl acetate), collect the product to give compound 8-2 (100.0 mg).

[0721] Step 3: Synthesis of Compound 8-3

[0722] Compound 8-2 (160.45 mg, 221.83 μmol) was added to a 100 mL reaction flask, followed by 10 mL of dichloromethane and stirring. Then, 2 mL of trifluoroacetic acid was added, and the reaction was allowed to proceed at room temperature for 2 h. The reaction was then monitored by LC-MS, indicating completion. The solvent was removed by concentration under reduced pressure at room temperature. The residue was redissolved in 60 mL of ethyl acetate, then washed once with 15 mL x 10% sodium carbonate aqueous solution. The aqueous layer was extracted once with 20 mL x 1 ethyl acetate. The combined organic phases were dried over anhydrous sodium sulfate and concentrated to dryness under reduced pressure to obtain compound 8-3 (130.0 mg), which was directly used in the next reaction.

[0723] Step 4: Synthesis of Compound 8-4

[0724] Compound 8-3 (140.45 mg, 225.38 μmol) was added to a 100 mL reaction flask, followed by 8 mL of N,N-dimethylformamide. The mixture was stirred, and then (S)-2-((tert-butoxycarbonyl)amino)-2-cyclopropylacetic acid (48.51 mg, 225.38 μmol), 2-(7-azabenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (111.41 mg, 293.00 μmol), and N,N-diisopropylethylamine (87.39 mg, 676.15 μmol) were added. The mixture was allowed to react at room temperature for 2 h, and the reaction was stopped by LC-MS. The system was diluted with methyl tert-butyl ether (60 mL), then washed once with water (20 mL x 1), once with saturated brine (20 mL x 1), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to dryness to give compound 8-4 (170.0 mg), which was used directly in the next reaction.

[0725] Step 5: Synthesis of Compound 8-5

[0726] Compound 8-4 (181.99 mg, 221.83 μmol) was added to a 100 mL reaction flask, followed by 10 mL of dichloromethane and stirring. Then, 2 mL of trifluoroacetic acid was added, and the reaction was allowed to proceed at room temperature for 2 h. The reaction was then monitored by LC-MS, indicating completion. The solvent was removed by concentration under reduced pressure at room temperature. The residue was redissolved in ethyl acetate (50 mL), washed once with 15 mL x 10% sodium carbonate aqueous solution, and extracted once with ethyl acetate (20 mL x 1). The combined organic phases were dried over anhydrous sodium sulfate and concentrated to dryness under reduced pressure to obtain compound 8-5 (160.0 mg), which was directly used in the next reaction.

[0727] Step Six: Synthesis of Compound 8

[0728] Compound 8-5 (170.0 mg, 236.02 μmol) and intermediate Int3 (75.34 mg, 236.02 μmol) were added to a 100 mL reaction flask, followed by acetonitrile (10 mL). The mixture was stirred and then added under argon protection. 1-Methylimidazole (58.13 mg, 708.05 μmol) was added, and finally N,N,N',N'-tetramethylchloroformamidine hexafluorophosphate (80.0 mg, 283.22 μmol) was added. The reaction was carried out at room temperature for 4 h, and the reaction was detected by LC-MS. The solvent was removed by concentration under reduced pressure. The residue was redissolved in ethyl acetate (50 mL) and then washed twice with water (20 mL x 2). The solvent was removed by concentration under reduced pressure. The residue was purified by preparative separation (chromatographic column: Ultimate C18, 5 μm 150 mm; flow rate: 20 mL / min, mobile phase A: water (0.05% NH3), mobile phase B: acetonitrile, acetonitrile gradient: 50-80%), yielding title compound 8 (91.0 mg).

[0729] LC-MS (ESI): m / z = 1021.72 [M+H] +

[0730] 1 H NMR(400MHz,DMSO-d6)δ8.47-7.99(m,2H),7.92(s,1H),7.61(s,1H),7.35-7.24(m,2H),7.22 -7.14(m,1H),5.34(d,J=51.8Hz,1H),4.88-4.39(m,4H),4.24(s,1H),3.88(s,3H),3.81-3.5 2(m,2H),3.27-3.13(m,2H),3.07-2.96(m,4H),2.91-2.81(m,4H),2.61(d,J=4.6Hz,3H),2.4 9-2.33(m,2H),2.12-1.77(m,4H),1.70-1.02(m,12H),0.91-0.65(m,8H),0.48-0.17(m,4H).

[0731] Example 9: (2S,4R)-N-((S)-2-(((3S,6S,9S)-3-(5-chloro-2-(1-methyl-1H-pyrazol-4-yl)benzyl)-15,15-difluoro-6-isobutyl-1,4-dimethyl-2,5,8-trioxo-1,4,7-triazacyclohexadecane-12-en-9-yl)(methyl)amino)-1-cyclopropyl-2-oxoethyl)-1-(3,3-difluoro-1-(trifluoromethyl)cyclobutane-1-carbonyl)-4-fluoropyrrolidine-2-carboxamide (Compound 9)

[0732] Step 1: Synthesis of Compound 9-2

[0733] Intermediate Int10 (92.0 mg, 127.76 μmol) and 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborhexacyclopentan-2-yl)-1H-pyrazole (53.17 mg, 255.53 μmol) were added to a 100 mL reaction flask, followed by 1,4-dioxane (8 mL) and water (1 mL). The mixture was stirred, and then potassium phosphate (108.48 mg, 511.05 μmol) and [1,1'-bis(diphenylphosphine)ferrocene]palladium dichloride (5.64 mg, 19.16 μmol) were added. The system was purged with argon three times, and the reaction was carried out at 90 °C for 8 h. The reaction was then analyzed by LC-MS, and the reaction was considered complete. Cool to room temperature, dilute with ethyl acetate (30 mL), wash once with saturated sodium chloride aqueous solution (10 mL), concentrate under reduced pressure to remove solvent, purify the residue by column chromatography with gradient elution (0-100% ethyl acetate), collect the product, and give compound 9-2 (85.0 mg).

[0734] Step 2: Synthesis of Compound 9-3

[0735] Compound 9-2 (160.45 mg, 221.83 μmol) was added to a 100 mL reaction flask, followed by 10 mL of dichloromethane and stirring. Then, 2 mL of trifluoroacetic acid was added, and the reaction was allowed to proceed at room temperature for 2 h. The reaction was then monitored by LC-MS, indicating completion. The solvent was removed by concentration under reduced pressure at room temperature. The residue was redissolved in ethyl acetate (50 mL), washed once with 15 mL x 10% sodium carbonate aqueous solution, and the aqueous layer was extracted once with ethyl acetate (20 mL x 1). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated to dryness under reduced pressure to obtain crude compound 9-3 (120.0 mg), which was directly used in the next reaction.

[0736] Step 3: Synthesis of Compound 9-4

[0737] Compound 9-3 (140.0 mg, 225.38 μmol) was added to a 100 mL reaction flask, followed by N,N-dimethylformamide (8 mL). The mixture was stirred, and then (S)-2-((tert-butoxycarbonyl)amino)-2-cyclopropylacetic acid (48.51 mg, 225.38 μmol), 2-(7-azabenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (111.41 mg, 293.00 μmol), and N,N-diisopropylethylamine (87.39 mg, 676.15 μmol) were added. The mixture was allowed to react at room temperature for 2 h, and the reaction was stopped by LC-MS. The system was diluted with methyl tert-butyl ether (60 mL), then washed once with water (20 mL x 1), washed once with saturated brine (20 mL x 1), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to dryness to give crude compound 9-4 (170.0 mg), which was directly used in the next reaction.

[0738] Step 4: Synthesis of Compound 9-5

[0739] Compound 9-4 (181.99 mg, 222.37 μmol) was added to a 100 mL reaction flask, followed by 10 mL of dichloromethane and stirring. Then, 2 mL of trifluoroacetic acid was added, and the reaction was allowed to proceed at room temperature for 2 h. The reaction was then monitored by LC-MS, indicating completion. The solvent was removed by concentration under reduced pressure at room temperature. The residue was redissolved in ethyl acetate (50 mL), washed once with 15 mL x 10% sodium carbonate aqueous solution, and the aqueous layer was extracted once with ethyl acetate (30 mL x 1). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated to dryness under reduced pressure to obtain crude compound 9-5 (150.0 mg), which was directly used in the next reaction.

[0740] Step 5: Synthesis of Compound 9

[0741] Compound 9-5 (140.0 mg, 194.91 μmol) and intermediate Int3 (62.22 mg, 194.91 μmol) were added to a 100 mL reaction flask, followed by acetonitrile (10 mL). The mixture was stirred and placed under argon protection. Then, 1-methylimidazole (53.06 mg, 646.25 μmol) was added, and finally N,N,N',N'-tetramethylchloroformamidine hexafluorophosphate (72.53 mg, 258.50 μmol) was added. The reaction was carried out at room temperature for 4 h, and the reaction was detected by LC-MS. The system was concentrated under reduced pressure to remove the solvent. The residue was dissolved in ethyl acetate (60 mL), washed twice with water (20 mL x 2), concentrated under reduced pressure to remove the solvent, and the residue was purified by preparative separation (chromatographic column: Ultimate C18, 5 μm 150 mm; flow rate: 20 mL / min, mobile phase A: water (0.05% NH3), mobile phase B: acetonitrile, acetonitrile gradient: 50-80%), to obtain title compound 9 (76.0 mg).

[0742] LC-MS (ESI): m / z = 1019.83 [M+H] +

[0743] 1 H NMR (400MHz, DMSO-d6) δ8.38(d,J=7.1Hz,1H),8.25(d,J=7.7Hz,1H),7.93(s,1H),7.63(s,1H),7. 35-7.26(m,2H),7.18-7.15(m,1H),5.70-5.66(m,1H),5.41-5.27(m,2H),4.81-4.32(m,6H),3.88( s,3H),3.84-3.52(m,4H),3.24-3.07(m,2H),3.04-2.94(m,4H),2.92-2.82(m,4H),2.64-2.52(m,4 H),2.44-2.38(m,1H),2.20-2.14(m,1H),2.00-1.34(m,8H),0.99-0.63(m,8H),0.47-0.19(m,4H).

[0744] Example 10: (2S,4R)-N-((S)-2-(((3S,6S,9S)-3-(5-chloro-2-(1-(3,3-difluorocyclobutyl)-1H-pyrazole-4-yl)benzyl)-6-isobutyl-1,4-dimethyl-2,5,8-trioxo-1,4,7-triazacyclohexadecane-9-yl)(methyl)amino)-1-cyclopropyl-2-oxoethyl)-1-(3,3-difluoro-1-(trifluoromethyl)cyclobutane-1-carbonyl)-4-fluoropyrrolidine-2-carboxamide (Compound 10)

[0745] Step 1: Synthesis of Compound 10-2

[0746] 3,3-Difluorocyclobutanol (10⁻¹, 500.0 mg, 4.63 mmol) was added to a 100 mL reaction flask, followed by 10 mL of dichloromethane. The mixture was stirred, and N,N-diisopropylethylamine (837.01 mg, 6.48 mmol) was added at 0 °C. The mixture was kept at 0 °C for 5 min, then trifluoromethanesulfonic anhydride (1.57 g, 5.55 mmol) was added. The mixture was allowed to warm to room temperature and reacted for 14 h. The reaction was then analyzed by TLC, indicating the end of the reaction. The mixture was used directly in the next reaction without any post-treatment purification.

[0747] Step 2: Synthesis of compound 10⁻³

[0748] 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborhecyclopentan-2-yl)-1H-pyrazole (300.0 mg, 1.55 mmol) was dissolved in 1,2-dichloroethane (20 mL) and added to the reaction solution of intermediate 10⁻² obtained in step 1. Then, N,N-diisopropylethylamine (999.11 mg, 7.73 mmol) was added. The system was stirred at 70 °C for 14 h, and the reaction was completed by LC-MS. The solvent was removed by concentration under reduced pressure, and the residue was purified by column chromatography with gradient elution (0-30% ethyl acetate). The product was collected and concentrated under reduced pressure to give compound 10⁻³ (140.0 mg).

[0749] Step 3: Synthesis of compound 10⁻⁴

[0750] Intermediate Int8 (170.0 mg, 247.77 μmol) and intermediate 10⁻³ (105.59 mg, 371.66 μmol) were added to a 100 mL reaction flask, along with 1,4-dioxane (8 mL) and water (1 mL). The mixture was stirred, and then potassium phosphate (210.37 mg, 991.08 μmol) and [1,1'-bis(diphenylphosphine)ferrocene]palladium dichloride (30.33 mg, 37.17 μmol) were added. The system was purged with argon three times, and the reaction was carried out at 90 °C for 10 h. The reaction was then analyzed by LC-MS, indicating the end of the reaction. After cooling to room temperature, the mixture was diluted with ethyl acetate (50 mL), washed once with saturated sodium chloride aqueous solution (10 mL x 1), concentrated under reduced pressure to remove the solvent, and purified by column chromatography with gradient elution (0-100% ethyl acetate). The product was collected to give compound 10⁻⁴ (180.0 mg).

[0751] Step 4: Synthesis of compound 10-5

[0752] Intermediate 10⁻⁴ (200.0 mg, 262.00 μmol) was added to a 100 mL reaction flask, followed by dichloromethane (10 mL) and stirring. Then, trifluoroacetic acid (2 mL) was added, and the reaction was allowed to proceed at room temperature for 2 h. The reaction was then monitored by LC-MS, indicating completion. The solvent was removed by concentration under reduced pressure at room temperature. The residue was redissolved in ethyl acetate (60 mL), washed once with 10% sodium carbonate aqueous solution (15 mL x 1), and the aqueous layer was extracted once with ethyl acetate (20 mL x 1). The combined organic phases were dried over anhydrous sodium sulfate and concentrated under reduced pressure to dryness, yielding crude compound 10⁻⁵ (170.0 mg), which was directly used in the next reaction step.

[0753] Step 5: Synthesis of compound 10-6

[0754] Intermediate 10⁻⁵ (170.0 mg, 256.32 μmol) was added to a 100 mL reaction flask, followed by N,N-dimethylformamide (8 mL). The mixture was stirred, and then (S)-2-((tert-butoxycarbonyl)amino)-2-cyclopropylacetic acid (55.17 mg, 256.32 μmol), 2-(7-azabenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (126.7 mg, 333.21 μmol), and N,N-diisopropylethylamine (99.38 mg, 768.95 μmol) were added. The mixture was allowed to react at room temperature for 2 h, and the reaction was stopped by LC-MS. The system was diluted with methyl tert-butyl ether (60 mL), then washed once with water (20 mL x 1), once with saturated brine (20 mL x 1), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to dryness to give crude compound 10⁻⁶ (200.0 mg), which was directly used in the next reaction.

[0755] Step 6: Synthesis of compound 10-7

[0756] Intermediate 10⁻⁶ (200.0 mg, 232.95 μmol) was added to a 100 mL reaction flask, followed by dichloromethane (10 mL) and stirring. Then, trifluoroacetic acid (2 mL) was added, and the reaction was allowed to proceed at room temperature for 2 h. The reaction was then monitored by LC-MS, indicating completion. The solvent was removed by concentration under reduced pressure at room temperature. The system was reconstituted with ethyl acetate (70 mL), then washed once with 10% sodium carbonate aqueous solution (15 mL x 1). The aqueous layer was extracted once with ethyl acetate (30 mL x 1). The combined organic phases were dried over anhydrous sodium sulfate and concentrated under reduced pressure to dryness, yielding crude compound 10⁻⁷ (150.0 mg), which was directly used in the next reaction step.

[0757] Step 7: Synthesis of Compound 10

[0758] Intermediate 10-7 (130.0 mg, 170.97 μmol) and intermediate Int3 (54.57 mg, 170.97 μmol) were added to a 100 mL reaction flask, followed by acetonitrile (10 mL). The mixture was stirred and placed under argon protection. Then, 1-methylimidazole (53.06 mg, 646.25 μmol) was added, and finally N,N,N',N'-tetramethylchloroformamidin hexafluorophosphate (72.53 mg, 258.50 μmol) was added. The reaction was carried out at room temperature for 4 h, and the reaction was detected by LC-MS. The reaction was then considered complete. The system was concentrated under reduced pressure to remove the solvent. The residue was dissolved in ethyl acetate (60 mL), then washed twice with water (20 mL x 2), and the solvent was removed by concentrated under reduced pressure. The residue was then purified by preparative separation (chromatographic column: Ultimate C18, 5 μm 150 mm; flow rate: 20 mL / min, mobile phase A: water (0.05% NH3), mobile phase B: acetonitrile, acetonitrile gradient: 60-80%) to obtain compound 10 (79.0 mg).

[0759] LC-MS (ESI): m / z = 1061.66 [M+H] +

[0760] 1 H NMR(400MHz,DMSO-d6)δ8.42-8.20(m,2H),8.08(s,1H),7.72(s,1H),7.35-7.15(m,3H),5.46-5.25(m, 1H), 4.96 (q, J = 7.2Hz, 1H), 4.77 (d, J = 11.8Hz, 1H), 4.65 (d, J = 8.5Hz, 1H), 4.52 (t, J = 7.3Hz, 1H), 4.14 (t ,J=11.8Hz,2H),3.86-3.52(m,3H),3.29-2.89(m,11H),2.84-2.62(m,8H),2.43-2.37(m,1H),2.08-1.8 2(m,2H),1.56(t,J=11.9Hz,2H),1.17(dd,J=80.3,21.8Hz,12H),0.95-0.58(m,8H),0.49-0.12(m,4H).

[0761] Example 11: (2S,4R)-N-((S)-2-(((3S,6S,9S)-3-(5-chloro-2-(1-(((3,3-difluorocyclobutyl)sulfonyl)-1H-pyrazole-4-yl)benzyl)-6-isobutyl-1,4-dimethyl-2,5,8-trioxo-1,4,7-triazacyclohexadecane-9-yl)(methyl)amino)-1-cyclopropyl-2-oxoethyl)-1-(3,3-difluoro-1-(trifluoromethyl)cyclobutane-1-carbonyl)-4-fluoropyrrolidine-2-carboxamide (Compound 11)

[0762] Step 1: Synthesis of Compound 11-1

[0763] The starting material 3-bromo-1,1-difluorocyclobutane (2.0 g, 11.70 mmol) was dissolved in dimethyl sulfoxide (10 mL), and potassium thioacetate (2.67 g, 23.39 mmol) was added. The reaction was carried out at 40 °C for 15 h, and the reaction was monitored by TLC until the end of reaction. Water (20 mL) was added to the system, and the mixture was extracted three times with ethyl acetate (25 mL x 3). The organic phases were combined, washed once with saturated sodium chloride aqueous solution (20 mL x 1), dried over anhydrous sodium sulfate, concentrated under reduced pressure to remove the solvent, and the residue was purified by column chromatography with gradient elution (petroleum ether: ethyl acetate = 10:1) to give compound 11-1 (1.58 g).

[0764] Step 2: Synthesis of Compound 11-2

[0765] N-chlorosuccinimide (401.0 mg, 3.01 mmol) was dissolved in acetonitrile (5 mL), cooled in an ice bath, and 2N hydrochloric acid (1.5 mL) and compound 11-1 (100.0 mg, 601.73 μmol) were added at 0 °C. The reaction was maintained at 0 °C for 20 min, and the reaction was monitored by TLC until the starting material was completely reacted. The system was concentrated under reduced pressure to remove the solvent, and the residue was added to dichloromethane (5 mL). The mixture was separated, and the organic phase was dried over anhydrous sodium sulfate. The solvent was removed by concentrated under reduced pressure, and the residue was purified by column chromatography with gradient elution (petroleum ether: ethyl acetate = 7:1) to obtain crude compound 11-2 (144.0 mg), which was directly used in the next reaction.

[0766] Step 3: Synthesis of Compound 11-3

[0767] 4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborhecyclopentan-2-yl)-1H-pyrazole (100.0 mg, 515.36 μmol) was dissolved in dichloromethane (3 mL), cooled in an ice bath, and then triethylamine (104.0 mg, 1.03 mmol, 142.88 μL) and compound 11-2 (118.0 mg, 618.44 μmol) were added. The mixture was allowed to rise naturally to room temperature for 15 h. The reaction was monitored by LC-MS until it was complete. The system was concentrated under reduced pressure to remove the solvent, and the residue was purified by column chromatography with gradient elution (petroleum ether: ethyl acetate = 5:1) to give compound 11-3 (40.0 mg).

[0768] Step 4: Synthesis of Compound 11-4

[0769] Intermediate Int8 (79.0 mg, 114.89 μmol) was dissolved in 1,4-dioxane (5 mL) and water (1 mL). Then, intermediate 11-3 (40.0 mg, 114.89 μmol), [1,1-bis(diphenylphosphine)ferrocene]palladium dichloride (17.0 mg, 22.98 μmol), and N,N-diisopropylethylamine (75.0 mg, 574.43 μmol, 100.33 μL) were added. The reaction was carried out at 85 °C for 5 h under argon protection, and the reaction was monitored by LC-MS until completion. Water (20 mL) was added to the system, and the mixture was extracted three times with ethyl acetate (25 mL x 3). The organic phases were combined, washed once with saturated sodium chloride aqueous solution (20 mL x 1), dried over anhydrous sodium sulfate, concentrated under reduced pressure to remove the solvent, and purified by column chromatography with gradient elution (petroleum ether:ethyl acetate = 5:1) to give compound 11-4 (60.0 mg).

[0770] Step 5: Synthesis of Compound 11-5

[0771] Intermediate 11-4 (60.0 mg, 72.51 μmol) was dissolved in 1,2-dichloromethane (5 mL), and trifluoroacetic acid (1 mL) was added. The reaction was carried out at room temperature for 5 h, and the reaction was monitored by LC-MS until completion. The system was directly concentrated to dryness under reduced pressure to obtain crude compound 11-5 (52.0 mg), which was used directly in the next step.

[0772] Step Six: Synthesis of Compound 11-6

[0773] Intermediate 11-5 (52.0 mg, 71.50 μmol) was dissolved in N,N-dimethylformamide (5 mL), followed by (S)-2-(tert-butoxycarbonyl)amino)-2-cyclopropylacetic acid (21.0 mg, 96.52 μmol) and 2-(7-azabenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (57.0 mg, 148.49 μmol). Under argon protection, N,N-diisopropylethylamine (48.0 mg, 371.23 μmol, 64.84 μL) was added. The reaction was carried out at room temperature for 1 h, and the reaction was monitored by LC-MS until it ended. Water (20 mL) was added to the system, and the mixture was extracted three times with ethyl acetate (25 mL x 3). The organic phases were combined, washed twice with saturated sodium chloride aqueous solution (20 mL x 2), dried over anhydrous sodium sulfate, concentrated under reduced pressure to remove the solvent, and purified by column chromatography with gradient elution (dichloromethane:methanol = 50:1) to give compound 11-6 (44.0 mg).

[0774] Step 7: Synthesis of Compounds 11-7

[0775] Intermediate 11-6 (44.0 mg, 47.59 μmol) was dissolved in 1,2-dichloromethane (10 mL), and trifluoroacetic acid (2 mL) was added. The reaction was carried out at room temperature for 1 h, and the reaction was monitored by LCMS until completion. The system was concentrated to dryness under reduced pressure to obtain crude compound 11-7 (39.0 mg), which was used directly in the next step.

[0776] Step 8: Synthesis of Compound 11

[0777] Intermediate 11-7 (39.0 mg, 47.31 μmol) was dissolved in N,N-dimethylformamide (5 mL), and intermediate Int3 (19.0 mg, 59.52 μmol) and 2-(7-azabenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (36.0 mg, 94.61 μmol) were added. Under argon protection, N,N-diisopropylethylamine (25.0 mg, 189.22 μmol, 33.05 μL) was added last. The reaction was carried out at room temperature for 2 h, and the reaction was monitored by LC-MS until it ended. Water (20 mL) was added to the system, and the mixture was extracted twice with ethyl acetate (25 mL x 2). The organic phases were combined, washed twice with saturated sodium chloride aqueous solution (15 mL x 2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to remove the solvent. The residue was then separated by preparative chromatography (column: Waters Xbridge Prep C18 5um OBD, 19*150 mm; flow rate 15 mL / min; mobile phase A: water (0.05% NH3), mobile phase B: acetonitrile, acetonitrile gradient: 55-80%), yielding the title compound 11 (20.4 mg).

[0778] LC-MS (ESI): m / z = 1125.3 [M+H] +

[0779] 1 H NMR(400MHz,Chloroform-d)δ8.23(s,1H),7.96(s,1H),7.35(m,1H),7.25-7.19(m,2H),7.16-7.12(m,1H),6.40(s,1H), 5.34(m,1H),5.22(m,1H),4.87(m,1H),4.82-4.72(m,2H),4.32-4.22(m,2H),4.13(m,1H),3.83(m,1H),3.52-3.41(m,2H ),3.29-3.06(m,8H),3.05-2.93(m,4H),2.86-2.76(m,5H),2.51(m,1H),2.44-2.31(m,2H),2.10(m,1H),1.48(m,2H),1. 42-1.21(m,10H),1.15-1.08(m,2H),0.97(m,3H),0.86(m,1H),0.78(m,3H),0.43(m,2H),0.30(m,2H),0.19-0.12(m,1H).

[0780] Example 12: (2S,4R)-N-((S)-2-(((3S,6S,9S)-3-((5-chloro-2-(difluoromethoxy)pyridin-3-yl)methyl)-6-isobutyl-1,4-dimethyl-2,5,8-trioxo-1,4,7-triazacyclohexadecane-9-yl)(methyl)amino)-1-cyclopropyl-2-oxoethyl)-1-(3,3-difluoro-1-(trifluoromethyl)cyclobutane-1-carbonyl)-4-fluoropyrrolidine-2-carboxamide (Compound 12)

[0781] Step 1: Synthesis of Compound 12-1

[0782] 2-Hydroxy-5-chloro-3-iodopyridine (SM, 5.0 g, 19.57 mmol) was dissolved in acetonitrile (50 mL), and sodium carbonate (2.28 g, 21.53 mmol) was added. Under argon protection, difluorobromomethyltrimethylsilane (4.77 g, 23.49 mmol) was added, and the reaction was heated at 80 °C for 20 h. The reaction was then terminated. Water (50 mL) was added to the system, and the mixture was extracted three times with ethyl acetate (50 mL x 3). The organic phases were combined, washed once with saturated sodium chloride aqueous solution (30 mL x 1), dried over anhydrous sodium sulfate, concentrated under reduced pressure to remove the solvent, and the residue was purified by column chromatography with gradient elution (petroleum ether:ethyl acetate = 10:1). The product was collected to give compound 12-1 (2.28 g).

[0783] Step 2: Synthesis of Compound 12-2

[0784] Add zinc powder (1.3 g, 20.04 mmol) to a three-necked flask, add N,N-dimethylacetamide (10 mL), purge with argon three times, add 1,2-dibromoethane (376.7 mg, 2.00 mmol), and then add trimethylchlorosilane (216.4 mg, 2.00 mmol) dropwise, keeping the temperature below 45°C. Stir for 10 min. Slowly add a solution (10 mL) of (2R)-2-[(tert-butyloxycarbonyl)amino]-3-iodopropionate (4.4 g, 13.36 mmol) in N,N-dimethylacetamide, keeping the temperature below 45°C until the addition is complete. Stir at room temperature for 16 h, and monitor the reaction by TLC until completion.

[0785] Intermediate 12-1 (2.4 g, 7.86 mmol) was dissolved in N,N-dimethylacetamide (20 mL), and cuprous iodide (299.3 mg, 1.57 mmol) and [1,1-bis(diphenylphosphine)ferrocene]palladium dichloride (1.28 g, 1.57 mmol) were added. Under argon protection, the solution prepared in the previous step was added to the system, and the reaction was heated at 80 °C for 10 h. The reaction was monitored by LC-MS until it ended. The system was allowed to cool naturally and quenched in ice water (50 mL). The mixture was extracted three times with ethyl acetate (40 mL x 3), and the organic phases were combined. The mixture was washed once with saturated sodium chloride aqueous solution (30 mL x 1), dried over anhydrous sodium sulfate, concentrated under reduced pressure to remove the solvent, and purified by column chromatography with gradient elution (petroleum ether:ethyl acetate = 5:1) to give compound 12-2 (2.4 g).

[0786] Step 3: Synthesis of Compound 12-3

[0787] Intermediate 12-2 (1.45 g, 3.81 mmol) was dissolved in N,N-dimethylformamide (10 mL), and silver oxide (4.41 g, 19.04 mmol) was added. Under argon protection, iodomethane (5.41 g, 38.08 mmol) was added, and the reaction was heated at 40 °C for 15 h. The reaction was monitored by LC-MS until the reaction was complete. The system was filtered through diatomaceous earth, and the filter cake was washed with ethyl acetate (15 mL). The filtrate was mixed with water (60 mL) and ethyl acetate (30 mL), stirred, and separated into layers. The aqueous phase was extracted three times with ethyl acetate (40 mL x 3). The organic phases were combined, washed twice with saturated sodium chloride aqueous solution (30 mL x 2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to dryness to obtain crude compound 12-3 (1.5 g), which was directly used in the next reaction.

[0788] Step 4: Synthesis of Compound 12-4

[0789] Intermediate 12-3 (2.23 g, 5.65 mmol) was dissolved in tetrahydrofuran (5 mL), and an aqueous solution of lithium hydroxide (676.4 mg, 28.24 mmol) (2 mL) was added. The reaction was carried out at room temperature for 15 h, and the reaction was monitored by LC-MS until the end of the reaction. Water (30 mL) was added to the system, and the mixture was extracted once with ethyl acetate (25 mL x 1). The organic phase was discarded, and the pH of the aqueous phase was adjusted to 4-5 with 2N dilute hydrochloric acid. The mixture was extracted three times with ethyl acetate (25 mL x 3), and the organic phases were combined. The mixture was washed once with saturated sodium chloride aqueous solution (20 mL x 1), dried over anhydrous sodium sulfate, and concentrated to dryness under reduced pressure to obtain crude compound 12-4 (2.1 g), which was used directly in the next reaction.

[0790] Step 5: Synthesis of Compound 12-5

[0791] Intermediate 12-4 (2.35 g, 6.17 mmol) was dissolved in N,N-dimethylformamide (40 mL), and N-methyl-5-hexen-1-amine (838.36 mg, 7.41 mmol), 2-(7-azobenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (4.69 g, 12.34 mmol), and N,N-diisopropylethylamine (2.39 g, 18.52 mmol, 3.23 mL) were added. The reaction was carried out at room temperature for 2 h, and the reaction was monitored by TLC until the end of the reaction. Water (80 mL) was added to the system, and the mixture was extracted three times with ethyl acetate (80 mL x 3). The organic phases were combined, washed twice with saturated sodium chloride aqueous solution (40 mL x 2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to dryness to give crude compound 12-5 (1.3 g), which was used directly in the next reaction.

[0792] Step Six: Synthesis of Compound 12-6

[0793] Intermediate 12-5 (1.3 g, 2.73 mmol) was dissolved in dichloromethane (10 mL), and trifluoroacetic acid (2 mL) was added. The reaction was carried out at room temperature for 2 h, and the reaction was monitored by LC-MS until completion. The solvent was removed by direct concentration under reduced pressure. The residue was redissolved in dichloromethane (20 mL) and concentrated to dryness under reduced pressure to obtain crude compound 12-6 (1.03 g), which was directly used in the next reaction.

[0794] Step 7: Synthesis of Compounds 12-7

[0795] Intermediate 12-6 (550.0 mg, 1.46 mmol) was dissolved in N,N-dimethylformamide (8 mL), and (tert-butoxycarbonyl)-L-leucine (406.2 mg, 1.76 mmol), 2-(7-azobenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (1.11 g, 2.93 mmol), and N,N-diisopropylethylamine (568.0 mg, 4.39 mmol, 766.75 μL) were added. The reaction was carried out at room temperature for 2 h, and the reaction was monitored by LC-MS until the end of the reaction. Water (20 mL) was added to the system, and the mixture was extracted three times with ethyl acetate (25 mL x 3). The organic phases were combined, washed once with saturated sodium chloride aqueous solution (25 mL x 1), dried over anhydrous sodium sulfate, concentrated under reduced pressure to remove the solvent, and the residue was purified by column chromatography with gradient elution (petroleum ether:ethyl acetate = 5:1) to give compound 12-7 (300.0 mg).

[0796] Step 8: Synthesis of Compounds 12-8

[0797] Intermediate 12-7 (300.0 mg, 509.24 μmol) was dissolved in dichloromethane (5 mL), and trifluoroacetic acid (1 mL) was added. The reaction was carried out at room temperature for 2 h, and the reaction was monitored by LC-MS until completion. The solvent was removed by direct concentration under reduced pressure. The residue was redissolved in dichloromethane (20 mL) and concentrated to dryness under reduced pressure to obtain compound 12-8 (249.0 mg), which was directly used in the next reaction.

[0798] Step Nine: Synthesis of Compounds 12-9

[0799] Intermediate 12-8 (249.0 mg, 509.21 μmol) was dissolved in N,N-dimethylformamide (5 mL), and (S)-2-((tert-butoxycarbonyl)(methyl)amino)pent-4-enoic acid (140.0 mg, 611.05 μmol), 2-(7-azobenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (291.0 mg, 763.81 μmol) and N,N-diisopropylethylamine (197.43 mg, 1.53 mmol, 266.80 μL) were added. The reaction was carried out at room temperature for 2 h, and the reaction was monitored by LC-MS until it ended. Water (20 mL) was added to the system, and the mixture was extracted three times with ethyl acetate (25 mL x 3). The organic phases were combined, washed once with saturated sodium chloride aqueous solution (20 mL x 1), dried over anhydrous sodium sulfate, concentrated under reduced pressure to remove the solvent, and the residue was purified by column chromatography with gradient elution (petroleum ether: ethyl acetate = 5:1) to give compound 12-9 (295.0 mg).

[0800] Step 10: Synthesis of Compounds 12-10

[0801] Intermediate 12-9 (295.0 mg, 421.28 μmol) was dissolved in 1,2-dichloroethane (30 mL), and Hovyda-Grubbs second-generation catalyst (27.0 mg, 42.13 μmol) was added. The reaction was carried out under argon protection at 70 °C for 2 h, and the reaction was monitored by LC-MS until the reaction was complete. The system was concentrated under reduced pressure to remove the solvent, and the residue was purified by column chromatography with gradient elution (petroleum ether:ethyl acetate = 5:1) to give compound 12-10 (150.0 mg).

[0802] Step 11: Synthesis of Compounds 12-11

[0803] Intermediate 12-10 (140.0 mg, 208.27 μmol) was dissolved in ethyl acetate (5 mL), and platinum dioxide (19.0 mg, 83.31 μmol) was added. The mixture was purged three times with hydrogen gas, and the reaction was carried out at room temperature for 3 h under a hydrogen atmosphere. The reaction was monitored by LC-MS until completion. The system was filtered through diatomaceous earth, and the filter cake was washed with ethyl acetate (10 mL). The filtrates were combined and concentrated to dryness under reduced pressure to obtain crude compound 12-11 (140.0 mg), which was directly used in the next reaction.

[0804] Step Twelve: Synthesis of Compound 12-12

[0805] Intermediate 12-11 (140.0 mg, 207.65 μmol) was dissolved in 1,2-dichloromethane (5 mL), and trifluoroacetic acid (1 mL) was added. The reaction was carried out at room temperature for 2 h, and the reaction was monitored by LC-MS until completion. The solvent was removed by direct concentration under reduced pressure. The residue was redissolved in dichloromethane (20 mL) and concentrated to dryness under reduced pressure to obtain crude compound 12-12 (119.0 mg), which was directly used in the next reaction.

[0806] Step Thirteen: Synthesis of Compounds 12-13

[0807] Intermediate 12-12 (100.0 mg, 174.19 μmol) was dissolved in N,N-dimethylformamide (5 mL), and 2-(7-azobenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (99.0 mg, 261.28 μmol), (S)-2-(tert-butoxycarbonyl)amino)-2-cyclopropylacetic acid (45.0 mg, 209.02 μmol), and N,N-diisopropylethylamine (68.0 mg, 522.56 μmol, 91.27 μL) were added. The reaction was carried out at room temperature for 2 h, and the reaction was monitored by LC-MS until it ended. Add water (20 mL) to the system, extract three times with ethyl acetate (25 mL x 3), combine the organic phases, wash once with saturated sodium chloride aqueous solution (30 mL x 1), dry with anhydrous sodium sulfate, concentrate under reduced pressure to remove solvent, purify the residue by column chromatography with gradient elution (dichloromethane:methanol = 50:1) to give compounds 12-13 (100.0 mg).

[0808] Step Fourteen: Synthesis of Compounds 12-14

[0809] Intermediate 12-13 (100.0 mg, 129.65 μmol) was dissolved in 1,2-dichloromethane (5 mL), and trifluoroacetic acid (1 mL) was added. The reaction was carried out at room temperature for 1 h, and the reaction was monitored by LC-MS until completion. The solvent was removed by direct concentration under reduced pressure. The residue was redissolved in dichloromethane (20 mL) and concentrated to dryness under reduced pressure to obtain crude compound 12-14 (87.0 mg), which was directly used in the next reaction.

[0810] Step 15: Synthesis of Compound 12

[0811] Intermediate 12-14 (87.0 mg, 129.62 μmol) was dissolved in N,N-dimethylformamide (5 mL), and intermediate Int3 (54.0 mg, 168.50 μmol), 2-(7-azobenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (99.0 mg, 259.23 μmol) and N,N-diisopropylethylamine (67.0 mg, 518.46 μmol, 90.55 μL) were added. The reaction was carried out at room temperature for 2 h, and the reaction was monitored by LC-MS until it ended. Water (20 mL) was added to the system, and the mixture was extracted three times with ethyl acetate (25 mL x 3). The organic phases were combined, washed once with saturated sodium chloride aqueous solution (20 mL x 1), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to remove the solvent. The residue was then purified by preparative separation (chromatographic column: Waters Xbridge Prep C18 5um OBD, 19*150 mm, flow rate: 15 mL / min; mobile phase A: water (0.05% NH3), mobile phase B: acetonitrile; acetonitrile gradient: 55-80%), finally yielding the title compound 12 (9.56 mg).

[0812] LC-MS (ESI): m / z = 972.59 [M+H] +

[0813] 1 H NMR(400MHz,Chloroform-d)δ8.00(d,J=2.5Hz,1H),7.99-7.40(m,2H),7.36-7.30(m,1H),6.40-6.29(m,1H),5.4 5-5.29(m,1H),5.26-5.10(m,1H),4.89-4.67(m,3H),4.47-4.30(m,2H),3.80-3.40(m,1H),3.50-3.30(m,3H),3. 28-3.04(m,7H),2.99-2.92(m,5H),2.83-2.54(m,3H),2.44-2.34(m,1H),2.20-2.07(m,1H),1.46-1.28(m,13H), 1.01-0.93(m,3H),0.90-0.77(m,4H),0.71-0.60(m,1H),0.48-0.37(m,2H),0.34-0.27(m,1H),0.21-0.12(m,1H).

[0814] Example 13: (2S,4R)-N-((S)-2-(((3S,6S,9S)-3-(5-chloro-2-(1-methyl-1H-pyrazol-4-yl)benzyl)-14,14-difluoro-6-isobutyl-1,4-dimethyl-2,5,8-trioxo-1,4,7-triazacyclohexadecane-9-yl)(methyl)amino)-1-cyclopropyl-2-oxoethyl)-1-(3,3-difluoro-1-(trifluoromethyl)cyclobutane-1-carbonyl)-4-fluoropyrrolidine-2-carboxamide (Compound 13)

[0815] Step 1: Synthesis of Compound 13-1

[0816] Intermediate Int 14 (112.0 mg, 155.54 μmol) was added to a 100 mL reaction flask, followed by 10 mL of ethyl acetate. The mixture was stirred, and then platinum dioxide (35.0 mg, 10% m / m) was added. The system was purged with hydrogen three times, and the reaction was allowed to proceed at room temperature for 0.5 h. The reaction was then monitored by LC-MS, indicating completion. The mixture was directly filtered, and the filtrate was concentrated to dryness under reduced pressure to obtain crude compound 13-1 (110.0 mg), which was used directly in the next reaction step.

[0817] Step 2: Synthesis of Compound 13-2

[0818] Compound 13-1 (100.0 mg, 138.49 μmol) and 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborhexacyclopentan-2-yl)-1H-pyrazole (57.63 mg, 276.97 μmol) were added to a 50 mL reaction flask, along with 1,4-dioxane (5 mL) and water (0.5 mL). The mixture was stirred, and then potassium phosphate (117.58 mg, 553.94 μmol) and [1,1'-bis(diphenylphosphine)ferrocene]palladium dichloride (16.95 mg, 20.77 μmol) were added. The system was purged with argon three times, and the reaction was carried out at 90 °C for 8 h. The reaction was then analyzed by LC-MS, and the reaction was considered complete. Cool to room temperature, dilute with ethyl acetate (30 mL), wash once with saturated sodium chloride aqueous solution (10 mL x 1), concentrate under reduced pressure to remove solvent, purify the residue by column chromatography with gradient elution (0-100% ethyl acetate), collect the product, concentrate under reduced pressure to give compound 13-2 (100.0 mg).

[0819] Step 3: Synthesis of Compound 13-3

[0820] Compound 13-2 (160.45 mg, 221.83 μmol) was added to a 100 mL reaction flask, followed by 10 mL of dichloromethane and stirring. Then, 2 mL of trifluoroacetic acid was added, and the reaction was allowed to proceed at room temperature for 2 h. The reaction was then monitored by LC-MS, indicating completion. The solvent was removed by concentration under reduced pressure at room temperature. The residue was redissolved in 60 mL of ethyl acetate, then washed once with 15 mL x 10% sodium carbonate aqueous solution. The aqueous layer was extracted once with 20 mL x 1 ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to dryness to obtain crude compound 13-3 (130.0 mg), which was directly used in the next reaction.

[0821] Step 4: Synthesis of Compound 13-4

[0822] Compound 13-3 (140.45 mg, 225.38 μmol) was added to a 100 mL reaction flask, followed by N,N-dimethylformamide (8 mL). The mixture was stirred, then (S)-2-((tert-butoxycarbonyl)amino)-2-cyclopropylacetic acid (48.51 mg, 225.38 μmol) and 2-(7-azabenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (111.41 mg, 293.00 μmol) were added. Finally, N,N-diisopropylethylamine (87.39 mg, 676.15 μmol) was added. The mixture was allowed to react at room temperature for 2 h. The reaction was then monitored by LC-MS, indicating the reaction was complete. The system was diluted with methyl tert-butyl ether (60 mL), then washed once with water (20 mL x 1), washed once with saturated brine (20 mL x 1), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to dryness to obtain crude compound 13-4 (170.0 mg), which was directly used in the next reaction.

[0823] Step 5: Synthesis of Compound 13-5

[0824] Compound 13-4 (181.99 mg, 221.83 μmol) was added to a 100 mL reaction flask, followed by 10 mL of dichloromethane and stirring. Then, 2 mL of trifluoroacetic acid was added, and the reaction was allowed to proceed at room temperature for 2 h. The reaction was then monitored by LC-MS, indicating completion. The solvent was removed by concentration under reduced pressure at room temperature. The residue was redissolved in ethyl acetate (50 mL), washed once with 15 mL x 10% sodium carbonate aqueous solution, and the aqueous layer was extracted once with ethyl acetate (20 mL x 1). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to dryness to obtain crude compound 13-5 (160.0 mg), which was directly used in the next reaction.

[0825] Step 6: Synthesis of Compound 13

[0826] Compound 13-5 (120.00 mg, 166.60 μmol) and intermediate Int 3 (69.13 mg, 216.58 μmol) were added to a 100 mL reaction flask, followed by acetonitrile (5 mL). The mixture was stirred and placed under argon protection. Then, 1-methylimidazole (54.71 mg, 666.40 μmol) was added, and finally N,N,N',N'-tetramethylchloroformamidin hexafluorophosphate (9.01 mg, 249.90 μmol) was added. The reaction was carried out at room temperature for 4 h, and the reaction was detected by LC-MS. The solvent was removed by concentration under reduced pressure. The residue was diluted with ethyl acetate (50 mL) and then washed twice with water (20 mL x 2). The solvent was removed by concentration under reduced pressure. The residue was purified by preparative separation (chromatographic column: Ultimate C18, 5 μm 150 mm; flow rate: 20 mL / min; mobile phase: A: water (0.05% NH3), B: acetonitrile, acetonitrile gradient: 50-80%), yielding the title compound 13 (46.0 mg).

[0827] LC-MS (ESI): m / z = 1021.57 [M+H] +

[0828] 1 H NMR(400MHz,DMSO-d6)δ8.42-8.16(m,2H),7.92(s,1H),7.61(s,1H),7.33-7.24(m,2H),7.11(d,J =10.5Hz,1H),5.36(dd,J=52.6,17.0Hz,1H),4.85-4.44(m,4H),4.30-4.21(m,1H),3.88(s,3H),3. 80-3.57(m,2H),3.30-3.21(m,2H),3.14-3.02(m,2H),2.93(s,2H),2.81(s,3H),2.75-2.65(m,2H ),2.64-2.54(m,4H),2.02-1.81(m,4H),1.70-1.00(m,12H),0.95-0.63(m,8H),0.51-0.21(m,4H).

[0829] Example 14: (2S,4R)-N-((1S)-2-(((3S,6S,9S)-3-(5-chloro-2-(1-methyl-1H-pyrazol-4-yl)benzyl)-6-isobutyl-1,4,15-trimethyl-2,5,8-trioxo-1,4,7-triazacyclohexadecane-9-yl)(methyl)amino)-1-cyclopropyl-2-oxoethyl)-1-(3,3-difluoro-1-(trifluoromethyl)cyclobutane-1-carbonyl)-4-fluoropyrrolidine-2-carboxamide (Compound 14)

[0830] Step 1: Synthesis of Compound 14-2

[0831] (2S)-2-(tert-Butoxycarbonylamino)hex-5-enoic acid (500.0 mg, 2.18 mmol) was added to a 100 mL reaction flask, followed by anhydrous tetrahydrofuran (20 mL). Under argon protection, sodium hydride (261.67 mg, 6.54 mmol, 60% purity) was added at 0 °C, and the mixture was stirred at 0 °C for 30 min. Then, iodomethane (3.10 g, 21.81 mmol) was added, and the reaction was allowed to proceed at room temperature for 16 h. The reaction was sampled and monitored by LC-MS; the reaction was complete. The reaction solution was quenched in a saturated ammonium chloride aqueous solution (20 mL), stirred, and the layers were separated. The aqueous phase was extracted twice with ethyl acetate (15 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to dryness to obtain crude compound 14-2 (400.0 mg), which was directly used in the next reaction step.

[0832] Step 2: Synthesis of compound 14-4

[0833] 2-Methylpent-4-en-1-ol (400.0 mg, 3.99 mmol) and pyridine (473.85 mg, 5.99 mmol, 483.52 μL) were added to dichloromethane (10 mL). Under argon protection, the mixture was cooled to 0 °C and stirred. Trifluoromethanesulfonic anhydride (1.35 g, 4.79 mmol) was added, and the mixture was kept at 0 °C and stirred for 10 min. Then, it was stirred at room temperature for 1 h. The reaction was monitored by TLC until it was complete. The reaction solution was diluted with dichloromethane (20 mL), washed once with 10% citric acid aqueous solution (10 mL x 1), washed once with saturated sodium chloride solution (10 mL x 1), dried over anhydrous sodium sulfate, filtered, and concentrated to dryness under reduced pressure to obtain crude compound 14-4 (775.0 mg), which was directly added to the next reaction.

[0834] Step 3: Synthesis of Compounds 14-5

[0835] Compound 14-4 (700.0 mg, 3.01 mmol) was dissolved in ammonia in methanol (22 mL, 7 M, 150.72 mmol), and stirred at 45 °C for 2 h. The reaction was complete under TLC monitoring. The reaction solution was directly concentrated under reduced pressure to remove the solvent. The residue was dissolved in dichloromethane (50 mL), followed by the addition of tert-butyl carbonate (4.62 g, 21.17 mmol, 4.86 mL) and 4-dimethylaminopyridine (86.23 mg, 705.83 μmol). Finally, triethylamine (1.43 g, 14.12 mmol, 2 mL) was added. The system was heated to 40 °C and stirred for 1 h. The reaction was complete under TLC monitoring. The reaction solution was directly concentrated under reduced pressure to remove the solvent, and the residue was purified by column chromatography with gradient elution (0-30% ethyl acetate) to give the title compound 14-5 (700.0 mg).

[0836] Step 4: Synthesis of Compounds 14-6

[0837] Compound 14-5 (400.0 mg, 2.01 mmol) was dissolved in N,N-dimethylformamide (10 mL). Under argon protection, sodium hydride (401.39 mg, 10.04 mmol, 60% purity) was added at 0 °C, and the mixture was stirred at 0 °C for 30 min. Then, methyl iodoformane (4.27 g, 30.11 mmol) was added, and the reaction was carried out at room temperature for 16 h. The reaction was sampled and monitored by LC-MS until completion. The reaction solution was quenched in 20 mL of saturated ammonium chloride solution, extracted twice with ethyl acetate (15 mL x 2), and the organic phases were combined. The mixture was washed once with 10 mL of saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and concentrated to dryness under reduced pressure to obtain crude compound 14-6 (400.0 mg), which was directly used in the next reaction.

[0838] Step 5: Synthesis of compounds 14-7

[0839] Compound 14-6 (400.0 mg, 1.88 mmol) was dissolved in acetonitrile (10 mL), followed by the addition of p-toluenesulfonic acid (1.29 g, 7.50 mmol). The mixture was stirred at room temperature for 2 h, and the reaction was monitored by LC-MS until completion. The reaction solution was directly concentrated under reduced pressure to remove the solvent. The residue was stirred with ethyl acetate (10 mL) for 30 min, and a solid precipitated. The solid was filtered and dried under reduced pressure to give compound 14-7 (300.0 mg). Step 6: Synthesis of compound 14-8

[0840] Intermediate Int 1 (545.72 mg, 1.06 mmol), compound 14-7 (100.0 mg, 350.39 μmol), and 2-(7-azobenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (403.07 mg, 1.06 mmol) were added to a 50 mL reaction flask. N,N-dimethylformamide (5 mL) was added, and under argon protection, N,N-diisopropylethylamine (342.52 mg, 2.65 mmol, 462.86 μL) was added. The reaction was carried out at room temperature for 2 h. Samples were taken, and LC-MS analysis was performed to determine the reaction was complete. The system was diluted with ethyl acetate (40 mL), washed twice with saturated brine (15 mL x 2), dried over anhydrous sodium sulfate, filtered, and concentrated to dryness under reduced pressure to obtain crude compound 14-8 (500.0 mg), which was directly used in the next reaction step.

[0841] Step 7: Synthesis of compounds 14-9

[0842] Compound 14-8 (500.0 mg, 0.82 mmol) was dissolved in dichloromethane (20 mL), and piperidine (5 mL) was added. The mixture was stirred at room temperature for 16 h, and the reaction was monitored by LC-MS until completion. Saturated ammonium chloride (30 mL) was added to the system, and the mixture was stirred and separated into layers. The aqueous phase was extracted twice with dichloromethane (20 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure to remove the solvent, and the residue was mixed with silica gel for column chromatography purification. Gradient elution (0-5% methanol) was used to obtain compound 14-9 (475.0 mg).

[0843] Step 8: Synthesis of compounds 14-10

[0844] Compound 14-9 (400.0 mg, 1.03 mmol), (2S)-2-(tert-butoxycarbonylamino)-4-methylpentanoic acid (357.9 mg, 1.55 mmol), and 2-(7-azobenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (588.38 mg, 1.55 mmol) were added to a 50 mL reaction flask. N,N-dimethylformamide (10 mL) was added, and the mixture was reacted under argon protection. Finally, N,N-diisopropylethylamine (399.99 mg, 3.09 mmol, 540.52 μL) was added, and the reaction was allowed to proceed at room temperature for 1 h. Samples were taken, and LC-MS analysis was performed to determine the reaction was complete. The system was diluted with water (20 mL), extracted twice with ethyl acetate (20 mL x 2), the organic phases were combined, washed twice with saturated brine (15 mL x 2), concentrated under reduced pressure to remove the solvent, the residue was mixed with silica gel, purified by column chromatography with gradient elution (0-30% ethyl acetate), the product was collected, and concentrated under reduced pressure to dryness to obtain compound 14-10 (600.0 mg).

[0845] Step 9: Synthesis of compounds 14-11

[0846] Compound 14-10 (500.0 mg, 831.93 μmol) was dissolved in 1,4-dioxane (2 mL), followed by the addition of a dioxane solution in hydrochloric acid (4 M, 21 mL). The mixture was stirred at room temperature for 2 h, and the reaction was monitored by LC-MS until completion. The reaction solution was then concentrated to dryness under reduced pressure to obtain crude compound 14-11 (440.0 mg), which was directly used in the next reaction.

[0847] Step 10: Synthesis of compounds 14-12

[0848] Compound 14-2 (327.86 mg, 1.35 mmol), compound 14-11 (450.0 mg, 898.39 μmol), and 2-(7-azobenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (512.39 mg, 1.35 mmol) were added to a 10 mL reaction flask. N,N-dimethylformamide (3 mL) was added, and the mixture was reacted under argon protection. Finally, N,N-diisopropylethylamine (348.33 mg, 2.70 mmol, 470.72 μL) was added, and the reaction was allowed to proceed at room temperature for 2 h. Samples were taken, and LC-MS analysis was performed. The reaction was considered complete at this point. The system was diluted with water (20 mL), extracted three times with ethyl acetate (10 mL x 3), the organic phases were combined, washed twice with saturated brine (10 mL x 2), concentrated under reduced pressure to remove the solvent, the residue was mixed with silica gel, purified by column chromatography with gradient elution (0-30% ethyl acetate), the product was collected, and concentrated under reduced pressure to dryness to obtain compound 14-12 (500.0 mg).

[0849] Step 11: Synthesis of compounds 14-13

[0850] Compound 14-12 (580.0 mg, 798.70 μmol) was dissolved in dichloromethane (10 mL), and trifluoroacetic acid (2 mL) was added. The mixture was stirred at room temperature for 2 h, and the reaction was monitored by LC-MS until complete. The reaction solution was directly concentrated under reduced pressure to remove the solvent. The residue was redissolved in dichloromethane (30 mL), washed once with saturated sodium bicarbonate aqueous solution (15 mL x 1), and the aqueous phase was extracted once with dichloromethane (20 mL x 1). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to dryness under reduced pressure to obtain crude compound 14-13 (480.0 mg), which was directly used in the next reaction.

[0851] Step 12: Synthesis of Compounds 14-14

[0852] Compounds 14-13 (380.0 mg, 606.96 μmol), (S)-2-((tert-butoxycarbonyl)amino)-2-cyclopropylacetic acid (195.97 mg, 910.45 μmol), and 2-(7-azobenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (346.18 mg, 910.45 μmol) were added to a 100 mL reaction flask. N,N-dimethylformamide (10 mL) was added, and the mixture was reacted under argon protection. Finally, N,N-diisopropylethylamine (235.34 mg, 1.82 mmol, 318.02 μL) was added, and the reaction was allowed to proceed at room temperature for 2 h. Samples were taken, and LC-MS analysis was performed. The reaction was considered complete at this point. The system was diluted with water (50 mL), extracted twice with ethyl acetate (30 mL x 2), the organic phases were combined, washed twice with saturated brine (20 mL x 2), concentrated under reduced pressure to remove the solvent, the residue was mixed with silica gel, purified by column chromatography, and eluted with gradient (0-50% ethyl acetate) to obtain compound 14-14 (480.0 mg).

[0853] Step 13: Synthesis of compounds 14-15

[0854] Compound 14-14 (300.0 mg, 364.39 μmol) was dissolved in 1,2-dichloroethane (30 mL) under argon protection, and then Hoveyda-Grubbs-2 was added. nd The catalyst (45.62 mg, 72.88 μmol) was stirred at 70 °C for 4 h. The reaction solution was directly concentrated under reduced pressure to remove the solvent, and the residue was mixed with silica gel and purified by column chromatography with gradient elution (0-6% methanol) to give compounds 14-15 (100.0 mg).

[0855] Step 14: Synthesis of compounds 14-16

[0856] Compounds 14-15 (100.0 mg, 125.75 μmol), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxapentoborane-2-yl)-1H-pyrazole (31.4 mg, 150.90 μmol), and potassium phosphate (80.07 mg, 377.24 μmol) were added to a 10 mL reaction flask. 1,4-dioxane (2 mL) and water (0.5 mL) were added, followed by [1,1'-bis(diphenylphosphine)ferrocene]palladium dichloride (9.20 mg, 12.57 μmol). The mixture was purged three times with argon gas, and the reaction was carried out at 90 °C for 4 h. Samples were taken, and the reaction was monitored by LC-MS. The reaction was complete. The reaction solution was directly concentrated to remove the solvent. The residue was mixed with silica gel and purified by column chromatography with gradient elution (0-2% methanol) to obtain compound 14-16 (50.0 mg).

[0857] Step 15: Synthesis of compounds 14-17

[0858] Compound 14-16 (30.0 mg, 37.67 μmol) was dissolved in ethyl acetate (5 mL), then platinum dioxide (34.21 mg, 150.67 μmol) was added. The mixture was purged with hydrogen three times, and the mixture was stirred at room temperature for 0.5 h. The reaction was monitored by LC-MS and found to be complete. The system was directly filtered, and the filtrate was concentrated to dryness under reduced pressure to obtain crude compound 14-17 (30.0 mg), which was directly used in the next reaction.

[0859] Step 16: Synthesis of compounds 14-18

[0860] Compound 14-17 (30.0 mg, 37.57 μmol) was dissolved in dichloromethane (4 mL), and trifluoroacetic acid (1 mL) was added. The mixture was stirred at room temperature for 2 h, and the reaction was monitored by LC-MS until complete. The solvent was removed by direct concentration under reduced pressure. The residue was redissolved in dichloromethane (15 mL), washed once with 10% sodium carbonate solution (10 mL x 1), and the aqueous phase was extracted once with dichloromethane (15 mL x 1). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to dryness under reduced pressure to give crude compound 14-18 (25.0 mg), which was directly used in the next reaction.

[0861] Step 17: Synthesis of Compound 14

[0862] Intermediate Int 3 (16.46 mg, 51.55 μmol), compounds 14-18 (30.0 mg, 42.96 μmol), and 1-methylimidazole (10.57 mg, 128.88 μmol) were added to a 10 mL reaction flask, followed by acetonitrile (1 mL). Under argon protection, N,N,N',N'-tetramethylchloromethamine hexafluorophosphate (1.86 mg, 51.55 μmol) was added, and the reaction was carried out at room temperature for 1 h. Samples were taken, and LC-MS analysis was performed to determine the reaction was complete. The reaction solution was concentrated under reduced pressure to remove the solvent. The residue was purified by preparative chromatography (column: Ultimate C18, 5 μm 150 mm; flow rate: 20 mL / min; mobile phase: A: water (0.05% NH3), B: acetonitrile, acetonitrile gradient: 50-80%) to obtain title compound 14 (8.9 mg).

[0863] LC-MS (ESI): m / z = 999.99 [M+H] +

[0864] 1H NMR (400MHz, DMSO-d6) δ8.28-8.08(m,2H),7.70(d,J=3.1Hz,1H),7.38(d,J=3.6Hz,1H),7.14-7. 00(m,3H),5.28-5.06(m,2H),4.66-4.26(m,4H),4.13-3.83(m,2H),3.71(s,3H),3.67-3.43(m,3 H),3.10-3.06(m,4H),2.97-2.88(m,3H),2.76(s,2H),2.69-2.61(m,2H),2.56-2.48(m,4H),1.9 7-1.63(m,4H),1.43-1.25(m,4H),1.06(d,J=3.6Hz,6H),0.97-0.88(m,3H),0.79-0.41(m,12H).

[0865] Example 15: ((2S,4R)-N-((S)-2-(((3S,6S,9S)-3-(5-chloro-2-(methyl(1-methyl-1H-pyrazol-4-yl)amino)benzyl)-6-isobutyl-1,4-dimethyl-2,5,8-trioxo-1,4,7-triazacyclic)hexadecane-9-yl)(methyl)amino)-1-cyclopropyl-2-oxoethyl)-1-(3,3-difluoro-1-(trifluoromethyl)cyclobutane-1-carbonyl)-4-fluoropyrrolidine-2-carboxamide (Compound 15)

[0866] Step 1: Synthesis of Compound 15-2

[0867] 1-Methylpyrazole-4-amine (500.0 mg, 5.15 mmol), di-tert-butyl dicarbonate (1.69 g, 7.72 mmol), and 4-dimethylaminopyridine (63.0 mg, 0.515 mmol) were added to a 100 mL reaction flask, followed by 20 mL of dichloromethane, and finally 2.14 mL of triethylamine (1.56 g, 15.45 mmol, 2.14 mL). The reaction was allowed to proceed at room temperature for 16 h. Samples were taken and analyzed by LC-MS, indicating the reaction was complete. The mixture was diluted with 60 mL of dichloromethane, washed twice with 30 mL x 2 of water, and once with 30 mL x 1 of saturated brine. The solvent was removed by concentration under reduced pressure, and the residue was mixed with silica gel and purified by column chromatography with gradient elution (0-30% ethyl acetate) to obtain compound 15-2 (800.0 mg).

[0868] Step 2: Synthesis of Compound 15-3

[0869] Compound 15-2 (200.0 mg, 1.01 mmol) was added to a 10 mL reaction flask, followed by 10 mL of tetrahydrofuran. Under argon protection, sodium hydride (81.11 mg, 2.03 mmol, 60% purity) was added with stirring at 0 °C. The mixture was kept at 0 °C and stirred for 30 min. Then, methyl iodoform (431.79 mg, 3.04 mmol) was added, and the reaction was carried out at 25 °C for 4 h. The reaction was sampled and monitored by LC-MS until completion. The reaction solution was quenched by pouring into a saturated ammonium chloride aqueous solution (20 mL), stirred, and separated into layers. The aqueous phase was extracted twice with ethyl acetate (15 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to dryness under reduced pressure to obtain crude compound 15-3 (200.0 mg), which was directly used in the next reaction.

[0870] Step 3: Synthesis of Compound 15-4

[0871] Compound 15-3 (100.0 mg, 473.35 μmol) was dissolved in dichloromethane (4 mL), and trifluoroacetic acid (1 mL) was added. The mixture was stirred at room temperature for 2 h, and the reaction was monitored by LC-MS until complete. The solvent was removed by direct concentration under reduced pressure. The residue was redissolved with ethyl acetate (20 mL), washed once with saturated sodium bicarbonate aqueous solution (15 mL x 1), and the aqueous phase was extracted once with ethyl acetate (15 mL x 1). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to dryness under reduced pressure to give crude compound 15-4 (50.0 mg), which was directly used in the next reaction.

[0872] Step 4: Synthesis of Compound 15-5

[0873] Intermediate Int 7 (80.0 mg, 117.1 μmol) was dissolved in dichloromethane (5 mL), followed by the addition of di-tert-butyl dicarbonate (38.3 mg, 175.65 μmol) and triethylamine (23.7 mg, 234.2 μmol). The reaction was carried out at room temperature for 6 h, and the reaction was monitored by LC-MS until completion. The solvent was removed by direct concentration under reduced pressure, and the residue was purified by column chromatography with gradient elution (0-50% ethyl acetate). The product was collected and concentrated to dryness under reduced pressure to give the title compound (80.0 mg).

[0874] Step 5: Synthesis of Compounds 15-6

[0875] Compound 15-4 (10.64 mg, 95.76 μmol), compound 15-5 (50.0 mg, 63.84 μmol), 4,5-bis(diphenylphosphine-9,9-dimethyloxanthracene) (7.39 mg, 12.77 μmol), and cesium carbonate (62.40 mg, 191.51 μmol) were added to a 10 mL reaction flask. Toluene (2 mL) was added, followed by tris(dibenzylacetone)dipalladium (5.85 mg, 6.38 μmol). The mixture was purged with nitrogen three times, and the reaction was carried out at 100 °C for 4 h. A sample was taken, and the reaction was monitored by LC-MS. The reaction was complete. The system was cooled to room temperature, filtered directly, and the filtrate was concentrated under reduced pressure to remove the solvent. The residue was purified by column chromatography with gradient elution (0-5% methanol) to obtain compound 15-5 (30.0 mg).

[0876] Step 6: Synthesis of compounds 15-7

[0877] Compound 15-6 (20.0 mg, 24.59 μmol) was dissolved in dichloromethane (2 mL), and trifluoroacetic acid (0.5 mL) was added. The mixture was stirred at room temperature for 2 h, and the reaction was monitored by LC-MS until complete. The solvent was removed by direct concentration under reduced pressure. The residue was redissolved with ethyl acetate (20 mL), washed once with saturated sodium bicarbonate aqueous solution (15 mL x 1), and the aqueous phase was extracted once with ethyl acetate (15 mL x 1). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to dryness under reduced pressure to obtain crude compound 15-6 (15.0 mg), which was directly used in the next reaction.

[0878] Step 7: Synthesis of Compound 15

[0879] Intermediate Int 3 (5.50 mg, 17.23 μmol), compound 15-7 (10.24 mg, 14.36 μmol), and 1-methylimidazole (5.18 mg, 43.08 μmol) were added to a 10 mL reaction flask, followed by acetonitrile (1 mL). Under argon protection, N,N,N',N'-tetramethylchloromethanemidane hexafluorophosphate (621.11 μg, 17.23 μmol) was added, and the reaction was carried out at room temperature for 2 h. Samples were taken, and LC-MS analysis was performed to determine the reaction was complete. The solvent was removed by concentration under reduced pressure, and the residue was purified by preparative chromatography (column: Ultimate C18, 5 μm 150 mm; flow rate: 20 mL / min; mobile phase: A: water (0.05% NH3), B: acetonitrile, acetonitrile gradient: 40-80%) to obtain title compound 15 (2.0 mg).

[0880] LC-MS (ESI): m / z = 1014.56 [M+H] +

[0881] 1H NMR (400MHz, DMSO-d6) δ8.33(s,1H),8.25(d,J=7.5Hz,1H),7.28-7.05(m,3H,6.90(d,J=5.6Hz,1H,6.62(s,1H) ,5.36-5.27(m,2H),4.85-4.64(m,2H),4.51(d,J=8.7Hz,2H,4.15(t,J=12.2Hz,2H),3.69(s,3H),3.58(s,3H),3 .03(s,3H),2.94(s,2H),2.84-2.77(m,3H),2.76-2.73(m,2H),2.68-2.65(m,2H),2.33(p,J=1.9Hz,1H),2.02-1 .97(m,4H),1.50-1.41(m,4H),1.27-1.21(m,16H),0.89-0.83(m,4H),0.69(d,J=6.3Hz,2H),0.42-0.32(m,2H).

[0882] Example 16: (2S,4R)-N-((1S)-2-(((3S,6S,9S)-3-(5-chloro-2-(1-methyl-1H-pyrazol-4-yl)benzyl)-6-isobutyl-1,4,16-trimethyl-2,5,8-trioxo-1,4,7-triazacyclohexadecane-9-yl)(methyl)amino)-1-cyclopropyl-2-oxoethyl)-1-(3,3-difluoro-1-(trifluoromethyl)cyclobutane-1-carbonyl)-4-fluoropyrrolidine-2-carboxamide (Compound 16)

[0883] Step 1: Synthesis of Compound 16-1

[0884] Intermediate Int 12 (90.0 mg, 128.9 μmol) and platinum dioxide (13.0 mg, 56.0 μmol) were dissolved in ethyl acetate (4 mL). The mixture was purged with hydrogen three times and reacted at room temperature for 2 h. The reaction was stopped by LC-MS. The reaction solution was directly filtered and washed with an appropriate amount of ethyl acetate. The filtrate was concentrated to dryness under reduced pressure to give crude compound 16-1 (74.0 mg), which was directly used in the next reaction.

[0885] Step 2: Synthesis of Compound 16-2

[0886] Compound 16-1 (65.0 mg, 92.84 μmol), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborhexacyclopentan-2-yl)pyrazole (21.4 mg, 102.84 μmol), [1,1'-bis(diphenylphosphine)ferrocene]palladium dichloride (12.54 mg, 17.14 μmol), and potassium phosphate (54.50 mg, 257.09 μmol) were dissolved in 1,4-dioxane (5 mL) and water (1 mL). The system was reacted at 90 °C for 6 h, and the reaction was completed by LC-MS. Dilute with ethyl acetate (50 mL) and wash once each with water (20 mL x 1) and saturated saline (20 mL x 1). Concentrate the organic phase under reduced pressure to remove the solvent. Mix the residue with silica gel and purify by column chromatography with gradient elution (0-100% EA). Collect the product and concentrate under reduced pressure to give compound 16-2 (71.0 mg).

[0887] Step 3: Synthesis of Compound 16-3

[0888] Compound 16-2 (71.0 mg, 101.2 μmol) was dissolved in dichloromethane (5 mL), followed by the addition of a dioxane solution of hydrogen chloride (2.5 M, 1.01 mmol). The reaction was allowed to proceed at room temperature for 2 h, and the reaction was confirmed by LC-MS. The reaction solution was then concentrated to dryness under reduced pressure to obtain crude compound 16-3 (50.0 mg), which was directly used for the next step.

[0889] Step 4: Synthesis of Compound 16-4

[0890] Compound 16-3 (48.0 mg, 79.05 μmol), (2S)-2-(tert-butoxycarbonylamino)-2-cyclopropylacetic acid (22.34 mg, 103.80 μmol), and 2-(7-azobenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (36.43 mg, 96.82 μmol) were dissolved in N,N-dimethylformamide (5 mL), and finally N,N-diisopropylethylamine (41.28 mg, 319.39 μmol) was added. The system was reacted at room temperature for 2 h under nitrogen protection, and the reaction was completed by LC-MS. Dilute with ethyl acetate (50 mL), and wash once with water (20 mL x 1) and once with saturated saline (20 mL x 1). Concentrate the organic phase under reduced pressure to remove the solvent. Mix the residue with silica gel and purify by column chromatography with gradient elution (0-10% MeOH). Collect the product and concentrate under reduced pressure to give compound 16-4 (37.0 mg).

[0891] Step 5: Synthesis of Compound 16-5

[0892] Compound 16-4 (37.0 mg, 46.34 μmol) was dissolved in dichloromethane (5 mL), followed by the addition of dioxane (2.5 M, 463.4 mmol) solution. The reaction was allowed to proceed at room temperature for 2 h, and the reaction was confirmed by LC-MS. The reaction solution was then concentrated to dryness under reduced pressure to obtain crude compound 16-5 (37.0 mg), which was used directly in the next reaction step.

[0893] Step 6: Synthesis of Compound 16

[0894] Compound 16-5 (37.0 mg, 52.98 μmol), intermediate Int 3 (17.75 mg, 55.61 μmol), and 2-(7-azobenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (21.14 mg, 55.61 μmol) were dissolved in N,N-dimethylformamide (5 mL). N,N-diisopropylethylamine (23.73 mg, 185.36 μmol) was added. The reaction was carried out at room temperature for 2 h under nitrogen protection. The reaction was stopped by LC-MS. The sample was diluted with ethyl acetate (40 mL) and washed once each with water (10 mL x 1) and saturated brine (10 mL x 1). The organic phase was concentrated under reduced pressure to remove the solvent. The residue was purified by preparative chromatography (column: YMC C18; flow rate: 25 mL / min; mobile phase: A: 0.7% sodium bicarbonate; B: acetonitrile, acetonitrile gradient: 35–95%) to give title compound 16 (2.0 mg).

[0895] LC-MS (ESI): m / z = 999.67 [M+H] +

[0896] Example 17: (3S,8aR)-N-((S)-2-(((3S,6S,9S)-3-(5-chloro-2-(1-methyl-1H-pyrazol-4-yl)benzyl)-6-isobutyl-1,4-dimethyl-2,5,8-trioxo-1,4,7-triazacyclohexadecane-9-yl)(methyl)amino)-1-cyclopropyl-2-oxoethyl)-6,6-diethyl-5-oxooctahydroindole-3-carboxamide (Compound 17)

[0897] Step 1: Synthesis of Compound 17-1

[0898] Compound 4-9 (130.0 mg, 318.93 μmol) was dissolved in tetrahydrofuran (4 mL). Under nitrogen protection, diisopropylaminolithium (2 M, 1.59 mmol, 797.31 μL) was slowly added dropwise at -78 °C. The mixture was stirred at -78 °C for 30 min, followed by the addition of iodoethane (498.0 mg, 3.19 mmol, 256.40 μL). The mixture was then slowly heated to room temperature and stirred for 24 h. The reaction mixture was quenched in ice water (20 mL) and extracted three times with ethyl acetate (15 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to dryness under reduced pressure to obtain crude compound 17-1 (140.0 mg), which was used directly in the next reaction.

[0899] Step 2: Synthesis of Compound 17-2

[0900] Compound 17-1 (140.0 mg, 301.90 μmol) was dissolved in tetrahydrofuran (10 mL), and then tetrabutylammonium fluoride tetrahydrofuran solution (1 M, 905.71 μmol, 905.71 μL) was added. The mixture was stirred at room temperature for 16 h. The solvent was removed by direct concentration under reduced...

Claims

1. The compound of formula (I) or its stereoisomer or its pharmaceutically acceptable salt: in, W 1 , W 2 , W 3 , W 4 , W 5 , W 6 is independently selected from O or S; X is selected from 5-10 heteroalkyl groups containing at least one heteroatom selected from O, S, or NH; -CH2-CH=CH-CH2-CH2-CH2-CH2-; -CH2-CH2-CH2-CH=CH-CH2-CH2-; -CH2-CH2-CH2-(CH 2)p -CH2-CH2-CH2-、-CR 1a R 1b -CR 2a R 2b -CR 3a R 3b -(CR 4a R 4b ) q -CR 5a R 5b -CR 6a R 6b -CR 7a R 7b - C6-C7 alkenyl groups substituted with deuterium or halogens, C8-C 10 alkenyl or C8-C 10 Alkylene, the C8-C 10 alkenyl or C8-C 10 The alkylene group may optionally be substituted with deuterium, halogen, or C1-C4 alkyl; R 1a , R 1b , R 2a , R 2b , R 3a , R 3b , R 4a , R 4b , R 5a , R 5b , R 6a , R 6b , R 7a , R 7b is independently selected from H, deuterium, halogen or C1-C4alkyl, and at least one is not H; p and q are independently selected from 0 or 1; or R 1a , R 1b , R 2a , R 2b , R 3a , R 3b , R 4a , R 4b , R 5a , R 5b , R 6a , R 6b , R 7a , R 7b any two substituents on adjacent carbon atoms form, together with the carbon atoms to which they are attached, a C3-C6cycloalkyl or 4-6 membered heterocyclyl, each independently optionally substituted with halo, OH, or C1-C4alkyl; or R 1a or R 1b or R 2a or R 2b or R 3a or R 3b or R 4a or R 4b or R 5a or R 5b or R 6a or R 6b or R 7a or R 7b any two substituents on adjacent carbon atoms form, together with the carbon atoms to which they are attached, a C3-C6cycloalkyl or 4-6 membered heterocyclyl, each independently optionally substituted with halogen, OH, or C1-C4alkyl; or R 1a , R 1b , R 2a , R 2b , R 3a , R 3b , R 4a , R 4b , R 5a , R 5b , R 6a , R 6b , R 7a , R 7b any two substituents on the same carbon atom form a C3-C6cycloalkyl or 4-6 membered heterocyclyl, each independently optionally substituted with halo, OH, or C1-C4alkyl; R 8 selected from H, C1-C6 alkyl or C3-C6 cycloalkyl, said C1-C6 alkyl or C3-C6 cycloalkyl being optionally substituted with halogen or OH; or R 7a , R 8 and the atom to which they are attached form a 4-10 membered heterocyclyl group, which is optionally substituted with halogen, OH, C1-C4alkyl, -O-C1-C4alkyl, or -O-C1-C4haloalkyl; or R 6a , R 8 and the atom to which they are attached form a 4-8 membered heterocyclyl group, which is optionally substituted with halogen, OH, C1-C4alkyl, -O-C1-C4alkyl, or -O-C1-C4haloalkyl; R 9 selected from H, C1-C6 alkyl or C3-C6 cycloalkyl, said C1-C6 alkyl or C3-C6 cycloalkyl being optionally substituted with halogen or OH; R 10a , R 10b each independently is selected from H, C1-C6alkyl, C2-C6alkenyl, C1-C6haloalkyl, C1-C6alkoxy, or C3-C6cycloalkyl, said C1-C6alkyl, C2-C6alkenyl, or C3-C6cycloalkyl optionally substituted with OH, C1-C6alkyl, or C3-C6cycloalkyl; R 11 selected from H, C1-C6 alkyl or C3-C6 cycloalkyl, said C1-C6 alkyl or C3-C6 cycloalkyl being optionally substituted with halogen or OH; R 12a , R 12b is independently selected from H, deuterium, C1-C4alkyl or C3-C6cycloalkyl; R 13 H, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 alkyl-OH, C3-C6 cycloalkyl, 4-6 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, -C1-C6 alkyl-C3-C6 cycloalkyl, -C1-C6 alkyl-4-6 membered heterocycloalkyl, -C1-C6 alkyl-phenyl, or -C1-C6 alkyl-5-6 membered heteroaryl, each optionally substituted with 0-3 R a substituents; Each R a Independently selected from CN, halogen, C1-C6 alkyl, or C1-C6 haloalkyl; R 14a , R 14b is independently selected from H, C1-C6 alkyl, C1-C6 deuterated alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 alkyl-OH, C1-C4 alkyl-NR b R d , C1-C4 alkyl-C(O)NHR b , C1-C4 alkyl-C(O)OR b , C3-C6 cycloalkyl, 4-6 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, -C1-C6 alkyl-C3-C6 cycloalkyl, -C1-C6 alkyl-4-6 membered heterocycloalkyl, -C1-C6 alkyl-phenyl, or -C1-C6 alkyl-5-6 membered heteroaryl, each independently substituted with 0-3 R e ; R b , R d is independently selected from H, deuterium, C1-C6alkyl, or C1-C6haloalkyl; Each R e Selected from CN, halogens, C1-C6 alkyl groups, or C1-C6 haloalkyl groups; or R 13 , R 14a with the atom to which it is attached forms a 5-8 membered heterocyclyl; R 15 selected from H or C1-C4alkyl; R 16 C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, 4-10 membered 10 heterocycloalkyl, 5-10 membered heteroaryl, each group optionally substituted by 0-5 R 10 substituents; each R is independently selected from the group consisting of halogen, -CN, -N3, -OH, -OR, -N(R )2, -S(R )2, -C(O)R, -C(O)N(R )2, -C(O)OR, -C(O)O f substituents; each R is independently selected from the group consisting of halogen, -CN, -N3, -OH, -OR, -N(R )2, -S(R )2, -C(O)R, -C(O)N(R )2, -C(O)OR, -C(O)O Each R f Independently selected from =CH2, =CF2, -SF5, OH, CN, =O, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or C3-C6 cycloalkyl; R 17 selected from H or Ci-C6alkyl; R 18 selected from H, halogen, C1-C6 alkyl or C1-C6 haloalkyl; or R 16 , R 17 and the atom to which it is attached form a 5-12 membered heterocyclyl group optionally substituted with OH, halogen, C1-C6alkyl, C1-C6haloalkyl, C1-C6alkylene-OH, or C1-C6alkoxy; Ring B is selected from C5-Ci2cycloalkyl, 5-12 membered heterocyclyl, 6-10 membered aryl, or 5-10 membered heteroaryl; 12 cycloalkyl, 5-12 membered heterocyclyl, 6-10 membered aryl, or 5- m is selected from 0, 1, 2, 3, 4 or 5; each R B is selected from =0, -C(O)NR g R h , -S(O)2R h , -NR g C(O)R h , halogen, NH2, C1-C6alkyl, C2-C6alkynyl, C1-C6alkoxy, C3-C6cycloalkyl, C4-C6cycloalkenyl, 4-10 membered heterocyclyl, phenyl, or 5-10 membered heteroaryl, each NH2, C1-C6alkyl, C2-C6alkynyl, C1-C6alkoxy, C3-C6cycloalkyl, C4-C6cycloalkenyl, 4-10 membered heterocyclyl, phenyl, or 5-10 membered heteroaryl is independently substituted with 0-5 R M substituents; Each R g R h Independently selected from H or C1-C6 alkyl groups; Each R M Selected from deuterium, halogens, CF2, -S(O)2-R X C1-C6alkyl, C1-C6deuteroalkyl, -C1-C6alkylene-OH, -NHC1-C6alkyl, -N(C1-C6alkyl)2, C1-C6alkyl, C3-C6cycloalkyl, 4-7 membered heterocyclyl, or 5-6 membered heteroaryl, each independently optionally substituted with R X substituents; R X selected from halogen, C1-C6alkyl, C1-C3alkoxy, or C3-C6cycloalkyl, said C1-C6alkyl or C3-C6cycloalkyl optionally substituted with halogen; or R on any 2 adjacent ring atoms B with the atoms to which it is attached forming C3-C 10 cycloalkyl, C3-C 10 cycloalkenyl, 4-10 membered heterocyclyl, phenyl, or 5-6 membered heteroaryl, each independently substituted with 0-5 R 10 cycloalkyl, C4-C 10 cycloalkenyl, 4-10 membered heterocyclyl, phenyl, or 5-6 membered heteroaryl, each independently substituted with 0-5 R C substituents; Each R C Selected from OH, halogen, NH2, C1-C6 alkyl, C3-C6 cycloalkyl, 5-6 membered heterocyclic group, phenyl or 5-6 membered heteroaryl; or R on any 2 adjacent ring atoms C with the atoms to which it is attached forming C3-C 10 cycloalkyl, 4-10 membered heterocyclyl, phenyl, or 5-6 membered heteroaryl, each of which is independently and optionally substituted with R 10 cycloalkyl, 4-10 membered heterocyclyl, phenyl, or 5-6 membered heteroaryl, each of which is independently and optionally substituted with R D substituents; R D selected from OH, halogen, C1-C6 alkyl or C1-C6 haloalkyl; or R 12a or R B and the atom to which it is attached forms a C5-C7cycloalkyl, C5-C7cycloalkenyl or 5-7 membered heterocyclyl group, said R B is located at the ortho position relative to the ring atom of ring B to which CR 12a R 12b is attached.

2. The compound of formula (I) according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, wherein, W 1 , W 2 , W 3 , W 4 , W 5 , W 6 S for any one of S, the rest are not O; or W 1 S, W 2 , W 3 , W 4 , W 5 , W 6 are each O; or W 1 , W 2 , W 3 , W 4 , W 5 , W 6 are each O.

3. The stereoisomer of the compound of formula (I) according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein, X is selected from 5-10 heteroalkyl groups containing at least one heteroatom selected from O, S or NH; Alternatively, X is a 6-7-membered heteroalkylene group containing at least one heteroatom selected from O, S or NH; Alternatively, X is a 6-7-membered heteroalkylene group containing one, two, or three heteroatoms independently selected from O, S, or NH; Alternatively, X is selected from -CH2-CH=CH-CH2-CH2-CH2-CH2-, -CH2-CH2-CH2-CH=CH-CH2-CH2-, or -CH2-CH2-CH=CH-CH2-CF2-CH2-; Alternatively, X is selected from -CH2-CH=CH-CH2-CH2-CH2-CH2- or -CH2-CH2-CH2-CH=CH-CH2-CH2-; Alternatively, X is selected from -CH2-CH2-CH2-CH2-CH2-CH2-CH2- or CH2-CH2-CH2-CH2-CH2-CH2-; or X is selected from -CR 1a R 1b -CR 2a R 2b -CR 3a R 3b -CR 5a R 5b -CR 6a R 6b -CR 7a R 7b - or -CR 1a R 1b -CR 2a R 2b -CR 3a R 3b -CR 4a R 4b -CR 5a R 5b -CR 6a R 6b -CR 7a R 7b - and R 1a , R 1b , R 2a , R 2b , R 3a , R 3b , R 4a , R 4b , R 5a , R 5b , R 6a , R 6b , R 7a , R 7b are independently selected from H, deuterium, halogen or C1-C4alkyl, and at least one is not H; Alternatively, X can be a C6-C7 alkenyl group substituted with deuterium or halogen. Alternatively, X is selected from C8-C 10 alkenyl or C8-C 10 Alkylene, the C8-C 10 alkenyl or C8-C 10 The alkylene group may optionally be substituted with deuterium, halogen, or C1-C4 alkyl.

4. The stereoisomer of the compound of formula (I) according to any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein, R 1a , R 1b , R 2a , R 2b , R 3a , R 3b , R 4a , R 4b , R 5a , R 5b , R 6a , R 6b , R 7a , R 7b is independently selected from H, F or CH3, and at least one is not H; or R 3a or R 3b with the carbon atom to which it is attached forms a C3-C6cycloalkyl or 4-6 membered heterocyclyl, each independently optionally substituted with halogen, OH, or C1-C4alkyl; or R 6a or R 6b with the carbon atom to which it is attached forms a C3-C6cycloalkyl or 4-6 membered heterocyclyl, each independently optionally substituted with halogen, OH, or C1-C4alkyl; or R 5a , R 6a and the carbon atom to which they are attached form a C3-C6cycloalkyl or 4-6 membered heterocyclyl, each independently optionally substituted with halogen, OH, or C1-C4alkyl; or R 2a , R 3a and the carbon atom to which they are attached form a C3-C6cycloalkyl or 4-6 membered heterocyclyl, each independently optionally substituted with halogen, OH, or C1-C4alkyl; or R 7a , R 8 and the atom to which they are attached form a 4-6 membered heterocyclyl group, each independently optionally substituted with halo, OH, or C1-C4alkyl.

5. The stereoisomer of the compound of formula (I) according to any one of claims 1-4, or a pharmaceutically acceptable salt thereof, wherein, R 8 is C1-C4 alkyl; or, R 8 is CH3.

6. The stereoisomer of the compound of formula (I) according to any one of claims 1-5, or a pharmaceutically acceptable salt thereof, wherein, R 9 is C1-C4 alkyl; or, R 9 is CH3.

7. The stereoisomer of the compound of formula (I) according to any one of claims 1-6, or a pharmaceutically acceptable salt thereof, wherein, R 10a , R 10b is independently selected from H or C1-C4 alkyl; or, R 10a is C1-C4 alkyl, R 10b is H; or, R 10a is CH2CH(CH3)2, R 10b is H.

8. The stereoisomer of the compound of formula (I) according to any one of claims 1-7, or a pharmaceutically acceptable salt thereof, wherein, R 11 is selected from H or C1-C6 alkyl; or, R 11 is H.

9. The stereoisomer of the compound of formula (I) according to any one of claims 1-8, or a pharmaceutically acceptable salt thereof, wherein, R 12a , R 12b are independently selected from H or deuterium; or, R 12a , R 12b are both H.

10. The stereoisomer of the compound of formula (I) according to any one of claims 1-9, or a pharmaceutically acceptable salt thereof, wherein, R 13 H, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C3-C6 cycloalkyl, 4-6 membered a heterocycloalkyl, phenyl, or 5-6 membered heteroaryl, each optionally substituted with 0-3 R or R 13 is selected from H, C1-C6 alkyl, C1-C6 deuterated alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C3-C6 cycloalkyl, or -C1-C6 alkyl-C3-C6 cycloalkyl, said C3-C6 cycloalkyl being substituted with 0-3 R a substituents; or R 13 selected from Ci-C6alkyl, Ci-C6haloalkyl, or Ci-C6alkyl-OH; or R 13 selected from Ci-C6alkyl or Ci-C6haloalkyl; or R 13 selected from Ci-C4-alkyl or Ci-C4-haloalkyl; or R 13 is selected from CH3, CH2CH2F or CH2CH2OH; or R 13 is selected from CH3or CH2CH2F; or R 13 , R 14a and the atom to which they are attached form a 5-6 membered heterocyclyl.

11. The stereoisomer of the compound of formula (I) according to any one of claims 1-10, or a pharmaceutically acceptable salt thereof, wherein, R 14a selected from C1-C4alkyl-NR b R d or C3-C6cycloalkyl, said C3-C6cycloalkyl being substituted with 0-3 R e substituents; or R 14a is selected from the group consisting of C1-C4alkyl-N(C1-C4alkyl)2, C1-C4alkyl-NH(C1-C4alkyl), or C3-C6cycloalkyl; and R 14b is H; or R 14a is selected from C1-C4alkyl-N(CH3)2, C1-C4alkyl-NHCH3or cyclopropyl, and R 14b is H; or R 14a is -CH2CH2CH2CH2N(CH3)2.

12. The stereoisomer of the compound of formula (I) according to any one of claims 1-11, or a pharmaceutically acceptable salt thereof, wherein, R 15 is H or CH3; or, R 15 is H.

13. The stereoisomer of the compound of formula (I) according to any one of claims 1-12, or a pharmaceutically acceptable salt thereof, wherein, R 16 For C3-C 10 cycloalkyl, the C3-C 10 Cycloalkyl groups are marked with 0-5 R groups. f replace; Or, R 16 It is a C3-C6 cycloalkyl group, wherein the C3-C6 cycloalkyl group is surrounded by 0-5 R groups. f replace; or R is H, or R 16 is cyclobutyl, said cyclobutyl being substituted with 0-5 R f substituents; Or, each R f Independently selected from =CF2, -SF5, OH, CN, =O, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or C3-C6 cycloalkyl; Or, each R f It is independently selected from OH, CN, =O, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C3-C6 cycloalkyl or =CF2; Each R f It is independently selected from OH, CN, =O, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or C3-C6 cycloalkyl; Or, each R f Selected from halogens or C1-C6 haloalkyl groups.

14. The stereoisomer of the compound of formula (I) according to any one of claims 1-13, or a pharmaceutically acceptable salt thereof, wherein, R 16 , R 17 with the atom to which it is attached forms a 5-12 membered heterocyclyl group optionally substituted with OH, halogen, C1-C6alkyl, or C1-C6haloalkyl; or R 16 , R 17 and the atom to which they are attached form a 5-8 membered heterocyclyl group, which is optionally substituted with OH, halogen, C1-C6alkyl, C1-C6haloalkyl, C1-C6alkyl-OH, or C1-C6alkoxy; or R 16 , R 17 and the atom to which they are attached form a 5-8 membered heterocyclyl group, which is optionally substituted with halogen or Ci-C6alkyl; or R 16 , R 17 with the atom to which it is attached forms a 5-6 membered heterocyclyl group, which is optionally substituted with halogen or C1-C6alkyl.

15. The stereoisomer of the compound of formula (I) according to any one of claims 1-14, or a pharmaceutically acceptable salt thereof, wherein, R 18 selected from halogen, C1-C6alkyl or C1-C6haloalkyl; or R 18 selected from Ci-C6alkyl or Ci-C6haloalkyl; or R 18 is C1-C6haloalkyl; or R 18 is CF3; or R 18 is halogen; or, R 18 is F.

16. The stereoisomer of the compound of formula (I) according to any one of claims 1-14, or a pharmaceutically acceptable salt thereof, wherein, Ring B is selected from C5-C8 alkyl, 5-8 membered heterocyclic, phenyl, or 5-6 membered heteroaryl; Alternatively, ring B is selected from 6-10 aryl or 5-10 heteroaryl; Alternatively, ring B is selected from phenyl or 5-6-membered heteroaryl; Alternatively, ring B is selected from phenyl, pyridyl, or pyrimidinyl; or ring B is phenyl. Alternatively, ring B is selected from C5-C. 12 Cycloalkyl or 5-12 membered heterocyclic groups; Alternatively, ring B is selected from C5-C8 cycloalkyl or 5-8 membered heterocyclic groups; Alternatively, ring B is selected from C5-C6 cycloalkyl or 5-6 membered heterocyclic groups.

17. The stereoisomer of the compound of formula (I) according to any one of claims 1-16, or a pharmaceutically acceptable salt thereof, wherein, Each R B Selected from halogens, NH2, C1-C6 alkyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C6 cycloalkyl, C4-C6 cycloalkenyl, 4-10 membered heterocyclic, phenyl, or 5-10 membered heteroaryl, wherein each of the NH2, C1-C6 alkyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C6 cycloalkyl, C4-C6 cycloalkenyl, 4-10 membered heterocyclic, phenyl, or 5-10 membered heteroaryl is independently bound by 0-5 R groups. M replace; Or, each R B Selected from =O, -C(O)NR g R h -S(O)2R h -NR g C(O)R h Halogen, NH2, C1-C6 alkyl, C2-C6 alkynyl, C1-C6 alkoxy, C4-C6 cycloalkenyl, 4-6 membered heterocyclic, phenyl or 5-6 membered heteroaryl, wherein each of the NH2, C1-C6 alkyl, C2-C6 alkynyl, C1-C6 alkoxy, C4-C6 cycloalkenyl, 4-6 membered heterocyclic, phenyl or 5-6 membered heteroaryl is independently bound by 0-5 R M replace; Or, each R B Selected from halogens, NH2, C1-C6 alkyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C6 cycloalkenyl, 4-10 membered heterocyclic, phenyl, or 5-10 membered heteroaryl, wherein each of the NH2, C1-C6 alkyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C6 cycloalkenyl, 4-10 membered heterocyclic, phenyl, or 5-10 membered heteroaryl is independently bound by 0-5 R groups. M replace; Or, each R B Selected from halogens, NH2, C1-C6 alkyl, C2-C6 alkynyl, C4-C6 cycloalkenyl, 4-6 membered heterocyclic, phenyl, or 5-6 membered heteroaryl, wherein each of the NH2, C1-C6 alkyl, C2-C6 alkynyl, C4-C6 cycloalkenyl, 4-6 membered heterocyclic, phenyl, or 5-6 membered heteroaryl is independently bound by 0-5 R groups. M replace; Or, R B It is a halogen; Alternatively, R on any two adjacent ring atoms B The atoms bonded to it form C7-C 10 Cycloalkenyl or 7-10 membered heterocyclic group, wherein the C7-C 10 Each cycloalkenyl or 7-10 membered heterocyclic group is independently bounded by 0-5 R groups. C replace; Alternatively, R on any two adjacent ring atoms B The atoms bonded to it form 7, 8, 9, or 10-membered heterocyclic groups, which are separated by 0-5 R atoms. C replace; Alternatively, R on any two adjacent ring atoms B The atoms bonded to it form a 7-membered heterocyclic group, which is then surrounded by 0-5 R atoms. C replace; Alternatively, R on any two adjacent ring atoms B The atoms bonded to it form C7-C 10 Cycloalkenyl or 7-10 membered heterocyclic group, wherein the C7-C 10 Each cycloalkenyl or 7-10 membered heterocyclic group is independently bounded by 0-5 R groups. C Instead, the C7-C 10 R on any two adjacent ring atoms of a cycloalkenyl or 7-10 membered heterocyclic group C The atoms bonded to it form C3-C 10 Cycloalkyl, 4-10 membered heterocyclic, phenyl, or 5-6 membered heteroaryl, wherein the C3-C 10 Cycloalkyl, 4-10-membered heterocyclic, phenyl, or 5-6-membered heteroaryl groups are independently and optionally R D replace; Alternatively, R on any two adjacent ring atoms B The atoms bonded to it form C7-C 10 Cycloalkenyl or 7-10 membered heterocyclic group, wherein the C7-C 10 Each cycloalkenyl or 7-10 membered heterocyclic group is independently bounded by 0-5 R groups. C Instead, the C7-C 10 R on any two adjacent ring atoms of a cycloalkenyl or 7-10 membered heterocyclic group C The atoms bonded to it form 5-6-membered heteroaryl groups, which are independently and optionally R D replace.

18. The stereoisomer of the compound of formula (I) according to any one of claims 1-17, or a pharmaceutically acceptable salt thereof, wherein, Each R C Selected from OH, halogens, or C1-C6 alkyl groups; Or, each R C It is a halogen; Alternatively, R on any two adjacent ring atoms C The atoms bonded to it form C3-C 10 Cycloalkyl, 4-10 membered heterocyclic, phenyl, or 5-6 membered heteroaryl, wherein the C3-C 10 Cycloalkyl, 4-10-membered heterocyclic, phenyl, or 5-6-membered heteroaryl groups are independently and optionally R D replace; Alternatively, R on any two adjacent ring atoms C The atoms attached thereto form phenyl or 5-6-membered heteroaryl groups, wherein each phenyl or 5-6-membered heteroaryl group is independently and optionally R D replace; Alternatively, R on any two adjacent ring atoms C The atoms bonded to it form 5-6-membered heteroaryl groups, which are optionally R D replace; Alternatively, R on any two adjacent ring atoms C The atoms bonded to it form a pyrazol group, which is optionally R D replace.

19. The stereoisomer of the compound of formula (I) according to any one of claims 1-18, or a pharmaceutically acceptable salt thereof, wherein, R 12a R B The atoms bonded to it form C5-C7 cycloalkenyl or 5-7 membered heterocyclic groups, wherein R B Located in CR 12a R 12b The adjacent positions of the ring atoms in the connected ring B; Or, R 12a R B The atoms connected to it form a C5 cycloalkenyl or a 5-membered heterocyclic group, wherein R B Located in CR 12a R 12b The adjacent positions of the ring atoms in the connected ring B; Alternatively, ring B is phenyl, and R 12a R B The atoms bonded to it form C5-C7 cycloalkenyl or 5-7 membered heterocyclic groups, wherein R B Located in CR 12a R 12b The adjacent positions of the ring atoms in the connected ring B.

20. The compound of formula (I) according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, wherein, The compound represented by formula (I), its stereoisomer or pharmaceutically acceptable salt thereof, is selected from the compound represented by formula (Ia), its stereoisomer or pharmaceutically acceptable salt thereof: Among them, Z 1 Z 2 Z 3 Z 4 Z 5 Independently selected from CH and CR B Or N; W 1 W 2 W 3 W 4 W 5 W 6 X, R 8 R 9 R 10a R 10b R 11 R 12a R 12b R 13 R 14a R 14b R 15 R 16 R 17 R 18 R B The definition as described in any one of claims 1-15 or 17-19.

21. The compound of formula (I) according to claim 20, its stereoisomer or a pharmaceutically acceptable salt thereof, wherein, Z 1 Z 2 Z 3 Z 4 Z 5 At least one of them is N; Or, Z 4 For N, Z 1 Z 2 Z 3 Z 5 Independently selected from CH or CR B ; Or, Z 1 Z 2 Z 3 Z 4 Z 5 Independently selected from CH or CR B ; Or, Z 1 Z 3 Z 4 Both are CH; Z 2 Z 5 All are CR B ; Or, Z 1 Z 3 Z 4 Both are CH; Z 2 Z 5 All are CR B ;R 12a R B The atoms attached to it form C5-C7 cycloalkyl, C5-C7 cycloalkenyl, or 5-7 membered heterocyclic groups; Or, Z 1 Z 3 Both are CH; Z 2 Z 4 Z 5 All are CR B R on adjacent ring atoms B The atoms bonded to it form C7-C 10 Cycloalkenyl or 7-10 membered heterocyclic group, wherein the C7-C 10 Each cycloalkenyl or 7-10 membered heterocyclic group is independently bounded by 0-5 R groups. C replace; Or, Z 2 Z 5 Both are CH; Z 1 Z 3 Z 4 All are CR B R on adjacent ring atoms B The atoms bonded to it form C7-C 10 Cycloalkenyl or 7-10 membered heterocyclic group, wherein the C7-C 10 Each cycloalkenyl or 7-10 membered heterocyclic group is independently bounded by 0-5 R groups. C replace.

22. The stereoisomer of the compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein, The compound represented by formula (I), its stereoisomer, or a pharmaceutically acceptable salt thereof is selected from the compound represented by formula (Ib), its stereoisomer, or a pharmaceutically acceptable salt thereof: in, Indicates a single or double bond; Y 1 Y 2 Y 3 Independently selected from CH2 and CHR C C(R) C 2. O, S, or NH; Y 4 Y 5 Independently selected from CH2 and CR C CHR C C(R) C 2. O, S, or NH; W 1 W 2 W 3 W 4 W 5 W 6 X, R 8 R 9 R 10a R 10b R 11 R 12a R 12b R 13 R 14a R 14b R 15 R 16 R 17 R 18 Z 1 Z 2 Z 3 R C The definition as described in any one of claims 1-15 or 17-19.

23. The stereoisomer of the compound of formula (I) according to claim 22, or a pharmaceutically acceptable salt thereof, wherein, Y 1 Y 2 Y 3 Y 4 Y 5 Independently selected from CH2 and CHR C , O, S or NH; Y 1 Y 2 Y 3 Y 4 Y 5 At least one of them is O, S, or NH; Or, Y 1 Y 2 Y 3 Y 4 Y 5 At least one of them is 0; Or, Y 1 Y 5 Both are O, Y 2 Y 3 Y 4 Both are CH2; or, Y represents a single bond. 1 Y 5 Both are O, Y 2 Y 4 Both are CH2, Y 3 CH2 or C(R) C )2; or, Y represents a single bond. 4 Y 5 All are CHR C Y 1 Y 3 Both are CH2, Y 2 It is CH2 or O; Or, Y 4 Y 5 Independently selected from CR C or CHR C Y 1 Y 3 Both are CH2, Y 2 It is CH2 or O, and the R on the adjacent ring atom C The atoms bonded to it form C3-C 10 Cycloalkyl, 4-10 membered heterocyclic, phenyl, or 5-6 membered heteroaryl, wherein the C3-C 10 Cycloalkyl, 4-10-membered heterocyclic, phenyl, or 5-6-membered heteroaryl groups are independently and optionally R D replace; Or, Y 4 Y 5 Independently selected from CR C Y 1 Y 3 Both are CH2, Y 2 It is CH2 or O, and the R on the adjacent ring atom C The atoms bonded to it form 5-6-membered heteroaryl groups, wherein the 5-6-membered heteroaryl groups are optionally R D replace.

24. The stereoisomer of the compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein, The compound represented by formula (I), its stereoisomer or pharmaceutically acceptable salt thereof, is selected from the compound represented by formula (Ic-X), its stereoisomer or pharmaceutically acceptable salt thereof: Among them, among them, Indicates a single or double bond; R 6a R 6b It is independently selected from H, deuterium, halogen or C1-C4 alkyl, and at least one of them is not H; W 1 W 2 W 3 W 4 W 5 W 6 R 8 R 9 R 10a R 10b R 11 R 12a R 12b R 13 R 14a R 14b R 15 R 16 R 17 R 18 Ring B, R B m is defined as described in any one of claims 1-19.

25. The stereoisomer of the compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein, The compound represented by formula (I), or its stereoisomer or pharmaceutically acceptable salt thereof, is selected from the compound represented by formula (II) or formula (III), or its stereoisomer or pharmaceutically acceptable salt thereof: Among them, rings B and W 1 W 2 W 3 W 5 W 6 X, R 8 R 9 R 10a R 10b R 11 R 12a R 12b R 14 R 15 R 16 R 17 R 18 R B m is defined as described in any one of claims 1-19.

26. The stereoisomer of the compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein, The compound shown in formula (I), or its stereoisomer or pharmaceutically acceptable salt thereof, is selected from the following compounds, or their stereoisomers or pharmaceutically acceptable salts:

27. A pharmaceutical composition comprising a compound of formula (I) according to any one of claims 1-26, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

28. A method of treating a disease mediated by Cyclin A and / or Cyclin B in a mammal, comprising administering to a mammal, preferably a human, a therapeutically effective amount of a compound of formula (I) of any one of claims 1-26 or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 27.

29. Use of the compound of formula (I) according to any one of claims 1-26, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 27, in the preparation of a medicament for the prevention or treatment of Cyclin A and / or Cyclin B mediated diseases.